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Both telomere regulation and the repair of DNA damage are essential processes for main-
taining genomic stability in eukaryotes. Distinctions between these processes have become
harder to make as we further our understanding of their governing pathways and the over-
lap of proteins involved.
The CST complex was originally discovered in budding yeast, it is the capping complex
that ensures telomeric deoxyribonucleic acid (DNA) is appropriately replicated and pro-
tected. In 2009 the CST complex was identified in humans, but the role of the human
CST complex has been found to extend beyond the telomere.
Here I report that whilst loss of the CTC1-STN1-TEN1 (CST) complex component CTC1
in human cells does result in telomere mis-regulation, it also induces a rapid compromise
to genomic stability unrelated to its telomeric function. My data suggest CTC1∆ human
cells are failing to correctly repair DNA damage. I also show that STN1 , another CST
complex component, can significantly compromise genomic stability when overexpressed.
This instability may be due to the fact that a high level of STN1 appears capable of sup-
pressing homology-directed repair (HDR) whilst promoting non-homologous end joining
(NHEJ). Human STN1 mRNA, like the budding yeast homologue, appears to be degraded
by nonsense-mediated decay (NMD), perhaps as a mechanism for NMD and the stress
response to regulate repair pathways via STN1.
Finally, I report that the recently proposed critical role for the nuclease/helicase Dna2 at
the telomeres of budding yeast appears to be conserved in the nematode C. elegans.
The overlap in proteins that regulate the telomere and those that play an active role in
the repair of DNA damage continues to grow. The human CST complex was originally
characterised as a regulator of the telomere but appears to also play a significant role in
the DNA damage response. Telomere regulation and DNA damage repair play key roles in
both the ageing processes and cancer development, and the data presented in this thesis
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1.1 The Eukaryotic Cell
The Eukaryotic cell consists of a nucleus, surrounded by a membrane, inside a cytoplasm-
filled outer membrane. Within the cytoplasm exists organelles that carry out specialised
cellular functions, such as the Golgi apparatus and mitochondria. The surrounding of
organelles in membranes is what separates eukaryotes from prokaryotes [1]. The genomic
content of the nucleus consists of one or more linear chromosomes; DNA wrapped tightly
around histones to form a nucleoprotein structure called chromatin [2]. Eukaryotes can be
single or multi-cellular, with cells specialising into structures of different cell types called
tissues.
The eukaryotes are composed of four kingdoms: animalia, plantae, fungi, and protista.
The development of molecular phylogenetic technologies highlighted the complex phylo-
genetic relationships between eukaryotes, producing wildly different trees depending on
the genes analysed, and the specifics of the analytical approaches. The broad consensus
now is the eukaryote phylogenetic tree consists of 5 supergroups: opisthokonta (containing
animals, fungi, and some protists), amoebozoa, excavata, archaeplastida (plantae), and
SAR (stramenopiles, alveolates, and rhizaria) [3]. The main three organisms discussed
in this thesis are Homo sapiens (humans), Saccharomyces cerevisiae (budding yeast) and
Caenorhabditis elegans (a nematode). The latter two being common model organisms
from the fungi and animalia kingdoms respectively.
1.2 The Structure of DNA
DNA is the carrier molecule of genetic information in the cell, consisting of two polynu-
cleotide strands. The polynucelotides are chains of four different monomers known as
nucleotides. Each nucleotide consists of a phosphate group; a deoxyribose sugar; and
one of 4 nuclear bases, adenine (A), thymine (T), guanine (G) or cytosine (C). The two
strands of DNA are held together by hydrogen bonds between adenine and thymine or
guanine and cytosine. The two strands are considered antiparallel, running in opposite
directions (determined by the orientation of the phosphate-sugar backbone) and compli-
mentary; adenine always opposite thymine and guanine always opposite cytosine [4]. The
human genome consists of 3.2 billion base pairs [5], and is estimated to contain around
21 thousand protein coding genes [6]. Protein-coding sequences account for only approx-
imately 1.5% of the genome [7], the rest is regulatory elements, introns, long interspersed
nuclear element (LINE)s, short interspersed nuclear element (SINE)s, DNA specifying
non-coding ribonucleic acid (RNA), and DNA yet to be functionally determined. The
human nuclear genome is split between 46 chromosomes [8].
DNA strands are wrapped around histones to form nucleosomes and the nucleoprotein
1
complex chromatin. The chromatin can supercoil and compact to varying degrees during
the cell cycle [9]. This compaction of DNA allows it to be sorted during mitosis and
meiosis. The human genome consists of two copies of each chromosome, one of paternal
origin and one of maternal origin. Human somatic cells have 22 autosomal chromosome
pairs and one pair of sex chromosomes, X and Y for males and two X chromosomes for
females.
1.3 The Cell Cycle and DNA Replication
The basic purpose of every living organism, the driving force of natural selection, is the
propagation of genetic information. Evolution describes the process by which an organism
adapts and changes so that it is more likely to succeed in producing offspring and passing
on its genetic to the next generation. DNA replication is therefore obviously a crucial
process. The process is largely semi-conservative, DNA must be copied accurately enough
that the offspring is essentially the same organism, but with enough variation that allows
the species to evolve and adapt to its environment.
Human cells (along with most members of the animalia kingdom) are diploid, they have
two copies of each chromosome (one that was maternally inherited and one that was pater-
nally inherited). When our cells replicate they must produce a copy of every chromosome
and then equally divide them between two daughter cells. In somatic cells this process
is mitosis, where a 2N cell copies its genome to become 4N, which is then evenly divided
into two 2N daughter cells.
1.3.1 The Cell Cycle
Somatic cells divide by a process called mitosis, but germline cells can also use a second
process called meiosis . During mitosis one diploid cell replicates its genome then divides
once, producing two diploid daughter cells. During meiosis a diploid cell replicates its
genome, but then goes through two rounds of cell division (meiosis I and meiosis II)
to produce four haploid daughter cells [10]. During meiosis I a high degree of genetic
crossover occurs between maternal and paternal chromosomes [11], contributing to genetic
diversity of offspring. Meiosis is used by germline cells to produce haploid gametes for
use in sexual reproduction. The vast majority of cell divisions in a multicellular organism
are not meiotic but mitotic, as mitosis is how somatic cells replicate and contribute to
the growth and repair of tissues.
The mitotic cell cycle can be broken down into five stages (Fig. 1). S-phase is the stage
of the cell cycle in which DNA is replicated. In humans the 46 chromosomes (23 maternal
origin and 23 paternal origin) are each copied to produce 92 chromosomes. At the end of
S-phase, once various checkpoints are satisfied that replication has successfully completed,





Figure 1. Overview of the mitotic cell cycle. Diploid cells replicate their genome to
become tetraploid in S-phase. After S-phase cells grow and produce proteins to be able
to divide (G2 phase). The large tetraploid cell divides in two, giving each daughter cell
one copy of the genome during M-phase. The diploid daughters have an intermediate
phase (G1) before re-entering S-phase for another round of replication and division.
Alternatively they can exit the cell cycle into G0.
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it is large enough to divide. The G2/M checkpoint ensures there is no lingering DNA
damage before allowing the cell to progress into mitosis (M-phase) [12]. During mitosis
the DNA content of the cell becomes highly condensed to allow its easy segregation. The
nuclear membrane breaks down and the chromosomes are pulled towards opposite poles.
The cell then divides into two daughter cells, each with one complete copy of the genome.
Once mitosis has completed the cell is now in G1, the intermediate phase between cell
division and the restart of the replication process [13]. Some cells exit the cell cycle and
remain in G1 indefinitely. These cells are referred to as being in G0.
The major cell cycle controlling proteins are cyclins and CDKs. Specific cyclin-CDK
complexes are formed at different stages of the cell cycle, phosphorylating a range of
downstream targets to promote or suppress cell cycle progression (table 6). Whilst CDK
levels remain relatively consistent throughout the cell cycle, cyclin levels rise and fall
during different phases [14].
CDK Cyclins Cycle Phase
CDK4 D1, D2, D3 G1





Table 6. Complexes of Cyclins and CDKs Present Throughout The Cell Cycle
Inhibition of cell cycle progression is an important function of the DNA damage response
(DDR). Up to ten thousand DNA lesions can occur in a single cell in one day, of which
DSBs are the most genotoxic [15]. Damage to DNA can interfere with various stages of
the cell cycle with catastrophic effects on genome integrity. It is often important that
the cell is able to recognise and repair such damage before moving into the next phase of
the cell cycle. As such the DDR is a major upstream inhibitor of CDK activity. It has
been shown that a single DSB is capable of triggering a robust DDR and arresting the
cell cycle [15].
1.3.2 DNA Replication
The process of DNA replication is highly conserved across all domains of life. A replication
fork moves along as a bubble in double-stranded DNA (dsDNA), one strand being copied
and synthesised in the same direction as the replication fork, and one strand in the
opposite direction. The ’leading’ strand that is synthesised in the same direction as the
travelling replication fork is produced in one continuous strand, whilst the anti-parallel
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strand is produced as a series of fragments called Okazaki fragments [16]. Each individual
fragment is synthesised in the opposite direction as the replication fork, however each
subsequent fragment is started upstream of the previous fragment, and as such the net
synthesis of ’lagging’ strand DNA is in the direction of the replication fork.
Assembly of the replisome can be split into four stages (Fig. 2) [17]. First the origin recog-
nition complex (ORC) recruits two MCM hexamers to the site of the replication origin,
the two MCM hexamers form a symmetrical double-hexamer, enclosing DNA [18]. The
second step is the Dbf4/Drf1-dependent kinase (DDK) and CDK driven recruitment and
assembly of a number of factors. Here the go-ichi-ni-san (GINS) complex, a heterote-
trameric ring-like complex tightly interacting with Pol-ε, is loaded onto the replisome
[19][20]. The third stage of replisome assembly is the separation of the two MCM hex-
amers to form two diverging replication forks, separating the dsDNA to form a bubble
of single-stranded DNA (ssDNA) strands. This step is catalysed by MCM10 and RPA
[21][22], and the MCM complex is rearranged to form an active helicase. The final step
is the binding of RPA to the ssDNA generated, which forms a binding site for Pol-α to
prime DNA synthesis.
The leading strand replicase consists of the Cdc45 Mcm2-7 GINS (CMG) helicase and Pol-
ε. Evidence suggests the MCM core travels along the leading strand ssDNA, unravelling
the dsDNA ahead of it in a 3′-5′ direction [23][24]. The helicase is adenosine triphosphate
(ATP) dependent, hydrolysis of which confers conformational changes to the complex
[25][26]. Once the DNA is unwound the leading strand is replicated by Pol-ε (Fig. 3a). The
N-terminal domain of Pol-ε is responsible for DNA polymerisation, essentially replacing
the now-displaced lagging strand with identical DNA. The N-terminal domain also has
exonucleolytic activity, through which it proofreads and removes erroneously placed mis-
matching bases [27][28].
Whilst both leading strand and lagging strand DNA synthesis are primed by Pol-α, lag-
ging strand synthesis is largely carried out by Pol-δ and not Pol-ε. For each fragment
DNA synthesis by Pol-α is terminated after 20-30 nucleotides, at which point Pol-δ takes
over [29]. The switch from Pol-α to Pol-δ appears to be driven by the loading of PCNA by
replication factor C (RFC) [30][31]. The PCNA sliding clamp significantly increases the
processivity of Pol-δ [32]. When the 3′ end of the Okazaki fragment extends and reaches
the 5′ end of the proceeding fragment, the 3′ end of the synthesised fragment displaces a
Figure 2 . Assembly of the replisome. The assembly of the eukaryotic DNA replisome
can be broken down into 4 stages. 1) Recruitment of the minichromosome maintenance
protein complex (MCM) complex by the ORC. 2) Assembly of the pre-initiation
complex. 3) Rearrangement of the MCM to form an active helicase. 4) Priming of DNA














small flap of the proceeding fragment (Fig. 3b). Pol-δ is capable of 3′ exonucleolytic ac-
tivity that resects the new fragment back to the position at which it meets the proceeding
fragment [33]. FEN1 is responsible for the excision of any 5′ flaps that are nonetheless
generated [34], although FEN1 is not competent at resecting particularly long flaps that
are prone to secondary structures or RPA coating. These long flaps are resected by the
nuclease/helicase Dna2 [35]. Finally the remaining nick is ligated by DNA ligase I [36] to
complete the synthesis of continuous dsDNA.
Figure 3 . Replication of The Leading and Lagging Strand. (A) The structure of the
replisome as it moves with the replication fork. The leading strand is copied
continuously by Pol-ε whilst the lagging is copied in short sections called Okazaki
fragments by Pol-δ. (B) Completion of the lagging strand by the joining of Okazaki
fragments. Newly synthesised Okazaki fragments often displace part of the proceeding
fragment, generating a flap that must be processed by Dna2 and FEN1. The fragments




































Mitosis is the process by which eukaryotic cells replicate asexually. The eukaryotic cell
copies its genome then divides into two daughter cells, each with one full copy of the
genome. The process of mitosis can be separated into seven stages (Fig. 4).
The first stage, prophase, sees the chromosomes condense by supercoiling to form individ-
ually distinguishable chromosomes, with the help of specialised proteins called condensins
[38]. The two condensed copies of each chromosome are held together at the centre by
a region called the centromere. As the chromosomes become more and more condensed
transcription is shut down as transcription factors are displaced [39]. By the end of
prophase the nucleolus has dispersed, and the nuclear envelope will begin to break down
[40]. Microtubules and microfilaments in the cytoplasm largely lose their stability and
break down [41], but some new microtubules begin to form what will become the mitotic
spindle at the two centrosomes.
During the second stage, prometaphase, the mitotic spindle further develops and extends
from each centrosome pole into the centre of the cell. The nuclear envelope rapidly breaks
down into small vesicles within the cytoplasm. Chromosomes engage with the spindle via
large multiprotein structure called the kinetochore [42]. The kinetochore contains fibrous
proteins that bind microtubule walls, and motor proteins that generate the forces used to
spatially organise chromosomes. Kinetochore-microtubule binding occurs stochastically
and often only transiently. This release and re-binding allows incorrectly bound kine-
tochores (ones which would segregate chromatids incorrectly) to be corrected [43][44].
Kinetochore components have kinase activities that control the spindle-assembly check-
point (SAC), prolonging the phase until correct assembly is determined to have been
reached (thought to be in response to microtubule attachment and tensioning [45]).
Chromosomes that are attached to the mitotic spindle begin to migrate to the centre of the
spindle, forming the metaphase plate. This third stage of mitosis, known as metaphase,
is the point at which all chromosomes are assembled at the equator of the cell.
If the SAC is satisfied that every chromosome kinetochore is correctly attached to the
spindle, then the metaphase state is short-lived and the cell progresses into the fourth
stage of mitosis, anaphase. Separase cleaves the Cohesin rings that hold sister chromatids
together, and the chromatids are pulled towards the centrosomes at opposite poles [46].
This is achieved by decreasing the distance of each centromere from the centrosome it
is attached to (anaphase A), and the increasing in the distance between the two centro-
some poles (anaphase B). These two mechanisms are performed by some cells simulta-
neously, whilst other cells might perform them in series or only perform one. Anaphase
A is achieved by the shortening of kinetochore microtubules (through the loss of tubulin
subunits) at one or both ends of the microtubule [47][48]. Anaphase B in contrast is
characterised by the sliding apart of overlapping microtubules at the spindle. The slid-










Figure 4. The stages of mitosis. Mitosis is the process by which eukaryotic cells
asexually divide, sharing identical copies of their genome between two daughter cells.
The process can be broken into 6 stages. In prophase chromosomes start to condense
and the nuclear membrane begins to break down. In prometaphase the nuclear
membrane breaks down completely and chromosomes begin to assemble on the
encroaching mitotic spindle. The cell reaches metaphase when all chromosomes are
correctly attached and assembled on the metaphase plate. In anaphase sister chromatids
are pulled towards opposite poles. The cell then starts to pinch in at the centre and
build a new nuclear envelope around the two groups of chromosomes in telophase.
Finally the cell initiates cytokinesis and splits into two daughter cells, now in interphase.
Figure adapted from Schellhaus et al. (2016) [37].
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force driven by both the breakdown of astral (beyond the centrosome) microtubules, and
dynein motors that exert a pulling force on those astral microtubules [49].
The next stage, telophase, involves the reforming of the nuclear envelope around the
two groups of chromosomes. Condensin activity peaks a second time to further con-
dense chromosomes, thought to help the separation of chromatids and capture within the
new nuclei [50]. Inner nuclear envelope proteins begin to associate with and encapsulate
the condensed chromosomes, eventually nuclear pore complexes are reintegrated and the
nucleoplasm-cytoplasm boundary is restored. Following that chromosome decondensation
begins, transcription restarts, and the nucleolus reforms.
Once the nuclear content of the two daughter cells-to-be has been spatially separated into
two nuclei the cell must perform cytokinesis. This requires the assembly and constriction
of a contractile ring of filamentous proteins at the equator of the cell [51]. The contractile
ring constricts, pinching the centre of the cell, forming the cleavage furrow after anaphase.
After telophase contraction of the centre of the cell continues, eventually resulting in
scission of the membrane, and completing cytokinesis to produce two daughter cells [51].
The daughter cells are now in interphase, the intermediate stage between rounds of mitosis
comprising G1, S-phase, and G2.
1.3.4 Cell Cycle Checkpoints
At many points during the cell cycle there are checkpoints that must be satisfied before
the cell will progress to the next phase. Some checkpoints are activated in response to
DNA damage, others are related to phase-specific activities such as DNA synthesis or cell
growth. Mutations in genes that take part in these checkpoints often result in oncogenesis
as cell proliferation becomes unchecked [52]. Generally speaking cell cycle checkpoints can
be split into four main points, G1/S, intra-S, G2/M, and Spindle Assembly (Fig. 5).
The G1/S checkpoint, referred to as the restriction point in mammalian cells, is the point
at which the cell commits to replication. The primary purpose of the G1/S checkpoint is
to ensure the DNA replication process is not started whilst DNA damage persists. Intra-
G1 cyclin-CDK complexes D-4 and D-6 are inhibited by DNA damage sensing pathways
via p53 and p21. The p53 pathway and the CHK1/CHK2 pathways inhibit the G1/S
transition cyclin-CDK complexs E-2 and A-2 [53][54]. These inhibitory pathways are
activated downstream of the DDR kinases ATM and ATR [55][56]. The cell will be
unable to progress into S-phase until the G1/S checkpoint is satisfied DNA damage is not
going to interfere with faithful replication of the genome.
The DNA damage-activated kinases ATM and ATR are key players throughout the ma-
jority of the cell cycle, inhibiting the cell from progressing to the next stage whilst DNA
damage persists. ATR in particular is also essential for sensing ssDNA and replication
stress during S-phase, and activating the intra-S checkpoint [57]. This intra-S checkpoint
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Figure 5. Checkpoint control throughout the cell cycle. Cyclin-CDK complex formation
is controlled to form checkpoints throughout the cell cycle. At many points these
checkpoints respond to DNA damage (primarily via the kinases ATM and ATR), but
also respond to stage-specific factors such as replication stress or mitotic
chromosome-spindle assembly.
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[58][59]. Once replication has completed the cell will continue to grow through G2. Here
the ATM and ATR kinases are again capable of triggering DNA damage-induced cell cycle
arrest. Evidence suggests this checkpoint is also controlled by cell size, ensuring the cell
is physically capable of dividing into two daughter cells [59][60].
During mitosis cell cycle progression is controlled by the SAC (Fig. 6), chromosome
kinetochores must be connected to the mitotic spindle and correctly orientated so as to
allow equal division of genomic content [61][62]. Once the SAC is satisfied then cleavage
of the Cohesin subunit Kleisin by Separase allows sister chromatids to separate, and



























Figure 6. The Spindle Assembly Checkpoint. Incorrectly attached kinetochores result in
the formation of the MCC complex, which blocks anaphase promoting complex (APC)
activation. APC activation is necessary to A) allow sister chromatids to physically
separate by cleavage of Cohesin and B) degrade Cyclin B and trigger entry into G1.
Figure adapted from Lara-Gonzalez et al. 2012 [63].
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1.4 The DNA Damage Response
Damage to DNA is a frequently occurring event in the cell. Damage can be induced by a
wide range of factors such as ionising and non-ionising radiation, reactive oxygen species
(ROS), chemical agents, or viruses. This damage can take the form of breaks in one
or both strands of DNA, or chemical modifications to nucleotides. When DNA damage
is detected the cell must activate the appropriate pathway for repair. If the amount of
damage is above a certain threshold then the cell cycle is arrested and not restarted until
the damage has been repaired. Unrepaired DNA damage can result in permanent exit
from the cell cycle (senescence) or apoptosis. Damage to DNA repair genes can result in a
positive feedback loop of greater and greater genomic instability and rearrangement, this
alongside damage to genes that regulate cell growth results in the unchecked proliferation
of cells that constitutes cancer.
The cell has specialised pathways for the different forms of DNA damage that can occur.
Base excision repair (BER) repairs relatively small DNA adducts that have a minimal
effect on the tertiary structure of DNA, such as damage from oxidation, deamination
and alkylation, and single-strand breaks. Nucleotide excision repair (NER) is responsi-
ble for the repair of larger, bulky adducts such as oxidation-induced endogenous lesions
and thymine dimers. Small mutations, insertions and deletions can be repaired by the
mismatch repair (MMR) pathway.
DSBs in DNA are repaired by one of four pathways (Fig. 7). The most frequently
used pathways are NHEJ and HDR. HDR, the most accurate form of DSB repair, uses
a template strand of DNA (such as from a sister chromatid in S-phase and G2) and
strand invasion to accurately replace the damaged DNA. NHEJ on the other hand does
not use a template strand for repair, and is capable of ligating blunt/near-blunt ends of
DNA together at the cost of accuracy (NHEJ can result in deletions, insertions, or even
chromosome fusions). The decision whether to use HDR or NHEJ is determined by cell
cycle stage and competing protein factors. The other two mechanisms for DSB repair are
microhomology-mediated end joining (MMEJ) and single-strand annealing (SSA), both
of which can occur at ssDNA overhangs and are relatively mutagenic.
The key controlling event that commits a cell to HDR instead of NHEJ is the resection of
the 3′ strand [65]. Once resection has been initiated the DNA end is no-longer an effective
substrate for the major NHEJ pathway proteins Ku70 and Ku80. The Ku complex and
MRN/CtIP compete for binding at DSBs. If MRN and CtIP bind without Ku they are
able to perform initial resection which is followed by extensive resection by EXO1 and
DNA2. Ku is a barrier to resection by EXO1 and DNA2 [66], but may be removed by
MRN-CtIP [67]. BRCA1 plays a major role in promoting HDR through the recruitment
of HDR factors to DSBs, competing with 53BP1 which recruits NHEJ factors [68][69].
Loss of either BRCA1 or 53BP1 effectively switches off their respective pathways, but
HDR can be restored in BRCA1-mutant cells through loss of 53BP1 [70].
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Homology Directed Repair















Figure 7. An overview of DSB repair pathways. When a DSB forms the most common
route of repair is NHEJ (I). Ku proteins rapidly localise to the break, then recruit other
NHEJ factors to process and re-ligate the blunt end. Particularly in S-phase or G2 the
cell may use HDR instead (II). For HDR to occur the DNA ends must be ssDNA
overhangs, typically produced by the activity of nucleases. These overhangs are used for
strand invasion into template DNA, and the template strand is copied to replace the
damaged DNA. How the strands are resolved affects whether permanent crossover of
DNA strands occurs. After end resection the two ends may be re-ligated by MMEJ (III)
or SSA (IV) instead of HDR. MMEJ uses 1-16 bp of homology to attach the ssDNA
strands, whilst SSA uses larger stretches of repetitive DNA. MMEJ and in particular
SSA result in significant deletions of DNA.
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1.4.1 Non-Homologous End Joining
The first step of NHEJ is the recognition of the DSB by the Ku70/Ku80 heterodimer [71],
which has a very high affinity to DNA ends. The heterodimer forms a ring-like structure
that slides onto the ends of the dsDNA [72], binding to the sugar backbone. The Ku
proteins act as a scaffold, recruiting other NHEJ factors including DNA-PKcs, XRCC4,
DNA ligase IV, XLF, and APLF [73–76]. DNA-PKcs is a phosphatidylinositol 3-kinase-
related kinase (PIKK) family protein, the kinase activity of which is activated upon its
localisation to DNA ends. XRCC4 acts as an additional scaffolding protein, recruiting
processing enzymes such as DNA polymerase-µ and the WRN helicase [77][78].
The Ku70/Ku80 heterodimer is responsible for more than just recruitment of other NHEJ
factors, it also protects the exposed DNA ends from non-specific processing. It has been
demonstrated that the Ku heterodimer can physically hold the two ends of a DSB together
[79]. DNA-PKcs and the XRCC4-XLF complex appear to also play a role in physically
bridging the two DNA ends [80][81].
The DNA ends must often be processed first before they can be ligated. This can include
resection, fill-in of DNA, and the removal of blocking end groups. PNKP is responsible
for the addition or removal of phosphate groups at the exposed backbone ends [82], and
Aprataxin removes adenylate groups from 5′ phosphate ends [83]. Artemis, WRN, and
APLF are responsible for the resection of DNA ends. Artemis has 5′ to 3′ exonucleolytic
and endonucleolytic activity that produces blunt duplex DNA [84]; WRN acts as a 3′ to
5′ exonuclease [85]; and APLF acts as an endonuclease and 3′ to 5′ exonuclease [86].
After the DNA ends have been processed, the final step is the ligation of DNA by DNA
ligase IV. XRCC4 stimulates DNA ligase IV, which can ligate incompatible DNA ends
and across gaps [87][88]. The release of DNA-PKcs is mediated by its autophosphoryla-
tion [89], but it is not known if it happens immediately before or after ligation. Once
ligation is complete the Ku70/Ku80 heterodimer is polyubiquitylated and degraded by
the proteasome [90].
Figure 8 . The Ku70/Ku80 complex rapidly recognises and binds to DSBs, recruiting
DNA-PKcs, other scaffolding proteins, processing factors, and DNA ligase IV. The DNA
ends are processed by nucleases or modified by kinases and phosphatases to prime them
for ligation. DNA ligase IV joins the blunt ends and DNA-PKcs dissociates from the
complex, followed by the remaining recruited NHEJ factors.
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1.4.2 Homology Directed Repair
Unlike NHEJ, HDR requires a 3′ ssDNA overhang. This overhang is generated by initial
resection of the 5′ strand of DNA by the MRN complex and CtIP [91], promoted by
BRCA1 [69]. Then further resection is performed by EXO1 or DNA2 [92] (Fig. 9).
The ssDNA overhang produced is coated by RPA, the key ssDNA sensing protein that
activates the ATR/ATM PIKK pathways.
RAD51 is a DNA-binding ATPase necessary for the next step of HDR that must replace
the RPA bound to the ssDNA overhang. This replacement of RPA with RAD51 is fa-
cilitated by BRCA2 in mammals and suppresses SSA [93][94][95]. The recruitment of
BRCA2 is promoted by BRCA1, but this role of BRCA1 does not appear to be essential
to HDR, unlike its role in initiating resection [96]. The RAD51 coated 3′ ssDNA filament
then undergoes strand invasion, invading the dsDNA of the template DNA (such as that
of the sister chromatid) forming a D-loop (Fig. 10).
New DNA synthesis occurs, using the undamaged second copy of the locus as a template
to replace the DNA that was damaged and resected. This invading DNA strand now has
a number of potential fates, resulting in crossovers and non-crossovers [97][98]. In mitotic
cells the BLM helicase and others function to resolve the strand invasion intermediates
without producing crossovers of DNA that result in large transfers of genetic material
from one chromatid to another [99]. A primary pathway of resolution that results in non-
crossover events in mitotic cells is dissociation of the newly extended 3′ overhang from the
D-loop and re-annealing with its original partner strand (Fig. 10a). If the D-loop captures
the second strand and forms a double-Holliday junction this can result in crossover events
(this process is biased towards crossover in meiosis) (Fig. 10b). However these double-
Holliday junctions can be resolved by BLM-mediated branch migration to be resolved
without a crossover (Fig. 10c). If the intermediate escapes BLM the intermediates may
also be targeted by other resolvases such as GEN1 which may or may not result in a
crossover (Fig. 10d). Once the strand invasion intermediate has been resolved HDR is
complete, having accurately repaired the DSB.
Figure 9 . Resection of DSBs for HDR. MRN is responsible for initiating resection of
DSBs and activating the ATM PIKK pathway. MRN-CtIP resection is followed by
further EXO1 or DNA2 resection, extensive RPA binding and activation of the ATR
PIKK pathway. ATM and ATR phosphorylate a wide spectrum of downstream
signalling proteins coordinating cell cycle arrest and apoptosis such as CHK1 and
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Figure 10. Resolution of HDR intermediates. (A) strand displacement and annealing
with the help of BLM is the simplest route of resolution and does not result in a
crossover. (B) Capture of the other strand end by the D-loop produces a
double-Holliday junction. In meiotic cells this is biased to resolve into a crossover. (C)
Branch migration by BLM allows double-Holliday junctions to be resolved by
topoisomerase without a crossover event. (D) The strand invasion intermediate escapes
BLM and is resolved randomly by other resolvases including GEN1. Figure adapted




The human PIKK family of kinases includes six proteins that play a vast range of signalling
roles within the cell. ATM and ATR play key signalling roles in the DDR, predominantly
activating in response to DSBs and ssDNA respectively. DNA-PKcs is important in
the orchestrating of NHEJ and immune system V(D)J recombination. SMG1 is part of
the NMD pathway of PTC detection and degradation of mRNA. mTOR controls the
translation machinery in response to nutrient and amino acid availability, whilst TRRAP
is an essential cofactor for c-MYC and the E2F transcription factor family pathways.
ATM, ATR, and DNA-PKcs play a crucial role in the cellular response to DNA dam-
age, coordinating DDR factors and cell-cycle arrest. Mutations in these pathways are
frequently associated with cancer.
ATM exists as a multimer until its autophosphorylation (at serine 1981 in humans) acti-
vates it and initiates disassociation of the homodimer [101]. ATM is recruited to DSBs by
the MRN complex [102]. ATM is then able to phosphorylate histone H2AX which recruits
ubiquitin ligases, facilitating chromatin changes that enable the assembly of large multi-
protein complexes [103]. ATM is responsible for the activation through phosphorylation
of HDR components such as CtIP which resect the DNA end. Following its activation,
ATM plays a major role in cell cycle regulation, particularly through the checkpoint kinase
CHK2 and p53 [104][105]. Activation of CHK2 induces phosphorylation and inhibition of
CDC25A, which is responsible for activating CDKs. Thus ATM activation induces cell
cycle arrest [106]. Failure to rapidly repair DNA results in the phosphorylation and sta-
bilisation of p53 (both directly by ATM and by CHK2) which upregulates transcription of
the CDK inhibitor p21. This typically results in persistent cell-cycle arrest and apoptosis.
ATR is involved in DSB repair, but is also crucial in the regulation of DNA replication in S-
phase, the primary activator of ATR being ssDNA [107]. The best characterised target of
ATR is CHK1, which is phosphorylated at serines 317 and 345 [108][109]. CHK1 regulates
replication integrity in S-phase [110], and plays a crucial role in the regulation of cell-
cycle progression. CHK1 slows progression through S-phase via CDC25 mediated CDK
inhibition, and also prevents cells from entering mitosis with damaged DNA. During HDR
a distinct switch from ATM to ATR activation occurs, as the blunt ATM-attracting end is
resected and replaced with an ATR-activating RPA-bound ssDNA overhang [111]. CHK1
initiates sequestration of CDC25C into the cytoplasm and the degradation of CDC25A,
which maintains inactive CDK1, resulting in G2/M arrest [112][113].
1.5 The Telomere
The linear nature of eukaryotic chromosomes comes at a cost. The natural breaks in
DNA at the end of these chromosomes would be indistinguishable from deleterious DNA
damage if it were not for an elaborate nucleoprotein complex that hides them from the
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DDR. This terminal DNA is the telomere and consists of many kilobases of TTAGGG
repeats in humans. At birth the human telomere averages 11 kilobases [114], but this can
be reduced to less than 4 kilobases in the elderly [115].
The telomere consists of double stranded DNA that ends with a G-rich, 3’ ssDNA overhang
of 35 to 600 nucleotides in length [116]. This ssDNA is looped back and invades the
upstream telomeric dsDNA, forming a structure called the T-Loop [117] (Fig. 11). This
structure, combined with the specialist telomere capping complexes Shelterin and CST
[118][119], serves to effectively hide the end of the telomere from DDR factors.
The telomere also solves an additional problem; the standard DNA replication machinery
is incapable of fully replicating the very end of the chromosome. As the replisome moves
along the chromosome, the replication fork consists of a leading and lagging strand. The
lagging strand is built out of short stretches of DNA called Okazaki fragments [120], but
this process is unable to extend to the very end of the chromosome. As such the last
few bases of DNA for this strand are not replicated. Telomeres solve this issue in two
ways. The first is that they provide a buffer of non-coding DNA that can be eroded
without compromising any genetic information, and the second is providing a substrate
for telomerase, a protein that is able to extend the telomeric overhang [118].
Shelterin is a six-subunit complex that binds both dsDNA and ssDNA at the telomere
[118]. The members of the Shelterin complex are also able to function as smaller subsets
that bind either ssDNA or dsDNA, but together bridge the ds-ssDNA junction and sup-
press activation of the DDR. They are thought to do this by suppressing RPA binding
to ssDNA (and therefore activating the ATR DDR pathway) [121], and assisting in the
formation of the T-Loop structure [122][123] (which inhibits end recognition by the MRN
complex and activation of the ATM DDR pathway [124]). Inappropriate targeting of
the telomere by the DDR can result in cell cycle arrest [125], telomere degradation and
even fusions [126] which have a catastrophic effect following replication. Shelterin is also
responsible for recruiting telomerase to the telomere, thereby promoting extension of the
3’ overhang [127].
The second telomeric complex is the CST complex. Comprising the 3 proteins CTC1,
STN1 and TEN1 in mammals [119], the CST complex’s role is assisting in the replica-
tion of both the telomere and telomere-like regions of the genome. STN1 and TEN1 are
highly conserved between humans and S. cerevisiae, together forming an RPA-like struc-
ture with multiple oligonucleotide/oligosaccharide binding (OB) folds [128]. CTC1 on
the other hand shares little to no sequence homology with its budding yeast homologue











Figure 11. The structure of human telomeric DNA. (A) Human telomeres consist of
TTAGGG repeats for multiple kilobases. The majority of the telomere is duplex DNA,
but it terminates in an overhang of 3′ G-rich ssDNA. (B) The ssDNA overhang loops
back and re-enters the upstream duplex DNA by strand invasion. The bubble of DNA
at the site of strand invasion is referred to as the D-Loop, whilst the overall structure is


































Figure 12. The structure of the Shelterin complex. (A) The subunits of the Shelterin
complex; TRF1 and TRF2 interact with dsDNA whilst POT1 interacts with ssDNA.
(B) The interaction of Shelterin complexes with a linear telomere. (C) The interaction
of Shelterin with the T-loop and D-loop telomere structures. Figure adapted from de
Lange (2018) [129].
25
1.5.1 Semiconservative Telomere Replication
Whilst budding and fission yeast telomere replication is initiated late in S-phase [130], the
majority of telomeres in mammalian cells are replicated throughout S-phase [131]. Timing
of replication origin firing and replication stress-inducing obstacles both affect telomere
length homeostasis [132][133]. Telomere replication typically occurs unidirectionally, mov-
ing away from the centromere and towards the end of the chromosome [134]. Telomeric
DNA poses a challenge to the replication machinery, behaving like fragile sites that are
prone to fork stalling and collapse [135]. Factors that inhibit replication fork progression
at the telomere include secondary structures of G-rich DNA called G-quadruplexes; R-loop
DNA-RNA hybrids; T-loop structures; and telomere compaction/topological restrictions
[136–139].
Stabilised by a monovalent cation, four guanines associating through Hoogsteen bonds can
form a planar G-quartet. G-quartets can stack and form a G-quadruplex structure. The
replication or transcription of G-rich loci can be inhibited by the ssDNA forming these
structures. At the telomere G-quadruplexes present a barrier to both replication forks
and telomerase, inhibiting the replication of the telomere [140]. It has been suggested that
G-quadruplexes may also act to protect the ssDNA overhang from deleterious processing
[141]. Unwinding of these G-quadruplex structures is performed by the RecQ family of
helicases, as well as the RecQ-like WRN and BLM helicases [142][143]. Cells lacking
WRN lose G-rich telomere strands [144], and BLM knockout induces the fragile telomere
phenotype [135]. The RTEL1 helicase resolves G-quadruplexes and interacts with PCNA,
and its knockout induces fragile telomeres. It is therefore believed that RTEL1 is recruited
to the replisome to aid the replication of the telomere [145].
T-loops are formed when the 3′ ssDNA overhang invades the upstream dsDNA of the
telomere, resulting in a closed circle. T-loops are an important part of protecting the end
of the chromosome but also present an obstacle for replication forks. Therefore T-loops
must be disassembled in order for the telomere to be replicated. The RTEL1 helicase
is involved in this process [138], mediated through interaction with TRF2 [146]. In the
absence of RTEL1 T-loops are resolved by the SLX1-SLX4 nuclease which results in the
excision of the T-loop from the telomere and the production of free circularized telomeric
DNA called a T-circle [138]. In vitro evidence suggests D-loop (and therefore T-loop)
disassembly might also be performed by other RecQ and RecQ-like helicases [147][148].
In many eukaryotes, including humans, telomeric DNA is transcribed to produce telomeric-
repeat-containing RNA (TERRA) [149]. These RNA molecules are capable of annealing
to their genomic template and forming DNA-RNA hybrids called R-loops [150]. R-loops
themselves are a barrier to replication fork progression, but additionally the displaced
ssDNA (if it is the G-rich strand) is capable of forming G-quadruplexes. RnaseH1 is the
major enzyme involved in R-loop resolution, degrading the RNA molecule [151]. Other
proteins associated with R-loop suppression are the chromatin remodeler ATRX, UPF1,
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and the helicase PIF1 [149][152][153].
One way that shelterin acts to protect the telomere is through mediating telomere com-
paction and topology, forming compact globular chromatin structures that occlude mem-
bers of the DDR [154][155]. Furthermore, human telomeres are anchored to the nuclear
matrix through shelterin and lamins [156]. This compaction and anchoring by shelterin
acts as a barrier to replication. Conversely, shelterin component TRF2 (along with the
5′-exonuclease Apollo and Topoisomerase 2α) is necessary for the removal of superheli-
cal/topological constraints and allowing decompaction [139].
1.5.2 Telomerase
The bulk of the telomere is replicated semiconservatively by the canonical replication
machinery. As this machinery is incapable of replicating the very end of the lagging strand,
telomeres would progressively shorten with each cell cycle. Telomerase is a specialised
polymerase that overcomes the end replication problem by adding TTAGGG repeats to
the end of the 3′ overhang [157].
Telomerase activity was first discovered in 1985 in T. thermophila [158] before being
identified in the human HeLa cell-line [157]. Outside of cancers human telomerase activity
is widespread only in early development, largely limited to embryonic stem cells [159]. The
reactivation of telomerase is a requirement of most human tumourigenesis [160]. Without
telomerase activity the cancerous cells’ telomeres would progressively shorten with each
cell division, eventually inducing an anti-proliferative signal.
Human telomerase is a ribonucleoprotein, comprising a catalytic core of the reverse-
transcriptase component TERT and an RNA primer component TERC. Catalytically
active telomerase in humans exists as a dimer, with two copies of TERT, TERC, and
Dyskerin [161].
1.5.3 Alternative Lengthening of The Telomere
Tumourigenesis requires the bypass of the Hayflick limit, a limit on the number of divisions
a cell can go through before becoming senescent due to the progressive shortening of
telomeres. In approximately 90% of cancers this bypass is achieved by the reactivation
of telomerase [162]. The remaining minority (but still a substantial number) of cancers
must use a different method of telomere extension, referred to as alternative lengthening
of telomeres (ALT) [163].
ALT appears to be facilitated by homologous recombination between telomeres. The first
direct evidence for homologous recombination of telomeres in ALT cells was the copying
of a neomycin resistance marker from one telomere into others in an ALT cell line [164].
Such behaviour is not seen in non-ALT cells. ALT cells exhibit an abundance of C-
circles (C-rich T-circles), suggesting increased intra-telomeric recombination events [165].
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Whilst ALT cells exhibit increased homologous recombination events at the telomere,
there appears to be no effect on general homologous recombination throughout the rest
of the genome, suggesting the pathway is telomere-specific [166].
Recent evidence suggests there are two break-induced repair (BIR) ALT pathways, one
RAD52-dependent, and one RAD52-independent but requiring BLM and BIR proteins
POLD3 and POLD4 [167]. BIR repair at telomeres requires a ssDNA end to invade and
capture template telomeric DNA, RAD52 appears important for facilitating this annealing
of ssDNA in the presence of RPA. This differs from RAD51 which is known to promote
D-loop formation but requires the presence of BRCA2 to overcome RPA [168] [169]. How
the RAD52-independent pathway operates is less clear, but it is this pathway that is
responsible for C-circle formation in ALT cells [167].
1.6 The CST Complex
The telomeres of higher order eukaryotes are protected from the DDR by the six-protein
complex Shelterin. The telomeres of the fission yeast S. pombe are protected by a
Shelterin-like complex, but the telomeres of the budding yeast S. cerevisiae are capped
by the trimeric RPA-like CST complex (comprising Cdc13, Stn1, and Ten1). Shelterin
and CST were believed to be mutually exclusive systems, until the homologues of the
budding yeast CST complex were discovered in plants and mammals in 2009; Arabidop-
sis first then mammals including mice and humans [128][119]. Whilst the budding yeast
CST complex plays a dual role in telomere protection and replication [170], it appears
the Shelterin complex in humans is largely responsible for the exclusion of DDR factors,
whilst the CST complex is concerned with telomere replication and regulation.
Mammalian and plant STN1 and TEN1 share sequence homology with their budding yeast
orthologues. A potential Arabidopsis STN1 orthologue was identified bioinformatically,
then confirmed by in vitro studies of STN1 knockouts. ArTEN1 was soon afterwards
identified based on sequence homology. CTC1 shares no sequence homology with Cdc13,
but was identified in Arabidopsis in 2009 in a genetic screen for telomere defects. Struc-
tural predictions suggested CTC1 formed multiple OB folds homologous to RPA70. The
sequence of ArCTC1 was then used in database searches to find the vertebrate homologue
[119]. Since its discovery the human CST complex has been shown to regulate the ssDNA
overhang of the telomere [171][172]; support the replication of the telomere and telomere-
like DNA throughout the genome [173][174]; and promote ssDNA overhang fill-in at DSBs
[175]. Mutations in CST complex components are associated with Coats Plus syndrome
[176][177].
1.6.1 The Roles of The Human CST Complex in DNA Replication
Throughout our lifespan the telomeres in our somatic cells shorten. This is due to the
end replication problem, the lagging strand during DNA replication cannot be replicated
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to the very end by the replisome. The lagging strand is replicated in short fragments that
are primed by polymerase-α primase, but the last stretch of DNA cannot be replicated as
there is no more upstream DNA for the primer to bind to. Telomeres are allowed to erode
with each cell division, and when they become critically short the cell becomes senescent
and ceases dividing, contributing to the ageing process. By enforcing a replicative limit on
cells the organism as a whole is protected from cancerous over-proliferation. As previously
discussed, this telomere erosion is avoided in stem cells and the germline by the action of
telomerase, a DNA polymerase that extends the 3′ G-rich ssDNA overhang [178][179]. In
human somatic cells TERT is expressed at very low levels, if at all [180].
The activity of telomerase is not completely unchecked in cells with telomerase expression,
the extension of the overhang must be appropriate to allow continuous proliferation,
but not generate excessive ssDNA that might erroneously attract DDR factors such as
RPA. Processive extension of the 3′ overhang of the telomere by telomerase is enabled
by the Shelterin components POT1 and TPP1. POT1-TPP1 slows telomerase primer
dissociation and promotes translocation on the polymerase [127][181]. The CST complex
restricts telomerase-mediated telomere extension to a single extension event [171]. CST
appears to bind to newly extended ssDNA and block the interaction of POT1-TPP1 with
telomerase (Fig. 13a).
The CST complex also limits the length of the 3′ ssDNA overhang by promoting the exten-
sion of the C-rich strand [182]. This contributes to the overall extension of the telomere,
whilst minimising the amount of ssDNA exposed to DDR factors. Before CTC1 was iden-
tified as the third member of the human CST complex it was identified as a protein that
interacted and precipitated with polymerase-α-primase [183][119]. It is therefore hypoth-
esised that the CST complex promotes the 5′ to 3′ polymerase activity of Polymerase-α
through direct interaction with the primase (Fig. 13a).
The CST complex promotes progression of replication forks through the telomere, but
also plays a role in replication outside the telomere [173]. CST has been shown to rescue
GC-rich stalled forks in situations of replication stress, and is suggested to facilitate
the firing of new origins of replication [184]. CST recruits RAD51 to GC-rich stalled
forks in an ATR dependant manner [185], which protects ssDNA at stalled forks from
nuclease activity [186]. It is unclear if the restart of stalled forks is in part due to the
interaction between CST and Pol-α-primase; Pol-α is an important part of the replisome
but proteomics studies indicate Pol-α is not enriched at stalled forks [187]. As the CST
complex binds G-rich ssDNA that is prone to forming secondary structures such as G-
quadruplexes, it has been suggested that the CST complex might resolve (or inhibit)
secondary structures that can block replication [185].
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Figure 13. The CST complex regulates telomere ssDNA overhang length and promotes
replication restart at stalled telomeric forks. (A) CTC1 interacts directly with
Polymerase-α primase to promote its activity at the telomere. Polymerase-α fills-in the
C-strand, extending the duplex DNA and shortening the ssDNA overhang. The CST
complex also inhibits the action of telomerase on the G-rich strand beyond a single cycle
of extension, preventing the build up of a long ssDNA overhang. (B) The CST complex
binds to telomeric and telomere-like (GC-rich) ssDNA at stalled replication forks,
possibly resolving secondary structures. By binding to the stalled fork the CST complex
recruits RAD51, necessary for the restart of replication.
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1.6.2 The Influence of The CST Complex on Double Strand Break Repair
Loss of BRCA1 function is common in many cancers, as it effectively eliminates the
accurate HDR DSB repair pathway, forcing the cell to use the error-prone NHEJ pathway.
Loss of BRCA1 results in unimpeded 53BP1 binding to DSBs, resulting in the recruitment
of NHEJ factors and the exclusion of nucleases necessary to initiate resection and HDR
[68–70]. BRCA1 deficient cancers are frequently treated with PARP inhibitors. PARP is
necessary for the repair of single-strand breaks (SSBs) by BER, therefore PARP inhibition
induces many DSBs within the cell as ssDNA breaks are not repaired and become DSBs
at replication forks. BRCA1-proficient non-cancer cells are able to use the accurate HDR
to repair these breaks, but BRCA1 deficient cells are not able to do so. PARP inhibitor-
treated BRCA1-deficient cancer cells therefore experience targeted lethality as (unlike
non-cancerous cells in the body) they are either unable to repair the damage at all, or
rely on extensive error-prone NHEJ and the mutagenesis of the NHEJ pathway eventually
triggers apoptosis.
Some BRCA1-deficient cells gain resistance to PARP inhibitors through the reactivation
of the HDR pathway. This can be achieved by loss of NHEJ promoting factors such
as 53BP1 [188]. ssDNA overhangs are once again able to be produced and maintained,
providing a substrate necessary for HDR. Recently, loss of CST complex members CTC1
or STN1 were identified in a CRISPR/Cas9 knockout screen as conveying PARP inhibitor
resistance in BRCA1-deficient cancers [175]. This resistance involved the rescue of the
resection defect of the BRCA1-deficient cells, therefore allowing them to perform HDR.
It has since been shown that CST-Pol-α recruitment to resected DSBs is performed by
the 53BP1-RIF1-Shieldin complex [189]. CST promotes the activity of Pol-α, filling-in
resected DNA and eliminating the ssDNA overhang.
PARP inhibitor sensitivity of BRCA1-deficient cells therefore relies on the CST complex
to fill-in resected DSBs and block HDR (Fig. 14II). When the CST complex is lost in
BRCA1 deficient cells this fill in does not occur and the overhang persists, enabling HDR.
The role of the CST complex in DSB fill-in has been hypothesised to exist in order to
limit excessive hyper-resection, which can promote the mutagenic SSA pathway of DSB
repair (Fig. 14I) [175].
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Figure 14. The CST complex promotes fill-in at DSBs. DSBs in DNA can be repaired by a variety of pathways, HDR requires the generation
of ssDNA overhangs in order to use strand invasion to generate a Holliday junction. NHEJ does not require an overhang, acting on blunt (or
near-blunt) ends. The CST complex is recruited to DSB overhangs by 53BP1/Shieldin/RIF1 and promotes the activity of Pol-α. (I) This
fill-in is hypothesised to prevent hyper-resection inducing erroneous SSA which can be highly mutagenic. (II) In BRCA1 deficient cancers the
CST complex is proposed to inhibit HDR by reducing/eliminating the ssDNA overhang. This HDR inhibition could result in misrepair of the
DSB.
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1.7 Transcription and Translation
The cell cycle, telomeres, and the DNA damage response are parts of a complex system
that serves a basic purpose: the accurate transmission of genetic information in the form
of DNA from one generation to the next. The central dogma of molecular biology is that
DNA is transcribed to make RNA, and RNA is translated to make proteins. RNA poly-
merases in the nucleus ’read’ the locus of DNA containing a gene to produce pre-mRNA.
Pre-mRNA is processed in various ways, after which the finished product (mRNA) leaves
the nucleus and is read by the ribosome. The ribosome uses the mRNA as instructions
for assembling individual amino acids to form polypeptides. The polypeptide chains fold
to form secondary and tertiary structures, and functional proteins.
Not all RNA produced is mRNA that is read to produce a protein. These non-coding
RNAs can have specialised functions such as TERC, the RNA component of telomerase,
or transfer RNA (tRNA) which is involved in the translation process at the ribosome.
1.7.1 Transcription
Pre-mRNA, the RNA required for protein production, is synthesised by the polymerase
RNA Polymerase II [190]. Transcription is initiated at the promoter of a gene, a specialised
region of DNA upstream of the coding sequence which attracts and assembles the RNA
polymerase enzyme and transcription factors [191].
The transcription machinery is assembled at the promoter, starting with the TFIID tran-
scription factor (Fig. 15). TFIID comprises TBP and TBP-associated factors [192].
TFIIB is responsible for locating the start of the gene, which binds then undergoes a
conformational change with TFIID. The result is the bending of the DNA double-helix,
initiating melting (separating hydrogen bonds between strands) and exposing ssDNA
[193]. Once this happens TFIIF and RNA Pol II are recruited, forming the pre-initiation
complex (PIC) [194]. The final step is the recruitment of TFIIE and TFIIF to complete
the transcription initiation complex [190].
Phosphorylation of the CTD of RNA Pol II initiates transcription, at which point most
transcription factors can dissociate. The RNA polymerase travels along the template
strand in the 3′ to 5′ direction, assembling an RNA copy of the opposite ’coding’ strand
[195][196]. RNA is built using 3 of the 4 bases that DNA uses, A, C, and G, but RNA
uses U (uracil) instead of T (thymidine). RNA nucleotides bind to the template strand by
hydrogen bonding. The sugar phosphate backbone is connected to that of the proceeding
nucleotide (by the RNA Pol II subunit RBP1) and the newly assembled nucleotide is
released from the template DNA, now part of the mRNA strand [190]. At the start of
transcription a methyl-cap is added at the 5′ end of the pre-mRNA molecule. This is
performed by a triphosphatase, a guanyl transferase, and a methyl transferase, which add
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Figure 15. Recruitment of RNA polymerase II and transcription initiation.
Transcription factors TFIID and TFIIB bind to the promoter region of a gene and
recruit TFIIF-bound RNA Pol II to form the Pre-Inititation Complex. Transcription is
initiated after the binding of TFIIE and TFIIH (forming the Transcription Initiation
Complex), and the phosphorylation of the RNA Pol II C-terminal domain (CTD).
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Transcription continues beyond the promoter region, through the body of the gene. The
elongation stage of transcription is regulated by elongation factors and chromatin remod-
elling complexes [198]. The transcriptome continues partially past the end of the coding
region of the gene before terminating. Multiple adenines are added to the 3′ end of the
pre-RNA molecule to prevent degradation, after which it is released. The transcriptome
dissociates from DNA, allowing the ssDNA bubble to close [199][200].
1.7.2 RNA Processing
Addition of the 5′ methyl cap and the 3′ Poly-(A) tail is not the only processing that
RNA goes through before translation. The genes of higher level eukaryotes are typically
split into introns and exons [201]. Introns are non-coding sequences that must be removed
from mRNA before it can be translated, whilst exons are the coding sequences of DNA
that are translated. Introns are removed by a process called splicing. Not all exons are
necessarily included in the final RNA product, some can be removed during the splicing
process to produce variations in protein functionality (Fig. 16). The range of different
mRNA products that originated from one gene are called splice variants. Alternative
splicing is thought to happen to 95-100% of human genes [202]. The mRNA splicing
process appears to generally occur co-transcriptionally. Assembly of the spliceosome at
an exon-intron junction can start before the downstream intron has even finished being
transcribed [203].
Alternative splicing patterns fall within one of five categories: (1) cassette exons, which
may be either selected or skipped; (2) mutually exclusive exons; (3) intron retention; (4)
alternative donor, and (5) acceptor sites which alter the length of exons [204]. Recognition
of splice sites is regulated by sequences that enhance or suppress splicing, present within
both exons and introns [205].
The spliceosome is a multiprotein complex that cleaves RNA at intron-exon boundaries
and ligates two exons. The spliceosome comprises five small nuclear ribonucleoprotein
(snRNP)s (U1, U2, U4, U5 and U6) and over one hundred different polypeptides [206]
(Fig. 17). The spliceosome is thought to assemble at recognised splice sites, remove
the RNA sequence between two exons by a double-cleavage process, ligate the ends of
two exons together, then largely dissociate as many components are recycled for another
splicing event elsewhere [207]. After splicing completes the EJC (comprising eIF4A-III,
MAGOH, and RBM8A) binds to each exon-exon junction site [208].
35




Exon 2 Exon 3
Intron
DNA
Exon 1 Exon 2 Exon 3Pre-mRNA
5’ UTR 3’UTR
M7G AAAAAAA
Exon 1 Exon 2 Exon 3
M7G AAAAAAA







5’ methyl cap Poly-(A) tail
Figure 16. Alternate splicing of pre-mRNA. Pre-mRNA is produced by the transcription
of a gene locus. The pre-mRNA contains an untranslated region (UTR) at both ends, a
methyl-cap at the 5′ end and a Poly-(A) tail at the 3′ end. Different combinations of
introns and exons can be removed from one pre-mRNA to produce multiple mRNAs
that code for different proteins by a process called alternate splicing. Once splicing is









































Figure 17. The splicing process. Introns (and some exons) are removed from pre-mRNA
by splicing. The U1, U2, U4, U5 and U6 snRNPs recognise 5′ and 3′ splice sites and
mediate the 2-step excision of introns from mRNA, before being released and recycled.
After splicing occurs the EJC binds to the sequence of exon-exon junction. Figure
adapted from Lee and Rio (2015) [207].
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1.7.3 Translation
mRNA is exported from the nucleus to be translated into proteins. RNA codons are
decoded into amino acid chains using tRNAs. Codons of three bases redundantly code
for one of the twenty amino acids used in protein synthesis. For example AUG (ATG
on DNA) codes for a methionine, whilst AGU codes for serine but so does AGC. tRNAs
specifically bind to amino acids and act as carriers, bringing amino acids to the translation
machinery for polypeptide synthesis. This is performed at the endoplasmic reticulum
by the ribosome. The eukaryotic ribosome comprises four ribosomal RNAs (rRNAs)
and approximately 80 proteins. The ribosome has two major subunits, the 60S (large)
subunit is made of rRNAs 28S, 5.8S and 5S plus 49 proteins, whilst the 40S (small)
subunit comprises 18S rRNA and 33 proteins [209–211].
The mRNA molecule is bound by the ribosome and read. When the ribosome reaches a
’start’ codon (which codes for a methionine) it can begin translation. A start codon is
necessary but not sufficient for translation initiation. Likelihood of translation initiation in
eukaryotes is determined by the similarity of start-adjacent bases to the Kozak consensus
sequence ((gcc)gccRccAUGG) [212]. Translation is initiated with a methionine-bound
tRNA, the next mRNA codon is read and a tRNA carrying the appropriate amino acid
brought into proximity with the methionine. A peptide bond is created between the
two amino acids [213]. The mRNA is moved through the ribosome which progressively
assembles the protein polypeptide. The polypeptide folds to produce the secondary and
tertiary structures of the final protein, and the ribosome has been shown to participate
in the folding process [214]. When the ribosome reaches a stop codon (TAA, TAG, or
TGA) translation is terminated and the polypeptide released. The ribosome components
may then disengage the mRNA molecule and re-enter the pool for use on a new mRNA,
but in some cases ribosome components continue scanning along the mRNA and are able
to re-initiate translation at a second start codon downstream [215]. This re-initiation
of translation is necessary for mRNAs with open reading frame (ORF)s in the 5′ UTR,
upstream of the main gene reading frame.
1.8 Nonsense Mediated Decay
1.8.1 Detection of Premature Termination Codons
Mutation of a gene that changes a non-stop codon to a stop codon terminates translation
prematurely and produces truncated proteins (Fig. 18b). Mutations that insert or delete
bases frequently introduce a premature termination codon as they shift the reading frame,
changing how all downstream codons are read. The truncated protein may be unable to
perform the necessary functions of the wild-type protein. Furthermore, the mutant protein
product may be a dominant negative, interfering with the function of the remaining wild-
type allele. Therefore stopping the mRNA from being translated is often a better option
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Figure 18. mRNA Open Reading Frames. (A) A typical mRNA transcript with a single
ORF which encodes the gene. (B) A mutant mRNA transcript with a PTC. (C) An
mRNA transcript with a upstream open reading frame (uORF) that starts and ends in
the 5′ UTR. (D) An mRNA transcript with a uORF that starts in the 5′ UTR and
partially overlaps with the main ORF, terminating at a stop codon within (but out of
frame with) the main ORF.
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for the cell than allowing a truncated version of the protein to be synthesised.
The machinery used to detect and eliminate mRNA with these PTCs is NMD. In mammals
NMD is largely linked to premRNA splicing and translation, with detection of stop codons
more than 50-55 nucleotides upstream of the final EJC inducing mRNA degradation
[216][217]. In contrast budding yeast NMD is exon-junction independent, with PTC
definition based on distance from the 3′ end [218]. The EJC remains associated with
mRNA until it is displaced by the translation machinery [219].
The central component of the NMD pathway is UPF1, an RNA helicase. Prevailing
models of NMD propose the recruitment of UPF1 and the PIKK SMG1 to the terminating
ribosome by interaction with the stop codon marker eRF3 [220][221]. Phosphorylation of
UPF1 is performed by SMG1 upon interaction of UPF1 with a downstream EJC-bound
UPF2 and UPF3b [222] [223]. This phosphorylation of UPF1 activates the NMD complex
of UPF1, UPF2 and UPF3b, translocating it from the 5′ end of the EJC to the 3′ end.
Subsequent to this translocation the NMD complex interacts with and activates SMG5,
SMG6, and SMG7. SMG6 is an endonuclease that cleaves the mRNA whilst SMG5 and
SMG7 catalyse the de-capping and de-adenylation of the mRNA leaving it exposed to the
action of exonucleases [224–226]. Consequently the mRNA containing a PTC is degraded
after a single round of translation.
It should be noted that stop codon distance from the poly-(A) tail can sometimes also
function as an alternative activator of NMD in mammalian cells. This is thought to be
due to the lack of interaction between the terminating ribosome and PABPC1 which is
bound to the tail. If PABPC1 does not interact with eRF3 at the ribosome then the
terminating ribosome will stall, allowing activation of UPF1 [227].
Figure 19 . EJC-dependant degradation of mRNA with PTCs by NMD. (A) On a
normal transcript the ribosome begins translation at the start codon of an mRNA, then
moves along the mRNA producing a polypeptide chain and displacing EJCs. When the
ribosome reaches the stop codon translation is terminated and the ribosome displaced.
(B) If an mRNA contains a PTC upstream of an EJC then NMD is activated. UPF1
interacts with stop-codon-bound ribosomes, and when UPF1 is brought into proximity
and interacts with EJC-bound UPF2 and UPF3b it is phosphorylated by SMG1.
Phosphorylation of UPF1 results in SMG5, SMG6 and SMG7 activation. SMG6 is an
endonuclease that acts on the mRNA, whilst SMG5-SMG7 initiates deadenylation and








































1.8.2 Open Reading Frames and Nonsense Mediated Decay
Whilst NMD primarily targets deleterious mutation-induced PTCs in mRNA, it also
targets some natural transcripts, affecting approximately 10% of the budding yeast tran-
scriptome [228]. It remains unclear why the cell regulates some genes through the NMD
pathway, but key features in mRNA that can attract the action of NMD are well charac-
terised.
Whilst the role of EJC location plays a major role in the direction of NMD, the mammalian
NMD pathway can also use distance from the poly-(A) tail as an indicator of a PTC.
Some wild-type mRNAs with long 3′ UTRs are consequently also degraded by NMD
[218]. Another feature of an mRNA that can activate NMD is an overlapping-uORF.
Some transcripts contain ORFs that start before the main gene-coding ORF and do not
code for a functional protein. These uORFs can terminate upstream or downstream of the
gene’s true AUG start codon (Fig. 18c,d). uORFs that overlap with the main ORF are
referred to as overlapping-uORFs. If translation is initiated on the uORF then logically it
will be terminated at the uORF’s stop codon. This termination site will typically be far
from the 3′ UTR/poly-(A) tail of the mRNA and upstream of many EJCs, both of which
are factors that promote degradation by NMD. Examples of human genes with uORFs
that trigger NMD include CFTR and SMG5 [229][230].
NMD affects Stn1 levels in S. cerevisiae because of the uORF that overlaps with the main
STN1 ORF [231]. Budding yeast STN1 mRNA also has a second uORF that does not
overlap with the main ORF, but loss of this uORF did not increase Stn1 levels when
removed [231]. The overlapping uORF introduces a stop codon within the body of the
gene just two nucleotides after the main ORF start codon, this close proximity of the over-
lapping uORF codon to the main STN1 start codon is key to the suppression of STN1,
as extension of the overlapping uORF further into the gene (moving the stop codon 72
amino acids downstream) increased STN1 mRNA and protein levels. This raised expres-
sion was not increased further after NMD inactivation [231]. This suggests that NMD in
budding yeast affects STN1 mRNA and protein levels due to the close proximity of an
overlapping uORF stop codon to the STN1 start codon. The human STN1 homologue
mRNA contains three overlapping uORFs, in frame with each other, terminating at a
stop codon that overlaps the STN1 start codon (Fig. 20). The similar presence of uORFs
suggests regulation of STN1 by NMD is possible. Data published by Torrance and Lydall
using part of the 5′ UTR of human STN1 in a luciferase expression assay indicate that the
sequence was capable of suppressing downstream protein expression [231], however this
only included two of the three uORFs in reported STN1 mRNA transcripts. It remains
unknown if NMD targets endogenous STN1 transcripts in human cells.
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Figure 20. The uORFS of human STN1 . STN1 mRNA has 3 overlapping-uORFs. All
three are in frame and terminate at a stop codon that overlaps the start codon of the
main gene ORF. Figure adapted from Torrance and Lydall (2018) [231].
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1.8.3 The Regulation of NMD
NMD activity varies between cell types and tissues [221]. Cellular levels of EJC peripheral
factor RNPS1 have been correlated with NMD activity [232]. NMD targets a number of
components of the NMD pathway itself, thus acting as a negative feedback loop regulating
its own activity [233].
In response to stress the cell activates a wide range of pathways that make large changes
to gene expression in an attempt to alleviate that stress. In a number of stress conditions
such as hypoxia or nutrient deprivation NMD is downregulated [234]. This reduction
in NMD, which is at least partially due to phosphorylation of eIF2-alpha, raises the
expression level of NMD targets and helps to support the stress response [235][236]. It
was recently reported that cells arrested in G0 that have persistent DNA damage (damage




The principle hypothesis of this project is that the CST complex (and its appropriate
regulation) is essential for maintaining genomic stability beyond the telomere. The CST
complex was, until 2009, believed to be budding yeast specific, with vertebrates dependant
on the Shelterin complex for telomere capping and regulation. The telomere-specific role of
the CST complex in S. cerevisiae has been well established, controlling ssDNA overhang
length and protecting the telomere from the DDR. Since its discovery the mammalian
CST complex has been shown to not only play a role in telomere regulation, but to
also support replication throughout the genome and promote polymerase-α activity at
DSBs. Interestingly the reported effects of CST complex component knock-down vary
significantly depending on the degree to which expression was inhibited, implying tight
regulation of CST component levels is very important. This project focusses on the role
CST complex components play in maintaining genome stability beyond their roles at the
telomere, and how levels of those components are regulated.
Specific aims include:
1) Establish the CTC1 lox/lox HCT116 cell line in our lab as a model system, and confirm
the reported effect of CTC1 loss on telomere regulation.
2) Examine the impact of CTC1 loss on genome stability that is separate from its role at
the telomere.
3) Investigate the regulation of STN1 levels and the impact loss of regulation has on the
cell, particularly on the response to DNA damage.
4) Perform preliminary experiments to determine if an essential telomeric role for Dna2
is conserved from S. cerevisiae to metazoans.
The hallmark of cancer is an increase in cellular proliferation, usually fueled by an increase
in mutagenesis and genomic instability. Through its role at the telomere and at DSBs the
CST complex can directly affect both proliferation and genome stability. It is becoming
more and more likely that the CST complex could play a significant role in a range of
disease pathogenesis beyond Coats Plus syndrome, including ageing related diseases and
cancer. Furthering our understanding of the role and regulation of the CST complex may
ultimately result in improved disease prognosis and treatment.
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3 Materials and Methods
3.1 Mammalian Cell Culture
3.1.1 Cell Lines
HCT116
The predominant cell line used in experiments was HCT116. HCT116 cells are near
diploid, with polyploids reported at a frequency of 6.8% . The HCT116 cell line was
derived from an adult male colorectal carcinoma [238].
Three variations of the HCT116 cell line were used during this project, each provided by
the lab of Carolyn Price (University of Cincinnati):
• CTC1 lox/lox HCT116 cells containing loxP sites flanking exon 5 of CTC1, as well as
a Cre-recombinase expression cassette (which also conveys resistance to puromycin).
Exposure of this cell line to tamoxifen induces deletion of CTC1 exon 5 and the
subsequent knockout of CTC1 [182].
• The above CTC1 lox/lox Cre-recombinase HCT116 cells that also contain a CTC1
expression cassette that constitutively expresses CTC1 even after knockout of en-
dogenous CTC1 by tamoxifen exposure.
• HCT116 cells that do not induce CTC1 deletion upon exposure to tamoxifen.
U-2 OS
U-2 OS cells are a highly altered hypertriploid adherent human cell line derived in 1964
from a sarcoma of the tibia of a 15-year-old girl. The cell population typically contains
chromosomal rearrangements involving chromosomes 1, 7, 9 and 11 [239]. This cell line
was used as it is highly transfectable and sensitive to the NMD inhibitor NMDI14.
RPE-1
RPE-1 cells are the only non-cancer derived cell line used, they are derived from human
retinal epithelial cells that have been immortalised with exogenous hTERT expression
[240]. These cells were selected for use in experiments requiring non-cycling cells as there
is a strong growth inhibition when these cells are confluent in culture [237].
3.1.2 Cell Culture Conditions
HCT116 cells were cultured in McCoy’s 5A medium with L-Glutamine (Lonza: BE12-
688F) supplemented with 10% sterile-filtered foetal bovine serum (FBS) (Gibco: 10270),
Penicillin, Streptomycin, and L-Glutamine (Corning: 30-006-Cl). Cells were kept in a
humidified incubator at 37oC with 5% CO2.
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U-2 OS and RPE-1 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
with 4.5g/L Glucose and with L-Glutamine (Lonza: 12-604F), but otherwise grown in the
same conditions as HCT116 cells.
For passage, cells were washed with calcium/magnesium-free Dulbecco’s phosphate buffered
saline (DPBS) (Lonza: BE17-512F) and dissociated from the culture vessel by incuba-
tion with Trypsin-Versene (Lonza BE02-007E) (made up from 10X in DPBS) at 37oC for
5-10 minutes. Trypsin was inactivated by addition of an equal volume of fresh culture
medium, and cells were resuspended into a single-cell suspension before counting or direct
reseeding. For passage cells were split between 1:5 and 1:8 after reaching 70-80% conflu-
ency. Cells were primarily maintained in T75 culture flasks with filter lids (TPP: 90076),
however 10cm and 15cm plates (TPP: 93100/93150) were used in some circumstances.
When necessary, single cell suspensions were centrifuged at 125 relative centrifugal force
(RCF) for 8 minutes and the supernatant removed before resuspension in culture media.
3.1.3 Frozen Cell Storage
Cells were washed with calcium/magnesium-free DPBS (Lonza: BE17-512F) and disso-
ciated from the culture vessel by incubation with Trypsin-Versene (Lonza BE02-007E)
(made up from 10X in DPBS) at 37oC for 5-10 minutes. Trypsin was inactivated by addi-
tion of an equal volume of fresh culture medium, and cells were pelleted by centrifugation
at 125 RCF for 8 minutes. Supernatant was removed, and cells were resuspended at 1x106
cells/ml in 4oC culture media with 5% dimethyl sulfoxide (DMSO) (Sigma: D2650). 1 ml
of cell suspension was aliquoted per cryovial, which were then incubated on ice for 10-45
minutes. Cryovials were placed inside a Nalgene Mr. Frosty (Sigma-Aldrich: C1562)
containing isopropanol (pre-chilled to 4oC) and stored at -80oC.
To thaw cells, cryovials were removed from -80oC storage and placed in a 37oC water-bath
with gentle agitation for 1-2 minutes until fully thawed. 1 ml of cell suspension was then
added to 9 ml of pre-warmed culture media before pelleting at 125 RCF for 8 minutes. The
supernatant was removed, and the cell pellet resuspended in 10 ml of pre-warmed media.
The 10 ml suspension was then placed into a T25 flask (TPP: 90026), and incubated
under standard conditions for 24 hours, at which point the media was changed to remove
dead cells and residual DMSO. Cells were regularly monitored over the following week to
ensure healthy recovery.
3.1.4 Drug Treatments
Small molecule drug treatments were used at otherwise standard cell culture conditions.
Drugs in DMSO were suspended at working concentration in fresh media prior to re-
placement of old culture media. Control culture media was replaced at the same time,
supplementing with the vector DMSO to the appropriate concentration.
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Mammalian Cell Drug treatments
Target Drug Concentration Source
CHK1 CCT245737 0.2-5 µM SelleckChem:
CCT245737
SMG7-UPF1 NMDI14 5 µM Sigma-Aldrich:
SML1538
Table 7. Mammalian Cell Drug Treatments
3.1.5 Mycoplasma Contamination
Cells were tested for mycoplasma using the MycoAlert detection kit (Lonza: LT07-218)
following the manufacturers protocol. Mycoplasma positive HCT116 cells were treated
with Plasmocin (Lonza: VZA-1012) following the manufacturer’s protocol to eliminate
mycoplasma, and all cell lines were retested periodically. All experiments were performed
following mycoplasma elimination.
3.2 CTC1 Knockout Induction
Exon 5 of both copies of CTC1 in the edited HCT116 cell line from Carolyn Price (hence-
forth identified as HCT116lox/lox) are flanked by locus of x-over P1 (loxP) sites. loxP sites
are recognised by the Cre-recombinase topoisomerase which is capable of recombining the
two sites, looping out and eliminating the genetic information between them [241]. These
HCT116lox/lox cells constitutively express Cre-recombinase fused to a ligand binding do-
main of the human oestrogen receptor. As a result, the recombinase is shuttled into the
nucleus only in the presence of tamoxifen [242]. The integrated Cre-recombinase expres-
sion cassette includes a puromycin resistance marker, as such the HCT116lox/lox cells were
grown in media containing 1 µg/ml puromycin (Cambridge Bioscience: CAY13884) to
ensure the locus was not silenced.
In order to induce the deletion of CTC1 , tamoxifen was added to the culture media at a
concentration of 10 nM. Extensive CTC1 deletion was detectable after 2 days. Tamoxifen
stock is dissolved in ethanol at 10 mM for long term storage, further diluted in ethanol
to 20 µM for a working stock and added 1:2000 to the media for a final concentration of
10 nM. Subsequently, ethanol was added 1:2000 to control cells.
3.3 Protein Analysis
3.3.1 Protein Extraction
Protein extraction of whole-cell lysates was performed using urea lysis buffer: 8M urea,
300 mM NaCl, 0.5% v/v nonyl phenoxypolyethoxylethanol (NP-40) substitute (Sigma-
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Aldrich: 74385), 50 mM Na2HPO4, 50 mM Tris (pH 8.0). 10 ml of lysis buffer was supple-
mented with 1 PhosSTOP phosphatase inhibitor cocktail tablet (Roche: 04906837001).
To harvest lysates cells were washed with DPBS before lysis buffer was added (200 µl
for cells in 6-well plate, 500 µl for 10cm dish). Cells were scraped before collection in
Eppendorf tubes, snap frozen on dry ice and stored at -80oC (if not immediately used).
Samples were sonicated to reduce viscosity using an MSE Soniprep 150. Sonication was
performed at an amplitude of 4 microns for 2 cycles of 30 seconds on, 30 seconds off.
3.3.2 BCA Assay
Protein lysates in urea lysis buffer were analysed by bicinchoninic acid (BCA) assay to
determine protein concentration. The Pierce BCA Protein Assay Kit (Thermofisher:
23227) was used following the manufacturers protocol.
3.3.3 Sample Preparation
Samples were made up to uniform concentration in loading buffer. Loading buffer was
diluted to 1x from 5x stock. Samples in loading buffer were heated to 95oC for 2-3 minutes
immediately before use to ensure suspension of sodium dodecyl sulphate (SDS).
3.3.4 SDS-PAGE
Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) was performed
using 4-15% or 7.5% Bio-Rad Mini-Protein TGX Precast Gels (Bio-Rad: 4561086/4561026).
Combs were removed, and the gels assembled in the running cassette of a Bio-Rad Mini-
Protein Tetra Vertical Electrophoresis cell (Bio-Rad: 1658004). The tank and cassette
chamber were filled with running buffer. 5 µl of PageRuler Plus Protein ladder (Ther-
mofisher: 26620) was loaded into lane 1 followed by 12 µl of protein samples in subsequent
wells. Samples were run at 100V (Bio-Rad: 1645050) until the dye front reached the bot-
tom of the gel.
3.3.5 Western Blot
Proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane using the
Bio-Rad Trans-Blot Turbo Transfer system (Bio-Rad: 1704150) and the Trans-Blot Turbo
RTA Mini LF PVDF Transfer Kit (Bio-Rad: 1704275) following the manufacturer’s in-
structions and using the 1 Mini Gel transfer pre-set. Membranes were blocked in blocking
buffer at room temperature for 1 hour, washed 3 times in tris-buffered saline with tween
20 (TBST) for 5 minutes, then incubated in 5 ml primary antibody solution at 4oC
overnight or for 1 hour at room temperature. After primary antibody incubation, mem-
branes were washed 3 times in TBST before incubation in 10-20 ml horseradish peroxidase
(HRP)-tagged secondary antibody solution for 1 hour at room temperature. Membranes
were washed again 3 times in TBST. All incubation and washing steps were performed
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0.2M Tris-HCl pH 6.8, 40% v/v glycerol, 8% SDS and
20% β-mercaptoethanol, bromophenol blue to dye
Running Buffer 90% MQ H2O, 10% 10x TGS buffer (Bio-Rad: 161-
0732)
Transfer Buffer 20% Trans-Blot Turbo 5x Transfer Buffer (Bio-Rad:
10026938), 20% ethanol, 60% MQ H2O
TBST 20 mM Tris-HCl pH 7.6, 120 mM NaCl, and 0.1%
Tween20 (Sigma-Aldrich: P7949)
Blocking Buffer 4% w/v Marvel Skimmed Milk Powder in TBST
Primary Anti-
body Solution
2% bovine serum albumin (BSA) (Sigma: A9647) in
TBST
Table 8. Buffers for Western Blot
with gentle agitation on a rocker or roller. Membranes were then treated with enhanced
chemiluminescence (ECL) substrate following the manufacturers protocol. Membranes
were placed in glossy plastic document sleeves and imaged using a FujiFilm LAS4000
luminescence imager taking incremental length exposures. Images were thresholded and
saved in the tagged image format (TIF).
3.3.6 Signal Quantification
8-bit TIF files were imported into the FIJI distribution of ImageJ [243]. Individual lanes
were assigned using the “Select First Lane” and “Select Next lane” commands. Lane den-
sity curves were plotted using the “Plot Lanes” command. Curves were closed using the
line tool as necessary, and the area under the curve measured using the wand tool. Graph-
Pad Prism software was used for calculation of statistical significance between groups using
analysis of variance (ANOVA) tests, correcting for multiple comparisons using Sidak’s or
Tukey’s method depending on the comparisons being made.
3.4 DNA Electrophoresis
Agarose gel electrophoresis was used for analysis of DNA fragment size as well as quan-
titative PCR (qPCR) primer validation. Depending on the size of the band expected,
0.8-2% agarose gels (Bioline: BIO-41025) were made up in 0.5x tris-borate-EDTA (TBE)
buffer or 1x tris-acetate-EDTA (TAE) buffer. The suspension was heated to boiling point
by microwave until all agarose had dissolved and then allowed to cool briefly. SYBR safe
dsDNA stain (Thermofisher: S33102) was then added to the still molten agarose 1:10,000
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Primary Antibodies










1:1000 Mouse Cell Signaling 2360 Monoclonal
P-CHK1
(s298)




1:1000 Mouse Abcam ab89250 Polyclonal
(Lot
GR129845-10)
Total p53 1:1000 Mouse Cell Signaling 9282 Monoclonal
P-p53
(s15)
1:1000 Rabbit Cell Signaling 9284 Polyclonal
(Lot 21)
p21 1:1000 Rabbit Cell Signaling 2947 Monoclonal
Table 9. Primary Antibodies for Western Blot
HRP-conjugated Secondary Antibodies
Target Concentration Source Catalogue No. Clonality
Mouse Ig 1:5000 Dako P0447 Polyclonal
(Lot
35941)
Rabbit Ig 1:5000 Dako P0448 Polylonal
(Lot
25020)
Table 10. Secondary Antibodies for Western Blot
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before the gel was poured and allowed to set. Gels were submerged in TBE or TAE in
a Bio-Rad Wide Mini-Sub Cell GT electrophoresis cell (Bio-Rad: 1704405). 6x DNA
loading buffer was added to the DNA samples, and the samples loaded into wells in the
gel. DNA ladder solution was loaded into one well for band size comparison. Gels were
then run at 70-150V depending on band size and desired resolution for 0.5-2 hours. Bands
were imaged using a Syngene G:Box.
Buffers for DNA electrophoresis
Buffer Ingredients
0.5x TBE Buffer Diluted 1:20 from 10x stock (Bio-Rad: 1610770)




30% Glycerol, Bromophenol blue dye
DNA Ladder So-
lution
1:6 6x Loading buffer, 10% 1Kb Plus DNA ladder (Ther-
mofisher: 10787018)
Table 11. Buffers for DNA Electrophoresis
3.5 Plasmid Cloning
3.5.1 Generating Competent E. coli
5 ml of lysogeny broth (LB) was inoculated with TOP10 E. coli and grown overnight in
a shaking incubator at 37oC. 1 ml of the overnight culture was used to inoculate 100 ml
of LB in a 1L flask. This culture was then grown at 37oC until an optical density (OD)600
of 0.5-0.6 was achieved. The next steps were all performed on ice in a cold room, and all
pipetting was performed very gently. 25 ml fractions of the E. coli culture was aliquotted
into 50 ml falcon tubes. Cells were centrifuged at 1000 RCF at 4oC for 10 minutes.
The supernatant was removed, and each pellet resuspended in 5 ml of ice cold 100 mM
MgCl2 by swirling. Cells were pelleted again at 1000 RCF for 10 minutes at 4
oC, and the
supernatant removed. The pellets were resuspended in 1 ml of ice cold 100 mM CaCl2
by swirling. The bacterial suspensions were left on ice for 2 hours before being combined
into a single 15 ml falcon tube. 1 ml of 100% glycerol was added to the suspension, and
the tube gently swirled to mix. The suspension was then aliquotted 100 µl at a time into
pre-chilled Eppendorf tubes and immediately transferred to a -80oC freezer.
3.5.2 Bacterial Transformation
For transformation of bacteria with very low plasmid concentration (such as following the
ligation step when cloning): Competent TOP10 derived E. coli were removed from -80oC
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storage and thawed on ice for 10 minutes. 5 µl of typical ligation reaction was added to
100 µl of E. coli in a 1.5 ml Eppendorf tube and left on ice for 30 minutes. The E. coli
DNA mix was then heat shocked at 42oC for 45 seconds before immediately placing back
on ice for 2 minutes. 900 µl of super-optimal broth with catabolite repression (SOC) was
added to the tube, and the suspension incubated on a rotating wheel at 36oC for 2 hours.
Cells were pelleted at 2700 RCF for 3 minutes, before 800 µl of supernatant was removed
and the pellet resuspended in the remaining 200 µl. Cell suspension was then plated out
onto a 10cm LB with ampicillin (LB+AMP) plate and incubated overnight at 37oC.
For transformation of bacteria with high plasmid copy number (such as when expanding a
plasmid from a miniprep stock): Competent TOP10 derived E. coli bacteria were removed
from -80oC storage and thawed on ice for 10 minutes. 1 µl of standard miniprep elute
was added to 50 µl of E. coli in a 1.5 ml Eppendorf tube and left on ice for 30 minutes.
The E. coli DNA mix was then heat shocked at 42oC for 45 seconds before immediately
placing back on ice for 2 minutes. 450 µl of SOC was added to the cell suspension, and
20 µl of suspension streaked onto a 10cm LB+AMP plate. The plate was then incubated
at 37oC overnight.
3.5.3 Plasmid Isolation
Using a sterile pipette tip, a single E. coli colony was picked from LB+AMP plates the
day after transformation. 1-5 ml of liquid LB+AMP was inoculated with the picked
colony. For isolation of approximately 10 µg of plasmid DNA in 30 µl of TE, the E.
coli suspension was incubated on a rotating wheel at 36oC overnight before the plasmid
was extracting using the Qiagen Plasmid Mini Kit (Qiagen: 12125) following the man-
ufacturer’s protocol. For isolation of approximately 100 µg of plasmid DNA in 50 µl
of tris-ethylenediaminetetraacetic acid (TE), the E. coli suspension was incubated on a
rotating wheel at 36oC for 8 hours as a starter culture. 25 ml of liquid LB+AMP was
inoculated with 25 µl of the starter culture and incubated with vigorous shaking at 37oC
overnight. The next day the plasmid was extracted using the Qiagen Plasmid Midi Kit
(Qiagen:12143) following the manufacturer’s protocol.
3.5.4 Restriction Enzyme Digestion
Restriction enzyme digestions were performed in volumes of 20 µl. All restriction enzymes
were supplied by New England Biolabs (NEB). Approximately 2 µg of miniprepped plas-
mid DNA in TE (8 µl) was digested in a reaction containing 10-20 units of restriction
enzyme (typically 0.1-2µL) and 2 µl of NEB 10x restriction enzyme buffer (2.1, 3.1 or
Cutsmart depending on the enzyme(s) used). Digestions were performed at 37oC or
65oC depending on the restriction enzyme for at least an hour. Many digestions required
optimisation of component concentrations or duration to achieve optimal results. If the
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linearised plasmid was to be used as a vector, 1 unit of calf intestinal alkaline phosphatase
(CIP) (NEB: M0290S) was added directly to the digestion reaction and incubated at 37oC
for a further 30 minutes.
3.5.5 Gel Purification
4 µl of loading buffer was added to each 20 µl digestion reaction tube and the entire re-
action was loaded into a 1% agarose gel with SYBR Safe for electrophoresis as previously
described. The agarose gel was then run at a low voltage (60-80V) for as long as possi-
ble for optimal band resolution. Once the band(s) had sufficiently resolved, the desired
fragment was cut from the gel using a fresh scalpel blade and an Invitrogen Safe Imager
transilluminator (Invitrogen: S37102). Care was taken to excise the minimum amount of
gel and to minimise exposure of the DNA fragment to ultraviolet (UV) light. The excised
gel fragment was placed in a pre-weighed Eppendorf tube. The tube was then weighed
again in order to estimate the volume of gel inside. DNA extraction was then performed
using the QIAquick polymerase chain reaction (PCR) Purification Kit (Qiagen: 28106)
per the manufacturer’s instructions.
3.5.6 Fragment Ligation
Ligation reactions were performed in volumes of 10 µl. When ligating a linearised vector
with a desired insert, vector-only and insert-only controls were performed. Sticky-end
ligations were performed at 16oC for 1 hour using the volumes outlined in table 6. The
volumes of purification elutions in table 6 were usually sufficient and appropriate, however
some volume optimisation was occasionally necessary to achieve a vector:insert molar
ration of approximately 1:3. Blunt end ligations were performed overnight. Following
ligation, 5 µl of each ligation reaction was used to transform 100 µl of competent E.
coli as described previously. If many colonies were present on only the Vector + Insert
plate then the transformation was likely to have worked, and 4 colonies were picked,
miniprepped, and sequenced.
3.5.7 Gibson Assembly
In instances where traditional cloning methods proved ineffective and sequence overlap
between vector and insert fragments was present, Gibson Assembly was used. Blunt-
end vector and insert fragments were produced by digestion reactions and gel purified as
described previously then ligated using the Gibson Assembly Cloning Kit (NEB: E5510S)
according to the manufacturer’s protocol. 5 µl of the reaction was then transformed into
100 µl of competent TOP10 E. coli as described previously.
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Water 6 µl 2 µl 0 µl
T4 Ligase (NEB: M0202S) 1 µl 1 µl 1 µl
10x T4 Buffer (Supplied with
Ligase)
1 µl 1 µl 1 µl
Gel-Purified Vector 2 µl 0 µl 2 µl
Gel-Purified Insert 0 µl 6 µl 6 µl
Table 12. Typical Ligation Reaction Volumes
3.6 Transient Transfection of Mammalian Cells
Transient transfection was used for assays requiring (over)expression of a specific protein
or proteins for a short period of time. Mammalian expression vector plasmids carrying
the gene of interest were prepared in TE at high concentration (0.5-2 µg/µl) by Qiagen
midiprep or maxiprep as described above. 1x106 HCT116 or U-2 OS cells were transfected
with up to 2 µg of DNA using the Amaxa Cell Line Nucleofector kit V (Lonza: VCA-1003)
following the manufacturer’s protocol.
3.7 Generation of Stable-Expression Clonal Cell Lines
3.7.1 Antibiotic Kill-Curve
HCT116 cells were grown in culture media containing G418 (Cambridge Bioscience: 1557)
at 0, 50, 100, 200, 400, 600, 800 and 1000 µg/ml for 10 days. Cell viability was assessed
by light microscopy. The lowest concentration with 100% cell death after 10 days was
used for resistance selection. G418 stock concentration was adjusted for potency directed
by manufacturer’s datasheet. Typical G418 potency was approximately 70%.
U-2 OS cells were grown in culture media containing puromycin at 0, 1, 2, 3, 4, and 5 µg/ml
for 10 days. Cell viability was assessed by light microscopy. The lowest concentration
with 100% cell death after 10 days was used for resistance selection.
3.7.2 STN1 Overexpression
HCT116 cells were transfected with a pcDNA3-STN1 mammalian expression plasmid
using the Amaxa Nucleofector as described previously. 48 hours following transfection the
cells were passaged (1:10, 1:50, 1:100, 1:200, each in duplicate) into 10cm plates containing
10 ml culture media with 400 µg/ml G418. Media containing G418 was refreshed every
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4 days. 16 days later large colonies had formed and the culture media was removed
and the cells gently rinsed with 10 ml warm DPBS. After removing the DPBS, small
sterile disks of blotting paper (made by holepunch and autoclaved) were soaked in warm
Trypsin-Versene and placed individually onto each clonal colony. Colonies were incubated
at 37oC for 5 minutes, during which time the cells dissociated from the plate surface but
adhered to the cloning disk. Using fine-nosed tweezers 48 cloning disks and associated
cells were moved to individual wells of 2 24-well plates (TPP: 92024). The disks were
lightly shaken once in the 24-well plate well so as to dislodge cells. When each well of
the 24-well plate became near-confluent, cells were passaged 1:2 in duplicate into a well
of a 6-well plate (TPP: 92006). Once 70-80% confluent, one of the wells of each clone
was harvested for STN1 expression analysis by Western blot using urea lysis buffer (as
described previously), whilst the other was frozen down in cryovials for temporary storage
at -80oC (as described previously).
3.7.3 DRGFP Reporter Expression
Generation of U-2 OS DRGFP stable cells was performed by transfection of 2 µg pDRGFP
as described previously. 48 hours after transfection cells were passaged 1:1 into media
with 4 µg/ml puromycin in a 10cm dish. Cells were maintained in 4 µg/ml puromycin
for 14 days as a heterogenous population of stable integrations. Cells were trypsinised as
described previously to generate a single cell suspension, counted by haemocytometer and
plated out in 10cm plates at a density of 50, 250, 500, 1000 and 2000 cells per plate. Media
was changed every 3-4 days until large clonal colonies of cells had formed. 48 colonies were
picked using cloning disks as described previously. Once the clones were near confluent
in the 24-well plates the media was removed and the cells rinsed with DPBS. 100 µl of
Trypsin-Versene was added to each well and incubated at 37oC for 5-10 minutes. 50%
of the Trypsin single-cell suspension was transferred into an Eppendorf tube, and 200 µl
of culture media with 10% DMSO was added to the remaining cells in the well. The
plate was then sealed in parafilm, wrapped extensively in paper towel and placed in a
-80oC freezer. The Trypsin-Versene in the Eppendorf tubes was neutralised with 50 µl of
culture media before being centrifuged at >20,000 RCF for 30 seconds. The supernatant
was removed and the cell pellets snap-frozen on dry ice before transfer to a -80oC freezer
for storage. Cell pellets were later used for RNA extraction and analysis by qPCR.
3.8 Genotyping
3.8.1 Crude Genomic DNA Lysates
Cells were grown in 6-well plates before scraping and collecting in a 1.5 ml Eppendorf
tube. Cells were then pelleted at >14,000 RCF for 30 seconds before the supernatant was
removed and the pellet snap frozen on dry ice. DirectPCR (Tail) Lysis reagent (Viagen:
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102-T) was supplemented with 0.4 mg/ml Proteinase K (Sigma-Aldrich: P4850). Each
cell pellet was resuspended in 50 µl lysis reagent and incubated at 56oC for 16 hours.
Proteinase K was inactivated by heating to 95oC for 10 minutes, and lysates were stored
at -20oC.
3.8.2 Genomic DNA Extraction for qPCR
For extraction of genomic DNA for qPCR, a higher quality DNA sample was required than
the crude lysate produced by DirectPCR lysis reagent. For this mammalian cells were
grown, scraped and pelleted as described previously. Genomic DNA was extracted using
the Qiagen DNeasy Blood & Tissue kit (Qiagen: 69504) following the manufacturer’s
protocol.
3.9 mRNA Analysis
3.9.1 Harvesting Cells for mRNA Extraction
Cells were grown to 70-80% confluence in a 6-well plate or 10cm dish. The culture media
was removed and the cells rinsed with DPBS before scraping into an Eppendorf tube.
Cells were then pelleted at >14,000 RCF for 30 seconds, the remaining DPBS supernatant
removed and the pellet snap-frozen on dry ice. Pellets were stored at -80oC if not used
immediately.
3.9.2 Extraction of RNA
The Qiagen RNeasy Mini Kit (Qiagen: 74106) was used for extraction of RNA from
cultured human cells. RNA was extracted following the manufacturer’s protocol, using a
needle and syringe for the lysate homogenisation step.
3.9.3 RNA Concentration and Quality Analysis
The concentration and quality of RNA eluted from the RNeasy Mini Kit was measured
by Thermo Scientific NanoDrop 2000C spectrophotometer (Thermofisher: ND-2000C),
blanked using RNase-free H2O. The 260/280 nM wavelength absorbance ratio was used
to calculate nucleic acid purity compared to aromatic amino acids, and 260/230 nM
wavelength absorbance was used to calculate purity compared to other contaminants.
Acceptable ratios were 1.8-2.2 and >1.7 respectively.
3.9.4 Production of cDNA from mRNA by Reverse Transcription
Complementary DNA (cDNA) was produced from up to 1 µg of RNA by reverse tran-
scription using the QuantiTect Reverse Transcription Kit from Qiagen (Qiagen: 205311)
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PCR Primers
Target Forward Primer Reverse Primer
RPL13A mRNA CCT GGA GGA GAA
GAG GAA AGA GA
TTG AGG ACC TCT GTG
TAT TTG TCA A
CTC1 mRNA TTT CTG TTC CCC CGT
TGG AG




CAC AGT AAG GCC CTA
TTT CTA C
ACC TGG CTG GGA
GTC TAG TT
STN1 mRNA GAG ATT CAT GCC ACC
GCT TAC
GCG CCT GGA TTG CTT
AGT G
TEN1 mRNA AAG AAA TCC GAG GAC
CGG C
GAA TTC CTC AGG
GGA AGG GC
ATF4 mRNA ACA ACA GCA AGG
AGG ATG CC
CCA ACG TGG TCA GAA
GGT CA
ORCL mRNA GGC AGC AGA TGA AAT
CTG AA




AAA CGG CTA CCA CAT
CCA AG
CGC TCC CAA GAT CCA
ACT AC
DRGFP DNA GGG ATC ACT CTC GGC
ATG G
TAT GTT TCA GGT TCA
GGG GGA G
Table 13. qPCR Primers
following the manufacturer’s protocol, which included a genomic DNA contamination
elimination step.
3.9.5 Primer Design and Validation
When well established primers were not found in the literature, primers were designed
using the national centre for biotechnology information (NCBI) primer basic local align-
ment search tool (BLAST), choosing an optimal melting temperature of 60.0oC, a product
length of 120-180 nucleotides and ensuring primers span an exon-exon junction. Primers
were checked for specificity using the NCBI reference sequence database. Primers were
custom ordered from Sigma-Aldrich and suspended at 200 µM in TE before storage at
-20oC. Optimal melting temperature was assessed by performing PCR with a range of
annealing temperatures and running the products on an agarose gel, checking for a single
strong band. Primer efficiency was performed by qPCR and assessing deviation from a
standard curve of cDNA concentrations.
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3.9.6 Quantitative PCR
20 µl reactions were performed in triplicate in 0.1 ml 96-well reaction plates (Applied
Biosystems: 4346907). 5 µl of typical cDNA suspension (Produced by Quantitect reverse
transcriptase PCR (RT-PCR) kit and further diluted 1:20 in DNase/RNase-free H2O)
or genomic DNA (Extracted by Qiagen DNeasy Blood & Tissue Kit and diluted 1:20
with DNase/RNase-free H2O) was combined with 15 µl of master mix (4 µl 5x GoTaq
Colourless Reaction Buffer, 3 µl 25 mM MgCl2, 2.5 µl 2.5 mM deoxynucleoside triphos-
phates (dNTP) mix, 0.2 µl GoTaq G2 DNA Polymerase, 0.5 µl 10 µM primer mix, 0.2 µl
SYBR Green (1:200 in DMSO) (Promega: M7845)). qPCR was performed in an Applied
Biosystems StepOnePlus Real-Time PCR system with the following reaction: 1 cycle:
95oC 10 minutes; 40 cycles: 95oC 30 seconds, 60oC 30 seconds, 72oC 30 seconds. The
reaction was terminated with a final stage of gradual temperature increase to produce
a melt curve. Cycle threshold (Ct) values were taken at the exponential amplification
phase and exported for analysis. Each gene master mix was tested with water in place of
template DNA to ensure no master mix contamination.
3.9.7 Relative mRNA Abundance Analysis
Relative RNA abundance between treated and untreated samples was calculated from
cDNA ∆∆Ct values, using RPL13A and ribosomal 18S as endogenous control genes. Melt
curve data were analysed to ensure a single PCR product was present in each reaction,
confirming primer specificity and a lack of contamination.
3.10 Locus Copy-Number Estimation
For rough estimation of locus copy number between clones, the Ct value of a genomic
qPCR product of the locus in question was compared to the Ct value of a PCR product
of identical size from a locus of known copy number. For identification of clones with
single pDRGFP integrations in hypertriploid U-2 OS cells, the clones with a DRGFP
PCR product signal 25% - 33% the magnitude of a CTC1 PCR product (which U-2
OS cells have 3-4 copies of) likely carried single integrations. In support of these clones
having single integrations there were no clones with significantly lower DRGFP locus PCR
product abundance.
3.11 Fluorescent Microscopy
3.11.1 Fixing Asynchronous Cells
0.3x106 cells were seeded onto a 19mm round glass coverslip (VWR: 631-0156) in a 6-
well plate well containing 3 ml of culture media. 48 hours later the culture media was
removed, and the cells washed with 3 ml DPBS. Cells were fixed in 2% formaldehyde
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(Sigma: F8775) in DPBS for 10 minutes. Formaldehyde was removed, and the coverslips
washed in 3 ml DPBS 3 times for 5 minutes. Fixed coverslips were stored at 4oC in DPBS
for up to 2 weeks.
3.11.2 Preparing Metaphase Chromosome Spreads
0.3x106 cells were seeded into onto a 19mm round glass coverslip (VWR: 631-0156) in a
6-well plate well containing 3 ml of culture media. 48 hours later 0.1 µg/ml Colcemid
(Thermofisher: 15210040) was added to the culture media for 3 hours. The media was
gently removed (so as not to dislodge mitotic cells) and replaced with room temperature
hypotonic buffer (0.2% KCl, 0.2% Na3C6H5O7) for 15 minutes. Coverslips were placed
face-up on glass microscope slides, clipped into inserts for a Shandon Cytospin 3, and spun
at 1000 rotations per minute (RPM) for 5 minutes. Immediately after centrifugation the
coverslips were removed from the cytospin inserts and placed in 2% formaldehyde DPBS
for 10 minutes. After fixation the coverslips were washed 3 times for 5 minutes each in 3
ml DPBS and stored in DPBS at 4oC.
3.11.3 Staining Cells for Immunofluorescence
Fixed coverslips were permeabilised in 1% Triton X-100 (Sigma: T8787) in phosphate
buffered saline with tween-20 (PBST) for 12-15 minutes at room temperature, which was
then removed and the coverslips washed once in PBST. The coverslips were then blocked
by incubation in 5% w/v BSA PBST at room temperature for 45 minutes. Primary
antibody was diluted as appropriate in 5% w/v BSA PBST, and the coverslips placed
face down onto a 100 µl droplet of antibody solution. The coverslips were incubated at
room temperature for >1.5 hours in a humidified chamber. The coverslips were washed
for 5 minutes 3 times in PBST before incubation with secondary antibody diluted as
appropriate in 5% w/v BSA PBST in a humidified chamber at room temperature for 1
hour. After incubation the coverslips were washed 3x in phosphate buffered saline (PBS)
for 5 minutes before rinsing with MQ H2O to remove salts and allowed to air dry for 5-10
minutes. Coverslips were then placed face down on a droplet of Prolong Gold Antifade
Mountant with 4’,6-diamidino-2-phenylindole (DAPI) (ThermoFisher: P36941) on a glass
slide. Slides were cured at room temperature in the dark for 24 hours before the edges
were sealed with nail varnish. Once the nail varnish was dry, slides were stored at -20oC.
3.11.4 Staining Cells for Co-Immunofluorescence/Fluorescent In Situ
Hybridisation
Cytospun metaphase spread coverslips were permeabilised in PST-Triton buffer for 10
minutes before blocking in co-IF/FISH antibody dilution buffer for 15 minutes at 37oC.
Coverslips were then incubated for 1.5 hours with primary antibody in Co-IF/FISH anti-








Telomere C-rich strand TTA GGG TTA
GGG TTA GGG
Cy5 PN-TG055-005
Centromere AAA CTA GAC
AGA AGC ATT
Alexa488 PN-CN060-005
Table 14. Eurogentec PNA probe details
Primary Antibodies









γH2AX 1:800 Rabbit Cell Signaling 2577 Polyclonal
(Lot: 11)
Table 15. Primary Antibodies for Immunofluorescence
were washed 3 times in PBST for 5 minutes then incubated with secondary antibody in
Co-IF/FISH antibody dilution buffer for 30 minutes (face down on a 100 µl droplet in a
dark humidified chamber). Coverslips were washed 3 times in PBST for 5 minutes before
antibodies were fixed in 4% formaldehyde PBS for 10 minutes at room temperature. Af-
ter rinsing the coverslips twice with MQ H2O, the cells were dehydrated with an ethanol
series at 4oC (70%, 90%, then 100% for 2 minutes each). A hotblock was heated to 90oC
then covered in a wet sheet of paper towel. A 40 µl droplet of 200 nM PNA probe (Table
14) in preheated hybridization buffer was placed on a preheated glass slide, and the fixed
coverslips placed face down on the droplet. The slide and coverslip were then incubated
on the damp hotblock for 3 minutes loosely covered with tin foil. Slides were then moved
to a dark humidified chamber, allowing the probe to anneal at room temperature for 2
hours. Coverslips were then washed twice in wash buffer A for 5 minutes, then twice in
wash buffer B for 5 minutes. After briefly rinsing with MQ H2O, coverslips were air dried
and mounted in a droplet of Prolong Gold Antifade Mountant with DAPI on a glass slide.
Slides were cured at room temperature in the dark for 24 hours before the edges were




PBS 10 mM Na2HPO4, 1.8 mM KH2PO4, 137
mM NaCl, 2.7 mM KCl
PBST 0.1% Tween-20 in PBS
PST-Triton Buffer 120 mM KCl, 20 mM NaCl, 10 mM Tris
pH 7.5, 0.1% Triton X-100
Co-IF/FISH Anti-
body Dilution Buffer
20 mM Tris pH 7.5, 2% w/v BSA, 0.2%
fish gelatine (Sigma: G7765), 150 mM




10 mM Tris-HCl pH 7.2, 70% formamide
(Promega: H5052), 1% blocking reagent





10% w/v Blocking reagent (Sigma-




Maleic Acid Buffer 100 mM maleic acid, 150 mM NaCl Adjusted to pH 7.5
with NaOH.
Wash Buffer A 70% formamide, 10 mM Tris pH 7.5, 0.1%
w/v BSA
Wash Buffer B 50 mM Tris pH 7.5, 300 mM NaCl, 0.8%
Tween-20
Table 16. Co-IF/FISH solutions
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Fluorophore Conjugated Secondary Antibodies



























Table 17. Secondary Antibodies for Immunofluorescence
3.11.5 Microscopy
Slides were removed from -20oC storage and allowed to reach room temperature before
cleaning with lens cleaning paper. Microscopy was performed on a Zeiss AxioImager (illu-
minated by Colibri light-emitting diode (LED) system) or Nikon Eclipse 50i (illuminated
by metal halide lamp) widefield microscopes. Multichannel fluorescent images were cap-
tured in Zeiss Zen software or Jentopik ProgRes software respectively. Sample exposure
to fluorescent light was kept to a minimum in order to avoid bleaching.
3.11.6 Scoring Micronuclei
Images captured at 20x objective lens magnification were scored blind using the File-
name Randomizer macro from Tiago Ferreira [244]. Total nuclei in the DAPI channel
were counted using a custom written macro. Micronuclei frequency was scored by eye.
Micronuclei were defined as an approximately round DNA body distinctly separate from
the main nucleus, and no larger than 1/3 the size of the main nucleus. “Micronuclei
frequency (%)” represents the frequency of nuclei with adjacent micronuclei and does not
distinguish between nuclei with a single micronucleus or multiple micronuclei.
3.11.7 Scoring Chromatin Bridges
Images captured at 40-100x objective lens magnification were scored blind. DAPI channel
nuclei were automatically counted by ImageJ macro, and chromatin bridges counted by
eye. A chromatin bridge was defined as a bridge of DNA connecting two distinct interphase
63
nuclei. “Chromatin bridge frequency (%)” is defined as number of bridges per 100 nuclei.
3.11.8 Scoring Nuclear γH2AX Foci
Images of interphase nuclei were captured at 40x objective lens magnification. γH2AX
foci frequency was scored using a custom ImageJ macro using the DAPI channel to define
individual nuclei. Foci in the γH2AX antibody channel were counted using the find
maxima tool.
3.11.9 Measurement of Telomere Length
C-strand telomere length was measured by PNA probe fluorescence. Cy5-labelled PNA
probes specific to the C-rich strand of human telomeres were annealed to metaphase
spreads as described previously. Telomere C-strand length and fluorescent signal intensity
are linearly proportional. Images were captured at 40-100x objective lens magnification by
widefield microscopy. Signal intensity was scored automatically using the FIJI distribution
of ImageJ.
3.11.10 Localisation of Telomeres and γH2AX
Multichannel fluorescent images were captured of co-IF/FISH stained metaphase chromo-
some spreads. Images were captured at 60-100x objective lens magnification by widefield
microscopy. The images were scored blind using the FIJI distribution of ImageJ for over-
lapping telomeric PNA probe signal and γH2AX foci.
3.11.11 Measuring Relative G-Quadruplex Abundance
G-quadruplex abundance was measured by IF staining of interphase nuclei with a G-
quadruplex specific antibody. Images were captured at 40x objective lens magnification
by widefield microscopy. Nuclear signal intensity was scored automatically using a custom
ImageJ macro.
3.11.12 Statistical Analysis
All statistical analysis of microscopy quantification was performed using the GraphPad
Prism software. Statistical significance was calculated by one or two-way ANOVA cor-
recting for multiple comparisons using Sidak or Tukey’s method as appropriate. Three
biological repeats were performed on separate days and fixed. Replicates were stained
and imaged together for consistency of fluorescent staining.
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3.12 Homology Directed Repair Analysis by DRGFP Reporter
Clonal populations of U-2 OS cells that had integrated 1-2 copies of the DRGFP re-
porter cassette (determined as described previously) were assessed for GFP expression.
pDRGFP was a gift from Maria Jasin (Addgene plasmid 26475) [245]. Clones with <0.2%
baseline GFP expression (assayed by fluorescent microscopy) were chosen and transfected
with 0.5 µg of pDNA3-SceI to transiently express the SceI endonuclease. 48 hours after
transfection cells were assessed for GFP expression again. A clone was chosen that sig-
nificantly increased GFP expression after transfection with pcDNA3-SceI. To assay the
impact of STN1 overexpression on HDR, an STN1 mammalian expression plasmid was
co-transfected with pcDNA3-SceI, and the frequency of GFP positive cells scored 48 hours
later. Empty pcDNA3 expression vector was used as a negative control, and total amount
of DNA transfected was consistent between samples.
3.13 Cell Growth
3.13.1 Cell Counting
Measurement of cell population size was performed using a haemocytometer. Once a single
cell suspension was achieved following trypsinisation, 15 µl of cell suspension was placed
on a glass haemocytometer and counted in at least duplicate. For long term population
growth assays cells were counted before passage every 2 days. The number of population
doublings between timepoints was calculated using the following formula:
log2(
cell count timepoint x
cell count timepoint x− 1
) = Population doublings
3.13.2 PrestoBlue Assay of Cell Viability
Cell viability was measured indirectly using PrestoBlue Cell Viability Reagent (Ther-
moFisher: A13261). 8 replicates of 2500 cells per well were plated in a 96-well plate with
200 µl of culture media. 24 hours after seeding, culture media was temporarily replaced
with 10% PrestoBlue media for 60 minutes. The PrestoBlue media was removed and
absorbance measured at 570nm to take a baseline measurement of population size. Cells
were then treated per the specific experiment for 24-72 hours before being incubated in
PrestoBlue media again for 60 minutes. Relative viable cell count was inferred from the
final absorbance value, correcting for seeding variation using the initial pre-treatment
reading.
3.13.3 Senescence-Associated β-Galactosidase Assay
Cellular senescence was measured by staining for senescence-associated β-galactosidase
activity. Mammalian cells were cultured in 6-well plates until 70-80% confluent before
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washing with PBS and fixing in 1% formaldehyde PBS for 15 minutes at room tem-
perature. The cells were then washed twice with PBS before incubating in 1 ml of β-
galactosidase assay buffer (38.6 mM citric acid pH6, 38.6 mM NaH2PO4 pH 6, 145 mM
NaCl, 1.93 mM MgCl2, 46 mM K4[Fe(CN)6]·3H2O, 46 mM K3[Fe(CN)6], 0.29 mg/ml X-
Gal) for 20 hours in the dark at 37oC (with atmospheric CO2). Assay buffer was removed,
and the cells preserved in 70% glycerol at 4oC. Images of the cells were captured using a
widefield visible light microscope, and the frequency of blue stained cells (considered to
be senescent) was scored blind in the FIJI distribution of ImageJ.
3.13.4 Trypan Blue Exclusion Assay
Dead mammalian cells were identified by addition of Trypan blue (ThermoFisher: 15250061)
to a single cell suspension. 0.4% Trypan Blue solution was added 1:1 to a cell suspension
before counting by haemocytometer. Blue stained cells were scored as dead as they were




Bristol N2 Wild Type
NB320 dna-2 (jh115)/mln1[dpy-10 (e128) mls14 (GFP) II
Unassigned fncm-1 mutant fncm-1 (tm3148)
CB5348 mrt-2 (e2663)
Table 18. C. elegans Strains
3.14.1 Maintaining Stock Populations
C. elegans were maintained on nematode growth medium (NGM) plates at 20oC in sealed
containers to preserve humidity. Plates were propagated by picking approximately 5 adult
worms twice a week. NGM plates were seeded with 50 µl of an OP50 E. coli culture the day
before use, allowing the bacterial lawn to grow overnight. All strains were maintained as
homozygotes except NB320, which was maintained as a mixed population of homozygotes
and heterozygotes, using the GFP balancer chromosome to distinguish genotype.
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Solutions for maintenance of C. elegans strains
Solution Ingredients
NGM with Agar 51 mM NaCl, 62.5 mg/ml Peptone (Formedium:
PEP03), 20 mg/ml Agar (Formedium: STDA01), 1 mM
CaCl2, 1 mM MgSO4, 25 mM KH2PO4, 0.1% cholesterol
solution.
Cholesterol Solution 0.5 mg/ml cholesterol (Sigma-Aldrich: C8667) in
ethanol.
M9 Buffer 5 mg/ml NaCl, 3 mg/ml KH2PO4, 6 mg/ml Na2HPO4,
1 mM MgSO4
Worm Freezing Solution 5.85 mg/ml NaCl, 6.8 mg/ml KH2PO4, 5.6 mM NaOH,
3 mM MgSO4, 30% glycerol.
Table 19. Solutions Used in the Maintenance of C. elegans Strains
3.14.2 Freezing C. elegans
An overgrown (but not dauer) plate that has been starved for approximately 1 day,
containing many L1/L2 larvae, was chosen. The plate was flooded with 2.5 ml sterile M9
buffer and gently swirled to dislodge the larvae. The buffer containing suspended larvae
was pipetted off and added to an equal volume of freezing solution. The solution was
vortexed and aliquotted into 4 cryovials. The cryovials were wrapped in paper towel and
placed in a -80oC freezer.
3.14.3 Crossing Strains
3 early adult stage hermaphrodites were picked and placed on a 6cm NGM plate with
a small OP50 colony (seeded from 20 µl overnight liquid culture) at the centre, along-
side 15 adult males. 5 days after plating, the plates were checked for male frequency. If
the plate contained many males, the cross was considered to have been successful. Adult
hermaphrodites or males were picked depending on requirement (under fluorescent stereo-
scope if discerning balancer chromosome absence/presence was necessary). Picked adults
were plated individually into 6 well plates containing NGM, and after 2-3 days (when
L1-L2 offspring were abundant but had not reached the L3 stage yet) the adults were re-
moved for genotyping by single-worm PCR. Once the adult genotypes were known, plates
containing offspring of the desired adult were taken forward.
3.14.4 Single-Worm PCR
Individual worms were picked and placed in a 200 µl PCR tube containing 10 µl 1 mg/ml
Proteinase K in 1x GoTaq Colourless Reaction Buffer. Tubes were then snap-frozen at
-80oC for a minimum of 10 minutes. Lysis was carried out in an Applied Biosystems Veriti
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96-well thermocycler, heating to 65oC for 90 minutes before proteinase K inactivation at
95oC for 15 minutes. Lysed worms were stored at -80oC before being used directly in
GoTaq PCR reactions as described previously.
3.14.5 Genotyping with Restriction Digestion
The mrt-2 mutation in strain CB5348 is a single base change that introduces a PTC.
This change cannot be detected by running a PCR product directly on an agarose gel.
The mutant allele can however be detected by attempting to digest a PCR product of
the locus with the endonuclease BstNI, as this mutation destroys a BstNI restriction site.
The mutant locus was amplified in a 20 µl PCR reaction as described previously, then 5 µl
of the PCR product was added to a 20 µl digestion reaction (1 µl BstNI (NEB: R0168S),
1 µl NEB 3.1 buffer, 13 µl H2O) and digestion was carried out at 65
oC for 1 hour. The
digestion reaction product was then run on a 2% agarose gel for analysis.
3.14.6 Embryo Development Rate
Homozygous L1 worms were grown at 16oC, 20oC or 25oC for 3 days (5 days for 16oC).
Adult worms were picked to fresh NGM plates and allowed to lay eggs for 3 hours. The
adults were removed, and the embryos grown at the same temperature. Embryo hatching
was scored by visible light stereoscope every 6 hours for 36 hours. For worm strains
carrying the dna-2 mutation, homozygous -/- worms grown from the L1 stage at 16oC,
20oC or 25oC were the first generation progeny from dna-2 (+/-) heterozygotes.
3.15 Representation of Statistical Significance
P values were calculated throughout using the Graphpad Prism software, using the ap-
propriate statistical method (such as ANOVA or t-test) and correcting for multiple com-
parisons as described previously. Data were considered statistically significant (and the
null hypothesis rejected) if a calculated P value was smaller than 0.05. Asterisks are used
to indicate P values. * = P<0.05, ** = P<0.01, *** = P<0.001, **** = P<0.0001.
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4 The Effect of CTC1 Loss on Human Cell Growth
and Telomere Homeostasis
Much of the following work was performed using an HCT116 cell line modified by the lab-
oratory of Carolyn Price to carry an inducible homozygous deletion of CTC1 . The aim of
this chapter was to establish this cell line as a model for CTC1 deletion in our laboratory,
confirming preliminary data characterising the effect of CTC1 loss on the telomere and
cell growth conveyed to us by Carolyn Price. The inducible CTC1 deletion in the HCT116
cell line uses the (ER)Cre-lox system. Introns flanking exon 5 of CTC1 were edited to
include loxP sites. loxP sites are 34bp sequences originating from the bacteriophage P1
that are capable of being recombined by the Cre recombinase. Recombination results in
the looping out and deletion of the DNA tract between the two sites [241]. In HCT116
CTC1 lox/lox cells deletion of the DNA tract results in the loss of exon 5 as well as the
formation of a premature termination codon. Cre recombinase is constitutively expressed
in these cells, but it is fused to a ligand-binding domain of the human oestrogen receptor.
As a result the Cre recombinase is retained in the cytoplasm, but enters the nucleus upon
interaction with the ER-binding drug tamoxifen. Knockout of CTC1 can be achieved
simply by exposing the HCT116lox/lox cells to 10 nM tamoxifen in the culture media.
To confirm the deletion of the CTC1 exon 5 locus by the Cre-loxP system cells were
exposed to 10 nM tamoxifen for 0 to 8 days, before the locus was assayed by PCR
using primers that flanked one of the loxP sites. The PCR products were run on an
agarose gel and the successful deletion of the locus confirmed (Fig. 21a). Whilst some
PCR product is still detectable at days 2-8 (indicating incomplete deletion of CTC1 in
the population), this method is only semi-quantitative. Band intensity of tamoxifen-
free samples is likely to be limited due to exhaustion of the PCR reaction, and the true
frequency of locus retention in tamoxifen-treated samples lower than appears. To address
this, non-recombined CTC1 mRNA level at day 2 was assayed by qPCR using primers that
were specific to the boundary of exon 4 and exon 5. Full CTC1 mRNA was determined to
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Figure 21. Knockout of CTC1 in CTC1 lox/lox HCT116 cells by 10 nM tamoxifen
exposure (1:2000 ethanol was used as a vector control). (A) Deletion of the loxP-flanked
CTC1 exon 5 locus was semi-quantitatively assayed by PCR. (B) Relative CTC1
mRNA levels after 2 days exposure to 10 nM tamoxifen was measured by qPCR. Bars
represent standard deviation between 3 separate experiments (Biological repeats
collected separately and analysed simultaneously). (C) Diagram of CTC1 exon 5 locus
and intronic loxP sites with forward and reverse PCR primer locations indicated as used
in (A). (D) Diagram of CTC1 mRNA exon 4/5/6 locus with forward and reverse primer
locations indicated as used in (B). The forward primer was located within exon 4 and
the reverse primer was located across the exon4/5 boundary.
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4.1 Loss of CTC1 Results in a Growth Defect
The Price lab reported a strong, albeit delayed, growth defect in HCT116 cells after CTC1
knockout by addition of tamoxifen. In order to confirm this effect, 10 nM tamoxifen
was added to the HCT116 CTC1 lox/lox culture media. Tamoxifen is a common endocrine
therapeutic agent used in cancer treatments that is capable of blocking oestrogen receptors
and affecting cell growth. HCT116 cells do not express ER-α, but do express ER-β.
However, no effect of oestrogen on HCT116 cell growth rate has been reported [246]. In
order to be sure the loss of CTC1 was the controlling growth factor and not the presence
of tamoxifen, a control HCT116 cell line that did not contain loxP sites were exposed
to tamoxifen. As ethanol was used as the vector for tamoxifen, both cell lines were also
exposed to 1:2000 ethanol as an additional control. Cells were counted and passaged every
2-3 days.
A slight decline in population doubling rate in the tamoxifen treated HCT116lox/lox cell
line was detectable by day 6 (Fig. 22). This decline continued until day 12, at which
point growth between time points became very limited. In contrast, neither the ethanol
treated CTC1 lox/lox or either of the wild-type CTC1 cell line cultures demonstrated any
growth defect. These data are congruent with that reported by the Price lab [182].
4.2 CTC1 Deletion Induces Telomere C-strand Shortening
Following the DNA replication process the telomere’s 3′ G-rich strand is extended by
telomerase, and the C-rich strand is potentially resected by exonucleases. This ssDNA
overhang can attract DDR factors. In order to maintain the dsDNA structure of the
majority of the telomere, and to limit the production of ssDNA, data from the Price lab
suggest that a major role of CTC1 in human cells is in telomeric C-strand fill-in. They
report knockout of CTC1 results in gradual loss of telomeric C-rich DNA. As CTC1 is
known to interact with polymerase α-primase [247], they propose the role of CTC1 is in
the promotion of C-rich strand fill-in.
CTC1 deletion was induced and the abundance of C-rich telomeric DNA was measured
after 10 days by PNA probe FISH. 10 days was chosen as the timepoint to maximise the
impact of CTC1 deletion before cell growth became severely limited and metaphase spread
generation would become more difficult (with fewer cells in mitosis). Fluorophore-tagged
PNA probes bind to their target DNA highly efficiently and with linear proportionality.
As such target abundance can be inferred directly from fluorescent microscopy of PNA
probe signal intensity. Telomeric C-rich DNA 10 days after CTC1 knockout-induction
































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
CTC1(f/f) + Ethanol
wt CTC1 + Ethanol















Figure 22. Growth defect after deletion of CTC1. Deletion of CTC1 from CTC1 lox/lox
HCT116 cells was induced by addition of 10 nM tamoxifen to the culture media (1:2000
ethanol used as a vector control). Cells were counted and passaged after 2-3 days.
HCT116 cells without loxP sites were also treated with 10 nM tamoxifen as a control.
Bars represent standard deviation between 3 experimental repeats.
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Figure 23. Reduction in telomeric C-strand signal 10 days after CTC1 knockout.
Deletion of CTC1 from CTC1 (lox/lox) HCT116 cells was induced by addition of 10 nM
tamoxifen to the culture media (1:2000 ethanol used as a vector control). Total
telomeric signal per nucleus was measured by PNA-probe FISH at day 10. (A)
Representative fluorescent images of a CTC1+/+ HCT116 cell. (B) Quantification of
telomeric C-strand probe signal per nucleus. n >350 nuclei per sample.
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4.3 Discussion
This chapter confirms pre-publication data reported to us by the Price lab, ensuring that
the model cell-line that was to be worked with behaved as expected. The Price lab data
are now published as of May 2017 [182]. The cells were received with a mycoplasma
infection, and as such it was particularly important to replicate the reported CTC1∆
phenotypes after mycoplasma elimination.
The deletion of the exon 5 locus of CTC1 quickly achieved high penetrance in the popu-
lation under these conditions as indicated in figure 21. Tamoxifen is a chemotherapeutic
ER ligand that inhibits ERα and ERβ activation and the subsequent proliferative or
anti-proliferative (respectively) signal by blocking the receptor binding sites. HCT116
cells, being colorectal carcinomas, express ERβ but not ERα. Consequently 10 nM ta-
moxifen, were it to have any effect on cell proliferation at all, would likely promote cell
growth and not inhibit it. Oestrogen has however been reported to not effect HCT116
cell growth, even at significantly higher concentrations than used here [246]. Despite this,
it was important to ensure that tamoxifen was not affecting the growth of HCT116 cells
in a way that might be enhancing or masking a growth defect. As shown in figure 22, 10
nM tamoxifen did not affect cell growth in control cells. In contrast, cells containing the
CTC1 lox/lox system had the gradually increasing growth defect described by the Price lab.
From this we can be confident that the growth defect is induced by the loss of CTC1 .
The gradual development of the growth defect is consistent with a telomeric defect, as
genome-protective cellular senescence becomes more and more frequent as the telomeres
of cells in the population shorten.
The Price lab reported a shortening of of the C-rich strand of the telomere after CTC1
knockout in the HCT116 CTC1 lox/lox cell-line. They proposed the essential role of CTC1
was in C-strand fill in, based on the gradual loss of the C-strand and the previously re-
ported interaction of CTC1 with polymerase-α primase. Here those data are replicated,
showing the average amount of telomeric C-strand signal per nucleus is reduced signifi-
cantly 10 days after the CTC1 knockout was initiated. Combined with the growth data,
the CTC1 inducible knockout cell line appears to be an effective and consistent model for
examining the function of CTC1 .
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5 Investigating the Effect of CTC1 Deletion on
Genomic Stability and Checkpoint Activation
What has become clear is that the roles of the CST complex and its components extend
beyond the telomere and into the wider genome. For example STN1 has been demon-
strated to support replication restart at stalled forks during DNA replication [173] (albeit
limited to GC-rich regions) through the recruitment of RAD51 [185]. Distinguishing
telomeric impacts of CTC1 loss from genome-wide impacts however is not straightfor-
ward. It has been reported that loss of CTC1 in Arabidopsis induces chromatin bridges
[119] (a marker of genomic instability). This appears to be a result of telomere uncapping
as CTC1 loss in Arabidopsis induces frequent telomere fusions, a precursor of chromatin
bridge formation. Additionally, inhibition of telomere fusions in ctc1 mutant Arabidopsis
(by eliminating end-joining pathways) restores normal plant growth [248]. In contrast to
this, whilst chromatin bridges have been reported in CTC1 partial knockdown human
cell lines [173], very few chromosome fusions were reported in CTC1 -/- cells [182]. An
additional complicating factor is that previously reported phenotypes of CTC1 depletion
appear to differ significantly depending on the efficiency of the knockdown and whether
the knockdown was stable or acute [173] (For example acute knockdown of CTC1 by
small interfering RNA (siRNA) in HeLa S3 cells increased the frequency of chromosomes
with telomere signal-free ends, but this was not seen in shCTC1 or shSTN1 HeLa clones).
The goal of this chapter is to examine the nature of the genomic instability observed in
CTC1 -/- HCT116 cells in order to elucidate telomeric from non-telomeric impacts of the
loss of CTC1 .
5.1 Loss of CTC1 Induces Genomic Instability
One marker for genomic instability is the presence of micronuclei [249]. Micronuclei are
small nuclei outside of the main nucleus of the cell. They contain DNA that was not
incorporated into one of the two daughter nuclei formed during cell division. The root
cause of micronuclei formation is typically one of three events: a chromosome failed
to correctly attach to the mitotic spindle and was subsequently not pulled into one of
the two new daughter nuclei (Fig. 24a); incorrectly repaired DNA DSBs generated a
dicentric chromosome and a centromere-free chromosome fragment that cannot attach
to the mitotic spindle (Fig. 24b); or telomeric fusions result is a dicentric chromosome
that is pulled in two directions simultaneous, trapping DNA in the cytoplasmic space
between the daughter nuclei (Fig. 24c) [250]. All three pathways mean a complete and
accurate copy of the genome is not transferred to both daughter cells of the division. If
the daughter cells survive the event this can result in a wide spectrum of diseases, from
developmental disorders (due to chromosome aneuploidy) to cancers (due to loss or gain
of function mutations in tumour suppressors and oncogenes). Micronuclei are a simple
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marker for a catastrophic failure in the maintenance of a cell’s genomic integrity.
To assess whether the loss of CTC1 increases micronuclei frequency in HCT116 cells,
deletion of CTC1 was induced. Four days after CTC1 lox/lox knockout induction micronu-
clei frequency increased approximately 3 fold (Fig. 26). This change was suppressed in
the exogenous CTC1 -rescue cell line. These data imply an important role for CTC1 in
maintaining genomic integrity in human cells.
The CTC1 knockout micronuclei phenotype shows a significant compromise to genomic
stability after the loss of CTC1 . What remained unclear is the nature of the micronu-
clei formation; micronuclei could be indicative of a chromosome-spindle assembly error,
telomeric fusions, or DSB repair errors/failure [250]. As shown in Fig. 24, the different
pathways of micronuclei formation produce distinguishable patterns of chromatin bridges
and telomere/centromere segregation. Spindle binding errors can produce micronuclei
by proceeding through anaphase with a kinetochore connected to both spindle poles (re-
ferred to as a merotelic kinetochore), which as a result lags behind the other chromosomes.
This produces no chromatin bridges, but does produce a micronucleus containing both
centromeric and telomeric DNA (Fig. 24a). Incorrect repair of DSBs can result in the
production of dicentric and acentric chromosomes (Fig. 25). If this happens then during
anaphase the dicentric chromosome is pulled in two directions simultaneously, producing
a (non-telomeric) chromatin bridge. The acentric chromosome is pulled towards neither
pole, and subsequently forms a micronucleus containing telomeres but not centromeres
(Fig. 24b). Additional micronuclei may form when the chromatin bridge is broken, but
these will contain no telomeric or centromeric signal. The production of micronuclei
by telomere fusion-induced dicentric chromosomes can be distinguished from the above
pathways by identifying the presence of their precursor, chromatin bridges that contain
telomeric signal. These telomere-positive chromatin bridges will form telomeric (but not
centromeric) micronuclei when they break and leave DNA trapped outside the daughter
nuclei (Fig. 24c).
To assess the origin of CTC1 knockout-induced micronuclei, CTC1 knockout was induced
in HCT116 cells and the micronuclei/chromatin bridges produced were probed for telom-
eric and centromeric content by PNA probe FISH. The predominant class of micronucleus
present both before and after CTC1 knockout contained telomeric but not centromeric
DNA (Fig. 27). At 4, 8 and 12 days post CTC1 knockout approximately 15% of all
nuclei had adjacent micronuclei containing only telomeric signal (Fig. 27b). This is an
approximately 6-fold change compared to 2.5% of nuclei at day 0. Micronuclei containing
only centromeric probe signal were very rare and the was no significant change in their
frequency (Fig. 27c). Micronuclei containing both telomeric and centromeric DNA were
10-fold less frequent than micronuclei with only telomeric signal, but there was a signif-
icant increase in their frequency from approximately 0.4% of nuclei at day 0 to 1.5% at
day 12 (Fig. 27d). Micronuclei containing neither telomeric nor centromeric signal were





Figure 24. Pathways of Micronucleus and Chromatin Bridge Formation. Telomeres are
indicated in green, centromeres are indicated in yellow. (A) A chromosome is
inappropriately attached to the mitotic spindle (such as being attached to both spindle
poles) and lags behind the group of correctly attached chromosomes during anaphase.
(B) Incorrect repair of DSBs can produce dicentric and acentric chromosomes (as shown
in figure 25). The acentric chromosome is unable to attach to the mitotic spindle and as
such is not pulled towards either pole during anaphase. Consequently it is not
integrated into either of the daughter nuclei. The dicentric chromosome is pulled
towards both poles simultaneously and as such produces a chromatin bridge. This
bridge can also form additional micronuclei if/when the bridge is broken. (C) The fusion
of telomeres can produce a multi-centric chromosome that is pulled towards both poles
simultaneously during anaphase, forming a chromatin bridge. This chromatin bridge is
discernible from the kind described in B as it contains telomeric DNA. As above,
breakage of this telomeric chromatin bridge can produce micronuclei. Figure adapted























Figure 25. Formation of Dicentric and Acentric Chromosomes from DSB Repair Errors.
When DSBs occur the two ends of the break must be re-ligated. (A) If an error-prone
repair mechanism is used to repair multiple blunt breaks simultaneously the the fusion
of chromosomes is possible. (B) If a cell with a single DSB fails to arrest and enters
S-phase, then one broken chromatid becomes two broken chromatids, and these sister
chromatids may be inappropriately ligated together. Telomeres are indicated in green,






















































Figure 26. Formation of micronuclei following CTC1 knockout in HCT116 cells.
Deletion of CTC1 from HCT116 cells was induced by addition of 10 nM tamoxifen to
the culture media (1:2000 ethanol used as a vector control). After 4 days cells were fixed
on coverslips and stained with DAPI. Micronuclei frequency was scored blind from 20x
magnification widefield fluorescent microscopy images. (A) Representative fluorescent
images of micronuclei in HCT116 cells. Yellow arrowheads indicate micronuclei. (B)
Quantification of the frequency of micronuclei. Bars represent standard deviation
between three experimental repeats. Statistical significance was performed by two-way
ANOVA correcting for multiple comparisons (Tukey’s method).
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telomere-only micronuclei (Fig. 27e).
The dominant presence of micronuclei with only telomeric signal from day 4 suggests the
primary cause of micronuclei in CTC1 -/- cells is either a global DSB repair defect, or telom-
eric fusions. The Price lab reported an insignificant effect of CTC1 knockout on telomere
fusion frequency [182] which suggests the former pathway is likely the cause. This can
be confirmed by examining chromatin bridge frequency and content. The increase in mi-
cronuclei containing neither telomeric nor centromeric DNA could be explained by either
telomere fusions or DSB repair errors as they are a product of chromatin bridge breakage.
Despite representing only a small portion of total micronuclei, the approximately 3-fold
change in the frequency of micronuclei containing both telomeric and centromeric DNA
was significant. Mis-segregation of whole chromosomes means the SAC failed to ensure all
chromosomes are attached to the mitotic spindle correctly before entering anaphase. This
suggests that whilst spindle assembly errors are very rare in HCT116 cells, CTC1 knock-
out does negatively impact the ability of the SAC to control chromosome segregation.
The main impact of CTC1 knockout on genomic stability appears to involve DSB repair
failure rather than telomere fusions (based on the logic above), but in order to rule out
telomere fusions, chromatin bridges in CTC1 -/- HCT116 cells were probed for telomeric
DNA. As expected from the micronuclei data, 4 days after knockout induction the fre-
quency of telomeric signal-free chromatin bridges increased from approximately 1 bridge
per 100 nuclei to more than 5 bridges per 100 nuclei (Fig. 28). A more than 5-fold increase.
The frequency of telomeric chromatin bridges at this time-point was effectively 0 in both
control and CTC1 -/- cells. 10 days after CTC1 knockout induction chromatin bridges
staining positive for telomeric signal occurred approximately 1.5 times per 100 CTC1 -/-
nuclei scored. These data suggest loss of CTC1 in human cells can induce telomere fu-
sions (as telomeric signal appears to be located between two centromeres on a dicentric
chromosome, see figure 24b), however these fusions appear at a relatively low frequency.
The telomeric bridges also do not appear until relatively late compared to the bulk of
CTC1 -/--induced chromatin bridges and micronuclei. From this data we can conclude the
bulk of the genomic instability induced by loss of CTC1 , particularly at early time-points,
is most likely a result of global DNA repair errors and not a telomere-specific phenotype.
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Figure 27 . Telomeric and centromeric DNA in CTC1 -deletion induced micronuclei.
Deletion of CTC1 from HCT116 cells was induced by addition of 10 nM tamoxifen to
the culture media (1:2000 ethanol used as a vector control). After 4, 8 or 12 days cells
were fixed on coverslips and probed with telomeric C-strand and centromere specific
PNA probes. Micronuclei content was scored blind from 60x magnification widefield
fluorescent microscopy images. (A) Representative fluorescent images of a CTC1 -/- (day
12) HCT116 nucleus. White arrowhead indicates micronucleus containing both
telomeric and centromeric DNA. (B) Quantification of the frequency of micronuclei
containing telomeric but not centromeric DNA. (C) Quantification of the frequency of
micronuclei containing centromeric but not telomeric DNA. (D) Quantification of the
frequency of micronuclei containing both telomeric and centromeric DNA. (E)
Quantification of the frequency of micronuclei containing neither telomeric nor
centromeric DNA. Bars represent standard deviation between three experimental
repeats. Statistical significance was performed by two-way ANOVA correcting for

















































































































































































































































































































































































Figure 28. Telomeric chromatin bridges in CTC1 -/- HCT116 cells. Deletion of CTC1
from HCT116 cells was induced by addition of 10 nM tamoxifen to the culture media
(1:2000 ethanol used as a vector control). After 4 or 10 days cells were fixed on
coverslips and probed with a telomeric C-strand specific PNA probe. Telomere signal on
chromatin bridges was scored blind from 60x magnification widefield fluorescent
microscopy images. (A) Representative fluorescent images of CTC1 -/- (day 10) HCT116
nuclei. The white arrowhead indicates a non-telomeric chromatin bridge. The yellow
arrowhead indicates a telomeric chromatin bridge. (B) Quantification of the frequency
of non-telomeric chromatin bridges at day 4 and day 10. (C) Quantification of the
frequency of telomeric chromatin bridges at day 4 and day 10. Bars represent standard
deviation between three experimental repeats. Statistical significance was performed by
two-way ANOVA correcting for multiple comparisons (Tukey’s method).
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5.2 Checkpoint Activation after Knockout of Human CTC1
Differs from Checkpoint Activation by cdc13-1 in
Saccharomyces cerevisiae
S. cerevisiae CTC1 homologue CDC13 has a well-characterised mutant allele cdc13-1.
cdc13-1 is a temperature sensitive mutant, at the non permissive temperature (>30oC)
ssDNA accumulates and a checkpoint-dependant G2/M arrest is induced [251]. This ar-
rest can be bypassed for multiple cell cycles by the deletion of CHK1 [252]. Telomere
damage induced by cdc13-1 activates the Mec1 kinase (homologue of human ATR) which,
via the adapter protein Rad9, results in the phosphorylation of Chk1 [253][254] (Rad9 also
activates Rad53, the budding yeast homologue of CHK2, which inhibits degradation of
the uncapped telomere [255]). Activated Chk1 mediates cell-cycle arrest via phosphory-
lation of Pds1 [256]. In human cells ATR is activated like Mec1 in response to ssDNA,
which phosphorylates (both directly and indirectly) CHK1. The primary effect of CHK1
phosphorylation is the phosphorylation of CDC25, resulting in its inhibition and degra-
dation. Inhibition of CDC25 leads to increased inhibitory phosphorylation of CDK-cyclin
complexes and cell cycle progression is stopped [257]. It has been reported that popula-
tions of CTC1 -/- cells have a slight increase in G2 cells after 20 days [182], which suggests
Chk1-mediated arrest seen in budding yeast might be mirrored in human CTC1 -/- cells.
In order to determine if a bypass of human CTC1 dependence could be achieved by
inhibiting CHK1, CTC1 knockout was induced and six days later the relative population
size was compared to that of a CTC1+/+ culture. Six days was chosen as it is the first
time-point at which a statistically significant change in growth rate can be detected.
Cells were exposed simultaneously to CHK1 inhibitor CCT245737 ranging from 0 to 5
µM, covering the range of concentrations CCT245737 has been reported to be effective
at in cell culture [258] and including the concentration at which CCT245737 appeared
Figure 29 . Checkpoint protein CHK1 is not activated after loss of CTC1. 4, 8 or 12
days after CTC1 knockout by addition of 10 nM tamoxifen the culture media (or 1:2000
ethanol as a vector control), whole cell protein lysates were collected from HCT116 cells.
CHK1 total levels and serine 296 phosphorylation status was assayed by Western blot.
Histone H3 was used as a loading control. (A) Representative Western blot of CHK1
total levels and serine 296 phosphorylation status. 3 mM Hydroxyurea (6 hours) was
used as a positive control for detection of CHK1 phosphorylation. (B) Quantification of
P-CHK1 (s296) signal normalised to loading control histone H3 and day 0. (C)
Quantification total CHK1 signal normalised to loading control histone H3 and day 0.
Bars represent standard deviation between three experimental repeats. Quantifications
were performed using the FIJI distribution of ImageJ analysis software. Statistical
significance was performed by two-way ANOVA correcting for multiple comparisons
(Sidak’s method).
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effective in inhibiting P-CHK1(s296) accumulation in response to etoposide (Fig. 30c).
In contrast to what is seen in S. cerevisiae, inhibition of CHK1 was not able to rescue
the growth defect of CTC1 -/- cells (Fig. 30). Human CHK1 has an essential function
in normal mitotic progression that can be uncoupled from the DDR [259], unlike in S.
cerevisiae which can be completely knocked-out without stopping cell cycle progression
[252]. In this sense it is perhaps unsurprising that inhibition of CHK1 in human cells is
not able to positively impact cell cycle progression.
To further rule out any role CHK1 may have in the response to loss of CTC1 , CHK1
phosphorylation at serine 296 (the autophosphorylation site of CHK1) was assayed by
Western blot 4, 8 and 12 days after CTC1 knockout. In concordance with the inability of
a CHK1 inhibitor to rescue the CTC1 -/- growth defect, no increase in phosphorylation of
CHK1(s296) was detectable after CTC1 knockout (Fig. 29). Taken together these data
imply that unlike cdc13-1 in budding yeast, cell cycle arrest after human CTC1 knockout
is CHK1 independent.
Whilst activation of CHK1 by ATR is necessary for the G2/M DNA damage checkpoint,
ATR can also induce cell cycle arrest by activating the p53-p21 pathway [260], predom-
inantly (but not strictly) at G1/S [261]. As CTC1 -/- induced growth arrest appears
CHK1-independent, the p53-p21 pathway presented a second potential candidate.
p21 is a potent inhibitor of cyclin-CDK2/CDK1/CDK4/CDK6 complexes [262][263], me-
diating cell cycle progression and promoting senescence. The expression of p21 can be
induced in p53 dependent and independent manners (although the expression of p21 is
clinically considered a marker for wild-type p53 expression [263]). To determine if the
CTC1 -/- growth defect involved p21, p21 protein level was assayed by Western blot. 4,
8 and 12 days after CTC1 knockout induction whole-cell protein lysates were collected
Figure 30 . Treatment with CHK1 inhibitor does not rescue the growth defect of CTC1
knockout cells. 6 days after CTC1 knockout with 10 nM tamoxifen (the first timepoint
at which the knockout growth defect is statistically significant), viable population size
was measured by PrestoBlue assay. The effect of a range of concentrations of CHK1
inhibitor CCT245737 on relative viable cell count was assayed. (A) Quantification of
relative viability of both CTC1+/+ and CTC1 -/- HCT116 cells whilst exposed to a range
of concentrations of CCT245737. Bars represent standard deviation between three
experimental repeats. (B) Quantification of CTC1 -/- cell viability relative to CTC1+/+
cells at each concentration. Bars represent standard deviation between three
experimental repeats, statistical significance calculated by one-way ANOVA, correcting
for multiple comparisons using Dunnett’s method. (C) Western blot of CHK1
phosphorylation at serine 296 to confirm efficacy of CHK1 inhibitor CCT245737 in
HCT116 cells. Cells were exposed in duplicate to 1 µM CHK1 inhibitor and/or 10 µM
etoposide for 6 hours.
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from HCT116 cells and p21 expression was assayed. An increase in p21 was statistically
significant by day 8, and particularly strong by day 12 (Fig. 31b). The conclusion drawn
from this is that the growth defect of CTC1 knockout is most-likely p21 mediated.
p21 can be activated in a p53 dependant and p53 independent manner; to determine if
p53 was activated after CHK1 knockout, p53 serine 15 phosphorylation and total p53
abundance was also assayed by Western blot. Like p21, p53 stabilisation was significantly
increased at day 12 after CTC1 knockout (Fig. 31d), as was its phosphorylation (Fig.
31c). These data suggest the growth defect in CTC1 -/- cells is due to the activation of




























































































































































Figure 31. p53 and p21 are activated after loss of CTC1. 4, 8 or 12 days after CTC1
knockout by addition of 10 nM tamoxifen the culture media (or 1:2000 ethanol as a
vector control), whole cell protein lysates were collected from HCT116 cells. Total p21,
total p53 and p53 s15 phosphorylation was assayed by Western blot. β-actin was used
as a loading control. (A) Western blot representative of three experimental repeats. (B)
Quantification of total p21 relative to β-actin. (C) Quantification of phosphorylated
p53(s15). (D) Quantification of total p53. Bars represent standard deviation between
three experimental repeats. Statistical significance was calculated by two-way ANOVA
using Sidak’s correction for multiple comparisons.
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5.3 Inhibition of G-Quadruplex DNA Structures by CTC1
The human CST complex facilitates recruitment of RAD51 to GC-rich stalled replica-
tion forks, promoting fork restart [185]. It was hypothesised that this might be at least
partly due to the suppression of DNA secondary structures by the CST complex. G-
Quadruplexes are secondary structures formed by G-rich tracts of DNA. They can be
formed by 1, 2 or 4 separate strands of oligonucleotides, but all forms rely on Hoog-
steen hydrogen bonds between guanine bases of DNA or RNA [264]. G-quadruplexes
occur naturally throughout the genome, particularly on the G-rich telomere strand [140].
These secondary structures have been demonstrated to inhibit the action of telomerase,
polymerases, and helicases at the telomere [140].
To determine if the CST complex might be inhibiting the formation of (and/or resolving)
G-quadruplex structures, G-quadruplex DNA abundance in CTC1 -/- cells was assayed
by immunofluorescence. CTC1 knockout was induced and 4 days later cells were fixed
and probed with anti-G4 monoclonal antibody 1H6 [265]. Interphase nuclei of CTC1 -/-
HCT116 cells contained an average of approximately 40% more G-quadruplex signal than
CTC1+/+ control cells. These data suggest than the CST complex is able to either inhibit
the formation of, or resolve, G-quadruplex DNA structures. Assisting the unimpeded
progression of replication forks through G-rich DNA by eliminating G4 structures is an
obvious benefit to the cell, but the telomeric impacts are perhaps more nuanced. G-
quadruplexes have been demonstrated to inhibit the activity of telomerase [140], but
the CST complex is also a telomerase inhibitor. The CST complex is responsible for
ensuring overextension of telomeric 3′ ssDNA does not occur [171], as this can attract DDR
factors. In a similar way, G-quadruplexes may be one of many important balancing factors




















































Figure 32. Increased G-Quadruplex DNA secondary structures after CTC1 knockout. 4
days after CTC1 knockout by addition of 10 nM tamoxifen the culture media (or 1:2000
ethanol as a vector control), HCT116 cells were fixed and stained for
immunofluorescence. Images were captured by widefield fluorescent microscopy and
signal quantification was performed using the FIJI distribution of ImageJ. (A)
Representative fluorescent images of G-Quadruplex signal in HCT116 cells. (B)
Quantification of G-Quadruplex immunofluorescent signal. Bars represent standard
deviation between 3 experimental repeats. Significance calculated by student’s t-test.
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5.4 Discussion
This chapter uses the inducible CTC1 knockout HCT116 cell-line to address the roles of
CTC1 and the CST complex beyond the promotion of polymerase-α activity at the telom-
ere. Non-telomeric roles for the CST complex have been previously identified by others,
such as recruiting RAD51 to stalled replication forks [185]. When replicating the HCT116
CTC1 knockout data from the Price lab, the rapid increase in micronuclei abundance was
surprising; all other reported CTC1 -/- phenotypes such as telomere shortening, γH2AX
foci, and growth-rate decline gradually accumulated over more than 10 days. Micronuclei
on the other hand were strongly apparent from as early as day 2, maintaining a consistent
frequency of 15-20% after that point. The disparity in time-frames between the micronu-
clei and the telomeric phenotypes pointed towards separate destabilising pathways.
A small fraction of chromatin bridges and micronuclei present 10 days after CTC1 knock-
out do appear to be due to telomere fusions (1 in 5 chromatin bridges contain telomeric
signal (Fig. 28). Telomere fusions are typically produced by activation of the DDR at
uncapped telomeres, resulting in NHEJ being used to attach the ends of two separate
chromatids/chromosomes. It appears that whilst compromise to telomere homeostasis in
CTC1 -/- cells is inducing some genomic instability at day 10, the bulk of the instability
induced by CTC1 loss is telomere independent. At earlier time-points this non-telomeric
destabilisation appears to be responsible for effectively all micronuclei formed due to the
loss of CTC1 . The high frequency of micronuclei with telomeric signal but not centromeric
signal (Fig. 27), and the low frequency of telomere-positive chromatin bridges (Fig. 28)
points to a DSB-repair issue (as explained in figures 24 & 25) [250]; either more DNA
damage is occurring after CTC1 knockout, or the same amount of damage is occurring
but a larger portion of it is being repaired incorrectly. Loss of CTC1 has been reported to
not affect non-telomeric γH2AX frequency [266] (these data are also replicated in chap-
ter 6), which suggests the latter could be true. CTC1 -/- HCT116 cells appear to have
compromised DSB repair.
Interestingly, there is a significant increase of micronuclei containing whole chromosomes
in CTC1 -/- cells (Fig. 27). The presence of micronuclei containing whole chromosomes is
an indicator of a failure during telophase to correctly integrate them into daughter nuclei.
The most common cause of aneuploidy in tumour cells is not a SAC error per se, but
rather lagging chromosomes during anaphase [267] (individual chromosomes that exhibit
delayed segregation during anaphase). The cause of lagging chromosomes is the pres-
ence of a persistent merotelic kinetochore, a kinetochore that is attached to microtubules
originating from both spindle poles [268] (Fig. 33). As kinetochore-spindle binding oc-
curs stochastically, merotelic kinetochores are common during the early stages of mitosis
but these are typically resolved by release and re-binding in the correct orientation [268].
Both increases in formation rates and decreases in resolution rates have been reported
in different aneuploid cancers [269]. It has been reported that 80% of lagging chromo-
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somes in HCT116 cells result in micronuclei formation [61]. The presence of micronuclei
containing whole chromosomes in CTC1∆ HCT116 cells therefore suggests a defect in
appropriate chromosome-spindle binding is present, perhaps due to increasing the rate of
kinetochore-microtubule binding, or by stabilising the binding and inhibiting the resolu-
tion of inappropriately bound merotelic kinetochores.
An increase in ≥4N (tetraploid) cells has been detected after CTC1 knockout [182], indi-
cating some mitotic slippage has occurred. Mitotic slippage is the exit of cells from mitosis
into G1 inappropriately. Often this means failure to complete telophase and cytokinesis,
where the mitotic spindle collapses without segregation of chromosomes into two daughter
cells, forming one multi-nucleated 4N cell. This happens after persistent SAC activation
(the delay required before slippage occurs can range from 4 to 20+ hours), and involves
the degradation of cyclin-B by the APC [270]. Typically merotelic kinetochores do not in-
duce persistent SAC activation as the microtubule binding requirements of the checkpoint
are satisfied [268]. However, syntelic attachment (where both chromosomes are attached
to the same spindle pole and not the other) does cause SAC activation and mitotic ar-
rest, possibly due to a lack of tension applied to the kinetochores [62]. A possible model
that explains the increase in both ≥4N cells and micronuclei containing whole chromo-
somes by a single mechanism is that loss of CTC1 stabilises kinetochore-spindle binding.
If merotelic or syntelic kinetochores are unable to release from the mitotic spindle then
they will produce lagging chromosomes or persistent SAC arrest and mitotic slippage re-
spectively (Fig. 33). Alternatively, the accumulation of ≥4N cells and the formation of
whole-chromosome micronuclei observed after CTC1 knockout may be due to two sepa-
rate pathways. It has been reported that chromatin bridges can cause cytokinesis to fail,
resulting in binucleated cells [271]. As reported here, loss of CTC1 induces chromatin
bridge formation. Therefore the origin of ≥4N cells may be chromatin bridge-induced
cytokinesis abortion, and not spindle collapse following syntelic kinetochore binding. No-
tably, 4N cells produced by cytokinesis abortion result in binucleated cells (as they have
passed through telophase) and not mononucleated 4N cells (which would be produced fol-
lowing spindle collapse [272]). The proportion of mono vs multi-nucleated ≥4N CTC1 -/-
cells is not currently known. This could be assessed by fluorescent microscopy, staining
for DNA and the cytoskeleton.
No role for the CST complex at the kinetochore and/or mitotic spindle has been reported
previously, however there are a number of proteins that function at both the telomere and
the kinetochore. For example, shelterin component TRF1 has been found at kinetochores,
and is essential there for regulating Aurora-B and ensuring proper chromosome segregation
[273][274][275]. Whilst TRF1 has not been demonstrated to interact with CTC1 directly,
the co-purification of STN1 with TPP1 [276] indicates physical interaction between the
CST complex and shelterin does occur. Evidence for a role of CTC1 in mitosis is so far
more circumstantial than direct, but is worth following up.
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Figure 33. The effect of merotelic and syntelic kinetochores on chromosome segregation.
(A) Merotelic kinetochores result in lagging chromosomes by resisting appropriate
segregation towards one pole. Lagging chromosomes are frequently trapped outside the
main nucleus in a micronucleus. (B) Syntelic kinetochores are thought to result in SAC
activation due to a lack of tension applied to the kinetochore. Persistent SAC activation
can eventually result in mitotic slippage and the generation of a single 4N cell in G1.
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Chk1 is phosphorylated and activated by Mec1 (The budding yeast homologue of ATR)
and Chk1 [253]. Chk1 activated by DNA damage phosphorylates and stabilises Pds1
[277]. Subsequently Pds1 inhibits Esp1, a protease that cleaves cohesin and allows sister
chromatid separation in anaphase [278]. Similar to budding yeast, the human CHK1
protein is activated through phosphorylation by ATR. RPA binds ssDNA, which recruits
ATR as well as a multitude of repair factors [56]. The formation of this complex of
proteins stimulates ATR to phosphorylate CHK1 at serines 317 and 345, which in turn
induces CHK1 autophosphorylation of serine 296 [279]. Two of the downstream targets
activated by CHK1 are the kinase WEE1 and the phosphatase CDC25C, both of which
inhibit CDK1 and arrest the cell before the G2/M transition. As budding yeast cdc13-1
triggers the activation of Chk1, and human CTC1 knockout induces RPA accumulation at
the telomere [182] (an event that typically occurs upstream of CHK1 activation), CHK1
presented the obvious candidate for mediating CTC1 -/--induced cell cycle arrest. Instead,
it appears the main pathway mediating the arrest is CHK1-independent p53/p21. p53
activation can occur downstream of CHK1 activation, but can also be induced by a
multitude of other pathways including direct phosphorylation of p53 serines 15 and 37 by
ATR [280]. Phosphorylation of p53 results in the stabilisation of p21, which is capable of
inducing arrest in both G1 and G2 through CDK2/CDK4 or CDK1 inhibition [281][282].
The data in this chapter demonstrates the importance of CTC1 beyond the telomere in
maintaining global genomic stability, and suggests a potential novel role in mitosis. This
is not to downplay the clearly crucial role of CTC1 at the telomere; whilst global genomic
instability is apparent from an early stage following CTC1 knockout, the growth defect is
minimal until the telomeric phenotypes become more advanced. On the other hand, the
model HCT116 cell line is derived from a colorectal carcinoma and it is hard to extrapolate
the tolerance of stresses to truly wild-type cells; different cell types may be more sensitive
than others to the non-telomeric genomic instability induced by CTC1 knockout.
Mutations in CTC1 are associated with diseases such as Coats plus syndrome affecting
the brain, bones, eyes, and gastrointestinal system [176]. It is possible that DSB re-
pair or chromosome segregation errors play a role in CTC1-related disease development,
potentially offering alternative avenues for the targeting of therapeutics.
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6 The Regulation of STN1 by Nonsense Mediated
Decay
NMD was originally defined as a quality control pathway ensuring polypeptides are not
produced from mRNA containing a PTC [283] (Fig. 18). However, NMD has also been
demonstrated to degrade a fraction of ’normal’ mRNAs that do not contain PTCs, in
S. cerevisiae this is estimated to be approximately 10% of all genes [284][285]. One of
the genes suppressed by the NMD mechanism in budding yeast is STN1 [286] (TEN1
appears to also be targeted by NMD, but not as strongly). NMD is targeted to STN1
mRNA due to the presence of a overlapping-uORF; the 5′ UTR contains two uORFs, one
of which overlaps with and terminates within the main STN1 ORF. The stop codon of the
overlapping-uORFs is interpreted as a PTC, inducing the degradation of the mRNA by
NMD [231]. Human STN1 mRNA also contains multiple uORFs, one of which overlaps
with the main reading frame (Fig. 20). Luciferase expression assay data using part of the
human STN1 mRNA 5′ UTR (containing 2 of the 3 uORFs) suggests the STN1 uORF
sequence is capable of reducing expression of downstream transcripts in human cells [231].
The purpose of this chapter is to determine if human STN1 is regulated by NMD.
6.1 U-2 OS Cell STN1 mRNA Abundance is Affected by
NMDI14, but TEN1 and CTC1 mRNA Abundance is Not
To determine if human STN1 mRNA is degraded by NMD, U-2 OS cells were exposed
to 5 µM NMD inhibitor NMDI14 for 3 days. The cell line and drug exposure conditions
were chosen after testing the inhibitor for efficacy in PC-3, HCT116 and U2-OS cells.
ATF4 mRNA was used as a positive control for NMD inhibition as it is known to be
degraded by NMD [287] (ATF4 mRNA also contains an overlapping-uORF). The mRNA
level of all three components of the human CST complex were assayed by qPCR after
NMDI14 exposure. A >2-fold increase in STN1 mRNA abundance was detected after
inhibition of NMD activity (Fig. 34a). No significant change in either TEN1 or CTC1
mRNA abundance was detected. To determine if this change in mRNA abundance was
reflected in the level of STN1 protein, whole-cell protein lysates were taken from U2-OS
cells treated identically with NMDI14 as before and the level of STN1 was measured by
Western blot. Consistent with the qPCR data, STN1 protein levels were increased on
average 1.8-fold after NMD inhibition (Fig. 34b). Taken together, these data support the
conclusion that human STN1 is degraded by NMD.
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Figure 34. Inhibiting Nonsense Mediated Decay raises STN1 levels. U-2 OS cells were
treated with 5 µM NMDI14 for 72 hours. (A) mRNA levels of the CST complex
components CTC1, STN1, and TEN1 were normalised to DMSO treated control
samples. ATF4 is a known NMD target and was used as a positive control for NMD
inhibition, ribosomal 18S and RPL13A were used as reference genes. Bars represent
standard deviation between three experimental repeats, Ct data were tested for
statistical significance using One-Way Anova correcting for multiple comparisons
(Sidak’s method). (B) STN1 protein levels were assayed by Western blot following 5 µM
NMDI14 treatment for 3 days. Blot is representative of 3 separately performed
biological repeats. (C) Quantification of 3 Western blots assaying STN1 levels after 5
µM NMDI14 treatment for 3 days (Blot in (B) is replicate 1). Quantification was
performed using the FIJI distribution of ImageJ.
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6.2 Nonsense Mediated Decay Inhibition after Prolonged G0
DNA Damage Stabilises STN1 mRNA
NMD is down-regulated in response to a number of cellular stresses including endoplasmic
reticulum stress, hypoxia and pathogen-induced stress [288]. It has recently been reported
that one situation in which NMD is downregulated is when non-cycling cells experience
prolonged DNA damage [237]. Nickless et al. (2017) grew RPE-1 cells to confluence
in order to arrest their growth, exposed them to 63 µg/ml bleomycin for 24 hours, then
removed the bleomycin and allowed the cells to recover for 96 hours. After the 96 hours (at
which point significant DNA damage was still present) they reported the down-regulation
of NMD in a MAPK14 (p38)-dependant manner, and the stabilisation of NMD targets.
To determine if STN1 mRNA degradation was reduced under similar conditions as the
above experiment was replicated, using ATF4 as a positive control for degradation by
NMD and ORCL as a negative control (as used by Martin et al. [289]). Following the 96
hour recovery period, the RPE-1 cells were exposed to 5 µM actinomycin-D in order to
inhibit the production of new mRNAs by RNA polymerase II (Fig. 35a). Relative mRNA
levels were compared from before and after transcriptional inhibition in order to determine
how quickly each mRNA was being degraded. Relative mRNA levels after actinomycin-D
treatments were assayed instead of just comparing absolute mRNA levels at day 4 in
order to exclude any effect of changes at the transcriptional level. Ribosomal subunit
18S mRNA was used as a reference gene due to its high abundance and stability [237],
but it should be noted that all degradation rates are relative to the degradation of 18S
mRNA. The percentage of mRNA remaining in bleomycin treated cells after the 2 hours
was compared to control cells that were not exposed to bleomycin. As expected, there
was no change in the degradation rate of ORCL mRNA between bleomycin treated and
untreated cells. The NMD target ATF4 was degraded in untreated cells (approximately
75% of the ATF4 mRNA remained after 2 hours) but this degradation was reduced in
the bleomycin treated cells, from which the down-regulation of NMD can be inferred. In
concordance with previous data indicating the degradation of STN1 mRNA by NMD,
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Figure 35. STN1 mRNA degradation after prolonged DNA damage in non-cycling
RPE-1 cells. (A) RPE-1 cells were grown to confluence over 72 hours in order to inhibit
cell cycle progression before exposure to bleomycin (63 mg/ml) or water for 24 hours.
Cells were allowed to recover for 96 hours before transcription was inhibited with 5 µM
Actinomycin-D for two hours. mRNA abundance was then compared before and after
transcription inhibition to determine mRNA decay rate. (B) qPCR data of relative
mRNA levels in cells treated as described before and after transcription inhibition for
two hours. ATF4 was used as a positive control for degradation by NMD, and ORCL
was used as a negative control. Ribosomal 18S was used as a reference gene due to its
high abundance and stability . Bars are standard deviation between three experimental




S. cerevisiae up-frame suppressor (UPF) genes (key NMD components) have long been
known to reduce Stn1 and Ten1 levels, and loss of these NMD genes induces telomere
shortening that is indistinguishable from the shortening seen when Stn1 and Ten1 are
over expressed [290]. More recently our lab reported that through inactivation of DDR
and NMD pathways the requirement for Cdc13 could be efficiently suppressed [291]. This
bypass was suggested to be due to the altered stoichiometry of CST complex components;
raising Stn1 and Ten1 levels allowed them to bind to the telomere without Cdc13.
This chapter showed a significant increase in STN1 mRNA after inhibition of NMD using
the small-molecule inhibitor NMDI14. No significant change in CTC1 or TEN1 level
was seen, but neither human CTC1 or TEN1 mRNA contain overlapping uORFs (TEN1
mRNA contains a uORF but it does not overlap with the main TEN1 ORF, terminating
93 nucleotides upstream). The increase in STN1 mRNA level was approximately 2-fold, a
similar magnitude change to the level of ATF4 , a positive control gene with an overlapping
uORF that is known to be targeted by NMD. The increase in STN1 protein levels was
consistent with the increase in mRNA abundance. NMDI14 inhibits the phosphorylation
of UPF1, a key step in the NMD pathway. It is unclear how efficient this inhibition is; if
the inhibitor is only partially effective then natural inactivation of NMD could result in
even higher levels of STN1 and ATF4 mRNA. However, STN1 appears to be affected by
NMDI14 to approximately the same degree as ATF4 .
Artificial inhibitors are rarely without their drawbacks, however the literature supports
NMDI14’s effective inhibition of NMD with little-to-no cytotoxicity at working concentra-
tions [289] (no cytotoxicity was observed at 5 µM). Assaying degradation of STN1 mRNA
following NMD down-regulation offered useful corroborative data; assessing mRNA degra-
dation rate rather than single-time-point abundance ruled out the effect of other regula-
tory mechanisms (such as transcription factors).
The question remains however, what is the benefit to the cell of regulating wild-type
STN1 mRNA by NMD? One hypothesis is that it allows genes to be more highly tran-
scribed without a necessarily high protein abundance. This could be beneficial for ensuring
essential genes are rapidly transcribed and made available after periods when global tran-
scription was inhibited such as during mitosis. Alternatively, it may be that high STN1
levels have a negative impact on cell viability under healthy/unstressed circumstances,
but are necessary during situations when NMD is down-regulated. NMD is suppressed in
response to a range of cellular stresses [288] including prolonged DNA damage in G0 as
discussed previously. To better understand why regulation of STN1 by NMD is important,
the impact of high STN1 levels on the cell must be assessed.
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7 The Influence of STN1 on Telomere Homeostasis
and Genomic Stability
7.1 Generation of STN1 -Overexpression HCT116 Cells with
an Inducible CTC1 Deletion
The degradation of human STN1 by NMD suggests a possible negative impact of high
STN1 levels on the overall health of the cell. The goal of this chapter is to determine
if a deleterious impact of high STN1 levels is indeed the case, and to understand what
the specific impact might be. Further to this goal, HCT116 cells that stably overexpress
STN1 were produced. The mammalian expression vector pcDNA3 containing flag-tagged
STN1 cDNA under the constitutive cytomegalovirus (CMV) promoter was constructed
and transfected into the CTC1 lox/lox HCT116 cells and stable integration of the STN1
expression cassette was selected for using G418 (STN1 cDNA was a kind gift from Carolyn
Price). Clones were screened for overproduction of STN1 by Western blot approximately
30 days after initial transfection. A clone that expressed approximately 6-fold STN1
compared to wild-type cells and a clone that expressed approximately 3.5-fold STN1
compared to wild-type cells were identified (Fig. 36a). STN1 -OE overexpression clone
DTC15-S9 was assayed for STN1 overexpression 90 days after initial transfection and
STN1 expression was still approximately 5 fold greater than wild-type (Fig. 36b). It is
worth noting that HCT116 cells are triploid for the long arm of chromosome 10 which
contains the STN1 gene, and as such may already have higher STN1 levels than the
average diploid cell line. The exogenous STN1 runs noticeably higher on an SDS-PAGE
gel than the endogenous STN1 due to the flag tag. A parallel CTC1 lox/lox HCT116 cell
line was maintained during the generation of STN1 -overexpression clones in order to have
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Figure 36. Stable overexpression of STN1 in clonal HCT116 cells. (A) Following
transfection with a STN1 expression plasmid and selection for integration with G418,
STN1 expression levels of clonal HCT116 cell populations were assayed (approximately
30 days post-transfection). Cells two days after transient transfection of the STN1
expression cassette were used as a positive control for STN1 overexpression. (B) STN1
expression level in DTC15-S9 overexpression clone 90 days after transfection. Relative
STN1 signal intensity was measured using the FIJI distribution of ImageJ.
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7.2 Increased Genomic Instability Markers in Cells that
Overexpress STN1
The CST complex appears important in maintaining genomic stability (Fig. 26). It has
been reported that overexpression of all three CST complex components simultaneously
can improve HeLa cell viability following exposure to a range of DNA-damage induc-
ing agents (although all agents tested generate cytotoxicity by blocking replication fork
progression, the collapse of which can produce DSBs) [266]. Interestingly there is evi-
dence in budding yeast that high levels of Stn1 can inhibit S-phase checkpoint activation
in response to genome-wide stalled replication forks [292], and the increased viability of
CST-overexpressing HeLa cells could be (at least partially) explained by checkpoint acti-
vation inhibition. The first step in assessing the effect of raising STN1 levels on genomic
stability was to score micronuclei frequency in otherwise unchallenged cells. Micronuclei
were counted by staining fixed STN1 -OE clones DTC15-S9 and DTC15-S12 with DAPI,
and the frequency was compared to the control HCT116 cell line with only endogenous
STN1 . HCT116 cells have a relatively high frequency of micronuclei (Fig. 37) compared
to non-cancerous cells [293], but they are derived from a colorectal carcinoma so the ge-
nomic instability is not necessarily surprising. The control cell line had a micronuclei
frequency of approximately 5%, but micronuclei were more abundant in the STN1 -OE
clones DTC15-S9 and DTC15-S12 with a frequency of approximately 7% (Fig. 37a,b). In
support of these data, average micronuclei abundance was significantly higher in HCT116
cells 3 days after transient transfection with the pcDNA3-STN1 expression vector com-
pared to control cells transfected with a GFP expression vector (Fig. 37c,d). This increase
in micronuclei could be due to a number of factors, but serves as initial evidence that in-
creasing STN1 levels can have negative effects in human cells and is perhaps why STN1
is usually maintained at a low level by NMD.
When DNA is damaged, histone variant H2AX is phosphorylated by ATM or ATR ki-
nases [294]. This phosphorylated histone (referred to as γH2AX) attracts DNA damage
repair factors, and can be easily detected by immunofluorescence using a phosphorylation
specific antibody. Whilst γH2AX phosphorylation spreads along chromatin [295], form-
ing the strong signal that can be detected by immunofluorescence, the phosphorylation
does remain localised enough to form individual foci which can be co-localised with other
signals/structures. Given that STN1 -OE appeared to exacerbate genomic instability in
HCT116 cells (Fig. 37), the presence of γH2AX foci and their location might present
some insight into the cause of the instability.
STN1 -OE HCT116 clone DTC15-S9 cells were arrested in metaphase, centrifuged by cy-
tospin, and fixed in formaldehyde to produce metaphase spreads. The cytospin step was
optimised to ensure effective separation of individual chromosomes without compromising
the chromosomes’ structure by over-centrifugation. The metaphase spreads were probed


















































































Figure 37. Micronuclei frequency in cells overexpressing STN1 . Micronuclei frequency
was assayed by fluorescent microscopy using the DAPI DNA stain. STN1 -OE HCT116
cells were compared to HCT116 cells with wild-type levels of STN1 at an equivalent
passage number. (A) A representative image of STN1 -OE clone DTC15-S9 nuclei
stained with DAPI and wild-type HCT116 cells. Micronuclei are indicated with white
arrowheads. (B) Quantification of micronuclei frequency in STN1 -OE clones DTC15-S9
and DTC15-S12 vs wild-type STN1 HCT116 cells. Quantification was performed using
the FIJI distribution of ImageJ. Bars represent standard deviation between 3 separate
biological repeats. Statistical significance was calculated by one-way ANOVA and
Dunnett’s correction for multiple comparisons. (C) Representative images of HCT116
cell nuclei and micronuclei 3 days after transient transfection with a GFP expression
vector or the pcDNA3-STN1 expression vector. Micronuclei indicated by white
arrowhead. (D) Quantification of micronuclei in (C), Statistical significance calculated
by student’s t-test.
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ondary antibody before hybridisation of telomere C-strand specific PNA probes. The
spreads were then mounted with DAPI to counterstain for total DNA. The frequency
of chromosomes with γH2AX was scored, differentiating between γH2AX foci that colo-
calised with telomeric signal and those that did not (Fig. 38a). The frequency of chro-
mosomes with non-telomeric γH2AX in HCT116 cells with only endogenous STN1 was
approximately 6%, and this increased to 8% in STN1 -OE DTC15-S9 cells (Fig. 38b).
The frequency of telomeric γH2AX foci was unchanged by STN1 overexpression (Fig.
38c). The increase in γH2AX foci further confirms that STN1 -OE HCT116 cells have
compromised genomic stability compared to wild-type cells, and that at any one time
DNA damage is more abundant throughout their genome. The fact that there is no in-
crease in γH2AX foci that colocalise with telomeric signal suggests that this instability is



























































































Figure 38. STN1 -OE HCT116 DTC15-S9 cells have increased non-telomeric γH2AX
foci. HCT116 cells with 5/6-fold raised levels of STN1 (DTC15-S9) were fixed in
metaphase and stained with an anti-γH2AX antibody and a telomeric C-strand PNA
probe. Fluorescent microscopy was used to score frequency of γH2AX foci and their
colocalisation with the telomere. (A) Representative fluorescent images of STN1 -OE
HCT116 DTC15-S9 metaphase chromosome spread. Yellow arrowheads indicate
non-telomeric γH2AX foci, white arrowheads indicate telomeric γH2AX foci. (B)
Quantification of non-telomeric γH2AX foci in STN1 -OE HCT116 DTC15-S9 cells. (C)
Quantification of telomeric γH2AX foci in STN1 -OE HCT116 DTC15-S9 cells. Bars
represent standard deviation between three biological repeats. Significance calculated by
student’s t-test.
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7.3 Overexpression of STN1 Inhibits Homology Directed
Repair
It is now known that the CST complex has a role in the fill-in of DSBs which might
influence the repair pathway taken by the cell [189]. To generalise, there are two main
pathways of DSB repair, HDR and NHEJ. HDR is a very accurate pathway that uses
additional copies of the damaged locus as a template for repair, the restriction of this
pathway is the requirement for easy access to template DNA which mostly limits HDR to
the S and G2 phases of the cell cycle. HDR depends on the generation of a long overhang
of ssDNA which is able to invade template dsDNA. At this point polymerases are able
to replace the damaged locus using a strand of template DNA. The alternative pathway
NHEJ does not require a template, blunt ends generated by DSBs are directly ligated
together. NHEJ is less accurate than HDR and more frequently results in mutations,
deletions, or the ligation of free ends that were not generated by the same DSB. However,
NHEJ does have the benefit of being faster and can easily be performed at any stage of
the cell cycle [296]. Which of the two pathways takes place ultimately depends on the
protein factors that localise at the break and tip the balance in favour of one pathway
over the other. For HDR to take place, the DNA is significantly resected to generate the
long ssDNA overhang that is capable of invading the template strand [297]. NHEJ can
take place without extensive resection.
The CST complex along with polymerase-α is recruited to DSBs by RIF1/Sheildin/53BP1,
and promotes the filling back in of dsDNA at the ssDNA overhang. In this way the
CST complex might inhibit HDR by eliminating the long ssDNA overhang HDR required
[189][175]. It is possible that overexpression of STN1 in otherwise HDR-competent cells is
inhibiting HDR and promoting the NHEJ pathway through the activity of polymerase-α,
a potential explanation of the reduced genomic stability of STN1 -OE HCT116 cells. To
determine if high levels of STN1 inhibit HDR the DRGFP system was used (Fig. 39).
The DRGFP cassette works as a reporter for HDR activity by expressing an inactivated
(non-fluorescent) copy of GFP that contains a restriction site for the endonuclease SceI.
When the endonuclease is expressed (such as by transient transfection of an expression
plasmid), the endonuclease generates a DSB within the inactivated GFP gene. The second
part of the DRGFP cassette is a truncated version of wild-type GFP with no promoter
and missing the 5′ and 3′ ends of the gene, but containing the correct genetic information
where the upstream inactivated GFP carries the SceI restriction site. If the SceI-induced
DSB is repaired by NHEJ then the break is simply re-ligated and the expressed GFP
protein remains inactivated (and possibly even mutated further). If HDR is used to
repair the break, the only template available is the downstream truncated GFP gene.
Using the downstream GFP as a template will restore the fluorescence of the expressed
GFP protein as the cut locus is repaired using the wild-type GFP DNA (Fig. 39). The
pDRGFP plasmid was stably integrated into the genome of U-2 OS cells. A clone likely
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to have integrated only have a single copy of the cassette (as determined by qPCR) was
isolated.
Clonal U-2 OS DRGFP reporter cells were transfected with mammalian expression plas-
mids carrying SceI, SceI + STN1 , or empty vector as a control. In all cases the cells were
transfected with the same total amount of DNA, using empty vector DNA to make up
the difference where applicable. 2 days after transfection, the cells were fixed and imaged
by fluorescent microscopy in order to score GFP-positive cells (Fig. 40a). GFP-positive
cells were present in the empty vector control population with a frequency of <0.1%
(Fig. 40b)(this phenomenon of low-level GFP activation has been previously reported
where random DSB recombination events within the cell are able to restore GFP func-
tion without SceI at a low frequency [245]). In contrast, when SceI was expressed in the
reporter cells the frequency of GFP-positive cells after 2 days was >6%. This suggests
the reporter cassette is functional, and that 6% of cells repaired cut GFP with HDR and
restored GFP fluorescence. When an STN1 expression cassette was co-transfected with
SceI, the fraction of GFP-positive cells was reduced from >6% of cells to approximately
4%. These data indicate that high levels of STN1 are capable of inhibiting HDR, which
possibly explains the increased genomic instability of HCT116 cells that constitutively
overexpress STN1 .
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GFP PuroR 5’/3’ truncated GFPN
HDR reporter cassette integrated into genome 
PuroR 5’/3’ truncated GFPN ?GFP
DSB religated by NHEJ
DSB repaired by HDR using truncated GFP sequence as a template 
Repair products following break induction by SceI
SceI cut site
PuroR 5’/3’ truncated GFPN SceGFP
Figure 39. Detection of Homology-Directed Repair using the DRGFP reporter. The
DRGFP reporter cassette contains a constitutively expressed mutated GFP gene fused
to a nuclear localisation signal (N). The gene has been mutated in a manner that
inactivates the fluorescent properties of GFP whilst also introducing an SceI restriction
site). Downstream of the mutated SceGFP gene is the 5′ and 3′ truncated sequence of a
non-mutated GFP gene. Expression of the endonuclease SceI induces a DNA
double-strand break in the SceGFP locus. If this break is repaired by NHEJ, then the
inactivated SceGFP will simply be re-ligated and it will not produce functional GFP.
However, if the break is repaired by HDR using the downstream truncated GFP











































Figure 40. Overexpressing STN1 inhibits Homology-Directed Repair. U-2 OS cells
carrying 1-2 copies of the DRGFP reporter cassette were transfected with expression
vectors carrying SceI and STN1. 48 hours later cells were assayed by fluorescent
microscopy for GFP fluorescence. (A) Representative images of GFP fluorescence
between samples transfected with empty vector, SceI and SceI + STN1. (B)
Quantification of GFP fluorescence-positive cells. Bars represent standard deviation
between three experimental repeats. Significance was calculated by one-way ANOVA
correcting for multiple comparisons (Sidak’s correction for multiple comparisons).
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7.4 Overexpression of STN1 Conveys Resistance to the
Chemotherapeutic Agent Etoposide
It has been reported that overexpression of the CST complex is capable of conveying
resistance to DNA damaging agents that introduce DNA single-strand breaks, lesions, or
other forms of damage that become DSBs when they are met by a replication fork [266].
To determine if STN1 overexpression affected the impact of replication fork-independent
DSBs on genomic stability STN1 -OE HCT116 DTC15-S9 cells were exposed to etopo-
side. Etoposide is a genotoxic agent that is used as a chemotherapeutic, it is a topoi-
somerase II poison that inhibits the re-ligation of DNA after a DSB is induced by the
topoisomerase. The genotoxic DSB introduced is replication fork independent. HCT116
STN1 -OE DTC15-S9 cells were exposed to 10 µM etoposide for 30 minutes to induce
DSBs, then allowed to recover for 24 hours. The cells were fixed and probed with an anti-
γH2AX antibody, counterstaining with DAPI. The abundance of γH2AX foci after the
recovery period was used to assess how effectively the DSBs were repaired, and micronu-
clei/chromatin bridge frequency was used as a measure of the overall impact of etoposide
on genomic stability.
24 hours after a 30 minute etoposide exposure, HCT116 cells with endogenous levels
of STN1 exhibit a high frequency of micronuclei, nearly 30% of nuclei have adjacent
micronuclei compared to approximately 5% of untreated endogenous-STN1 cells (Fig.
41a/b). A roughly 6-fold increase in micronuclei, consistent with the ability of etoposide
to rapidly induce DSB formation (by inducing a high frequency of DSBs the likelihood of
repair errors that can result in micronuclei (Fig. 24b) also increases). STN1 -OE HCT116
DTC15-S9 cells also exhibit a significant increase in micronuclei abundance after the 24
hour recovery period but this change is only 2-fold, in part due to the higher frequency
of micronuclei in unchallenged cells, but also due to micronuclei frequency in etoposide
treated cells being less than 20%. Chromatin bridge frequency followed a very similar
pattern to micronuclei, increasing approximately 5-fold in endogenous STN1 HCT116
cells after etoposide treatment, but only a 3-fold increase was seen in DTC15-S9 cells
that overexpress STN1 (Fig. 41c,d). When γH2AX foci were scored, the effect of high
STN1 levels was even greater. Following the 24 hour recovery period, at which point
etoposide-treated wild-type HCT116 cells have a 2-fold increase in γH2AX still (8% vs
4%), the difference in γH2AX foci between treated and untreated STN1 -OE DTC15-S9
cells was insignificant (Fig. 41e,f). Together these data show DTC15-S9 HCT116 cells
that overexpress STN1 are able to recover from etoposide-induced DSBs with less genomic
instability and residual damage compared to HCT116 cells with wild-type levels of STN1.
To assess if STN1 overexpression is actually improving cell viability following etoposide
exposure, wild-type and STN1 -OE DTC15-S9 cells were exposed to a range of etoposide
concentrations for 24 hours and relative population viability was measured by PrestoBlue
assay. PrestoBlue is an MTT/MTS-like assay that measures mitochondrial activity, and
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as such is an indirect measure of the number of live cells in culture. Population via-
bility was assayed after 24 hours etoposide exposure and plotted relative to untreated
cells (considered to have 100% viability). Both wild-type and STN1 -OE DTC15-S9 cells
have decreasing viabilities as etoposide concentration increases (Fig. 42), however the
STN1 -OE DTC15-S9 cells were significantly more viable than the wild-type cells at all
concentrations of etoposide (up to 50 µM). This increase in viability is concordant with
the micronuclei/chromatin bridge and γH2AX data, suggesting that highly abundant
STN1 is beneficial to the cell when challenged with etoposide-induced DSBs. Whilst high
STN1 levels may have a generally destabilising effect on genomic integrity (Fig. 37,38)
in unchallenged cells, it appears there is at least one condition in which high STN1 levels
are beneficial.
Figure 41 . STN1 -OE HCT116 DTC15-S9 cells have reduced genomic instability 24
hours after etoposide exposure compared to wild type. 0.1% DMSO was used as a vector
control. DTC15-S9 HCT116 cells overexpressing STN1 were exposed to 10 µM
etoposide for 30 minutes before being allowed to recover for 24 hours. Cells were fixed
and stained for fluorescent microscopy. Bars represent standard deviation between three
experimental repeats. Statistical significance was calculated by two-way ANOVA using
Tukey’s correction for multiple comparisons. (A) Representative images of DAPI stained
micronuclei in HCT116 cells. Yellow arrowheads indicate micronuclei. (B)
Quantification of micronuclei. (C) Representative images of DAPI-stained chromatin
bridges in HCT116 cells. Yellow arrowheads indicate chromatin bridges. (D)
Quantification of chromatin bridges in HCT116 cells. (E) Representative images of
γH2AX foci in HCT116 cells. DAPI channel is greyscale and γH2AX channel is red. (F)
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Figure 42. DTC15-S9 STN1 overexpression promotes resistance to etoposide. Cells were
exposed to a range of concentrations of etoposide for 24 hours. All samples were
exposed to 0.5% DMSO. Relative viable cell count was measured by PrestoBlue MTT
assay. 100% viability is that of untreated cells, to which all other viabilities are relative.
Bars represent standard deviation between three biological repeats. Statistical
significance calculated by two-way ANOVA, correcting for multiple comparisons using
Sidak’s method.
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7.5 Overexpression of STN1 Shortens the Telomere C-rich
strands of HCT116 Cells and Increases the Frequency of
Cellular Senescence
High STN1 levels in budding yeast lead to telomere shortening, thought to be mediated
by the CST complex’s role as a telomerase inhibitor [290][298]. Overexpressing STN1
in HCT116 cells did not appear to result in the activation of the DDR at the telomere
(Fig. 44), but telomere length homoeostasis may still be affected. To investigate any im-
pact on telomere C-strand length, DTC15-S9 and DTC15-S12 STN1 -OE cells were grown
for approximately 90 population doublings after transfection with the exogenous STN1
cassette, before being fixed and probed with telomere C-strand specific PNA probes con-
jugated to a fluorophore. Probe signal was measured by fluorescent microscopy and used
as an indicator of relative C-strand length. Telomere signal was compared to wild-type
STN1 HCT116 cells of equal age. Concordant with data from S. cerevisiae, DTC15-S9
and DTC15-S12 HCT116 cells overexpressing STN1 had approximately 25% less telom-
eric C-strand signal than the equivalent age wild-type cells (Fig. 44). This assay does not
address ssDNA overhang length, but indicates a loss of telomeric dsDNA.
A major trigger of cells entering G0 and becoming senescent is telomere shortening. Telom-
eres function as a buffer of non-coding DNA that is gradually eroded as cells replicate.
When this buffer becomes too short, cells become senescent in order to protect coding
DNA from being lost. To determine if cells become senescent when STN1 is overexpressed
the β-galactosidase assay was used. DTC15-S9 HCT116 STN1 -OE cells were fixed ap-
proximately 90 cell divisions after overexpression was induced by transfection, and the
presence of senescence associated β-galactosidase activity was assayed. After incubating
overnight with the β-galactosidase reporter buffers, cells were scored for blue colouration
by visible light microscopy. Blue stained cells were considered to be senescent (Fig. 43a).
Consistent with a decrease in average telomere length, the frequency of senescent cells in
the HCT116 cell population increased from 2% in wild-type cells to >4% in STN1 -OE
DTC15-S9 cells (Fig. 43b). These data further support the hypothesis that low levels of































Figure 43. STN1 overexpression increases the frequency of HCT116 cells entering
senescence. DTC15-S9 HCT116 cells approximately 90 cell divisions after integration of
an STN1 -overexpression cassette were assayed for senescence and compared to identical
aged wild-type HCT116 cells. Senescence was assayed by staining for
senescence-associated β-galactosidase. (A) Representative visible light image of
STN1 -OE HCT116 cells stained for β-galactosidase. White arrowheads indicate blue
staining (and therefore considered senescent) cells. (B) Quantification of blue stained
cells. Bars represent standard deviation between three experimental repeats.
Significance calculated by student’s t-test.
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7.6 STN1 -Overexpression Can Partially Compensate for Loss
of CTC1 at the Telomere but Enhances Non-Telomeric
DNA Damage
The CST complex component STN1 was originally characterised in budding yeast as a
protein capable of suppressing the cdc13-1 temperature sensitive mutation of CDC13 (the
name STN1 is derived from Suppressor of cdc ThirteeN ) [299]. As the STN1 overexpres-
sion cassette was integrated into the HCT116 cell-line with an inducible CTC1 knockout,
it was possible to determine if overexpression of STN1 was capable of compensating for
loss of CTC1 .
CTC1 knockout was induced in wild-type and STN1 -OE HCT116 cells, 10 days later rel-
ative telomere length was assayed as described previously using fluorophore-tagged PNA
probes. Both CTC1 knockout and STN1 -OE induce telomeric C-strand shortening (Fig.
44), but simultaneous CTC1 knockout and STN1 overexpression appears to suppress the
short telomere C-strand phenotype of those individual genotypes (Fig. 44). An explana-
tion for what initially appears to be counter-intuitive telomere length data is that CTC1
knockout cells lose C-strand signal as the CST complex is unable to promote polymerase-α
C-strand fill-in; STN1 -OE cells are able to fill in the C-strand, but the activity of telom-
erase is so effectively inhibited by STN1 that the G-rich overhang is not extended and the
whole telomere is gradually eroded every replication cycle; and in the CTC1 knockout
STN1 -OE cells telomerase inhibition by high STN1 is ineffective without CTC1, whilst
C-strand erosion by nucleases is inhibited by excessive STN1 (Fig. 45). Alternatively, as
the STN1-TEN1 complex has been demonstrated to retain some (albeit weak) binding
ability without CTC1 [300], high STN1 levels could be compensating for a lack of CTC1
by promoting some polymerase-α activity on the C-strand.
Given the apparent ability of high STN1 levels to suppress CTC1 -deletion-induced telom-
ere C-strand length defects in HCT116 cells, it is possible that STN1 is also able to sup-
press the activation of the DDR at the telomere. CTC1 -/- cells accumulate long ssDNA
G-rich overhangs that are likely responsible for attracting DDR elements [182]. To deter-
mine if increased STN1 can suppress this telomeric DDR, metaphase spreads of STN1 -OE
HCT116 cells after CTC1 knockout were probed for co-localisation of γH2AX foci and
telomeres (Fig. 46a). As predicted, the percentage of chromosomes with telomeric γH2AX
foci after CTC1 knockout was approximately 22%, a >5-fold increase over the 5% of chro-
mosomes in control cells (Fig. 46b). CTC1 knockout in STN1 -OE cells also significantly
increased the frequency of telomeric γH2AX, but by only 3-fold compared to CTC1+/+
cells (to approximately 15% of chromosomes) 46b). This statistically significant partial
suppression indicates high STN1 levels are able to limit telomeric DDR activation after
loss of CTC1 . This could be due to STN1 -OE limiting the ssDNA overhang produced in
the absence of CTC1: overexpression of STN1 could allow telomerase inhibition or Pol-α



















































































Figure 44. STN1 overexpression can suppress the short telomere phenotype of HCT116
CTC1 -/- cells. CTC1 knockout was induced by addition of 10 nM tamoxifen to the
culture media. Relative C-strand telomere length was measured by PNA probe
fluorescence. (A) Box plot of WT HCT116, DTC15-S9 and DTC15-S12 cell telomere
C-strand PNA-probe signal with and without CTC1 . N > 600. Data was plotted in R
using the ggplot2 package [301]. (B) Mean C-strand PNA probe signal in WT HCT116
or DTC15-S9 STN1 -OE cells. Bars represent standard deviation between three
experimental repeats. Statistical significance calculated by two-way ANOVA using












































Figure 45. Model of telomere strand regulation in CTC1∆,STN1 -OE cells. In wild-type
cells the CST complex functions as normal: inhibiting telomerase activity, promoting
C-strand fill-in by Pol-α, and possibly inhibiting the action of exonucleases. In the
CTC1∆ cells telomerase is no-longer inhibited which elongates the G-overhang, but the
C-rich strand shortens as Pol-α is no-longer recruited to fill-in the strand. When STN1
is overexpressed, telomerase inhibition is enhanced, and the gradual erosion of the
telomere occurs as cells replicate (Pol-α recruitment may be enhanced, but the
maximum possible length of the C-rich strand is limited by the shortening G-rich
strand). In cells that lack CTC1 and simultaneously overexpress STN1 , telomerase
extension of the G-rich overhang is not fully inhibited by STN1 as CTC1 is not present,
whilst the high levels of STN1 may be able to inhibit resection of the C-rich strand or
even promote Pol-α activity despite the absence of CTC1.
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available (Fig. 45) to attract DDR elements such as RPA.
In contrast to the apparent suppression of CTC1 knockout-induced telomeric γH2AX
by STN1 -OE, non-telomeric γH2AX appears significantly more abundant in CTC1 -/-
DTC15-S9 STN1-OE cells (Fig. 46c). Chromosomes with non-telomeric γH2AX foci
were approximately 1.6-fold more common in CTC1 -/- cells when STN1 was overexpressed
compared to CTC1 -/- cells with wild-type STN1 . This disparity supports the model of
separate roles for STN1 at the telomere and in DSB repair genome-wide, and that high
























































































Figure 46. STN1 overexpression can partially suppress telomeric γH2AX in CTC1 -/-
HCT116 cells, but enhances non-telomeric γH2AX. CTC1 knockout was induced by
addition of 10 nM tamoxifen to the culture media. 10 days later telomeric γH2AX
localisation was measured by PNA probe FISH combined with immunofluorescence. (A)
Representative fluorescent images of an STN1 -OE CTC1 -/- DTC15-S9 HCT116
metaphase chromosome spread. Yellow arrowheads indicate telomere signal and γH2AX
signal co-localisation, white arrowheads indicate non-telomeric γH2AX. (B)
Quantification of telomeric γH2AX frequency. (C) Quantification of non-telomeric
γH2AX frequency. Bars represent standard deviation between three experimental
repeats. Statistical significance calculated by two-way ANOVA using Tukey’s correction
for multiple comparisons.
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7.7 Loss of CTC1 Induces Cell Death in
STN1 -Overexpression HCT116 Cells
As STN1 is capable of partially suppressing telomeric phenotypes of CTC1 knockout cells,
but enhances non-telomeric DNA damage, it remained unclear whether high STN1 levels
would have a positive overall effect on cell viability. CTC1 knockout induces a strong cell
growth defect likely due to the activation of the DDR at the telomere, therefore the partial
suppression of telomeric defects by STN1 might also result in a reduced growth defect. To
address this, CTC1 was knocked out of HCT116 cells with and without the STN1 stable-
overexpression cassette. Cells were counted and passaged every 2-3 days, and population
doublings recorded. STN1 overexpression had no significant effect on cell growth in the
presence of CTC1 . The deletion of CTC1 induces the previously characterised gradual
growth defect in wild-type STN1 cells, however when CTC1 is knocked out of DTC15-S9
or DTC15-S12 (HCT116 cells that overexpress STN1 ) the growth defect is significantly
enhanced (Fig. 47). Whilst growth of CTC1 -/- cells with endogenous levels of STN1 slowly
declines from day 6 to day 12, the growth of the DTC15-S9 clone is reduced to near-zero 7
days after CTC1 knockout induction. DTC15-S12 exhibited an intermediate enhancement
of the CTC1∆ growth defect, concordant with its intermediate overexpression of STN1 .
Whilst the growth defect of CTC1 -/- cells is largely due to cellular senescence [182], the
knockout of CTC1 in STN1 -OE cells appeared to be inducing a significant amount of
cell death (based on observations of cell morphology made by eye during the population
growth assay). To confirm and quantify this cell death, DTC15-S9 STN1 -OE HCT116
cells were stained with trypan blue 10 days after CTC1 knockout. Trypan blue is only
capable of staining dead cells, as live cells are able to exclude the dye. At day 10 the
CTC1 knockout culture comprised approximately 6% dead cells, compared to 2% in
the CTC1+/+ population (Fig. 48). After knockout of CTC1 in the STN1 -OE cells,
approximately 25% of cells in the culture were dead. These data suggest that when STN1
is overexpressed, loss of CTC1 has a significantly more catastrophic effect on cell viability.
A possible explanation for this effect is that STN1 -OE cells are HDR compromised. Loss
of CTC1 results in more replication fork stalling and collapse [185], events which HDR
plays a key role in resolving. Additionally, Stn1 in budding yeast can suppress checkpoint
activation by stalled replication forks [292]. If the same were true of human STN1, then
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Figure 47. Growth of STN1 -OE HCT116 cells after CTC1 knockout. CTC1 knockout
was induced by addition of 10 nM tamoxifen to the culture media. Cells were counted
every 2-3 days and population growth calculated. Bars represent standard deviation
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Figure 48. Cell death after CTC1 knockout in DTC15-S9 HCT116 STN1 -OE cells.
CTC1 knockout was induced by addition of 10 nM tamoxifen to the culture media. 10
days after knockout initiation cells were stained with trypan blue to score cell death.
Bars represent standard deviation between three experimental repeats. Statistical




The data in this chapter demonstrate the significant negative impact that raising STN1
levels has on genomic integrity. Overexpression of STN1 induces short telomeres and
appears to hinder the accurate repair of DNA damage.
HCT116 cells with high STN1 levels exhibited increased markers of genomic instability
including micronuclei and (non-telomeric) γH2AX foci. HDR was significantly inhibited
when STN1 was overexpressed, whilst NHEJ appeared to be supported (manifested in the
resistance of STN1 -overexpressing cells to etoposide). Additionally, high levels of STN1
appear able to partially compensate for loss of CTC1 with regards to telomere length
regulation, but exacerbated the overall genomic instability of CTC1∆ cells.
7.8.1 The Inhibition of HDR by STN1
The CST complex is recruited to resected DSBs by 53BP1/RIF1/Shieldin where it pro-
motes the fill-in of dsDNA by Polymerase-α [189]. It has been previously demonstrated
that loss of CST complex members could restore HDR in BRCA1-deficient cancers [175]
as a lack of a functional CST complex allows hyper-resected ssDNA to persist and take
part in HDR. We show here that as STN1 levels are raised above endogenous levels in cells
with functional BRCA1 and HDR, HDR becomes significantly inhibited. Transient over-
expression of STN1 reduced HDR by approximately 40% when assayed using a DRGFP
reporter system.
Inhibition of HDR could explain the increase in γH2AX foci frequency and chromatin
bridges/micronuclei in cells overexpressing STN1 via a number of pathways. Filling-in
resected DSBs by Polymerase-α could increase the repair of DSBs by NHEJ, resulting in a
higher frequency of chromosome fusions and dicentric chromosomes (as outlined in figure
25). Alternatively, it could be that when HDR is inhibited the cell is not able to use an
alternative repair pathway and the damage remains unrepaired altogether. Additionally,
overexpression of STN1 in budding yeast overrides many aspects of the S-phase checkpoint
response [292]. As the HDR pathway is key for repair of stalled replication forks [302], it
is possible that high levels of STN1 are inhibiting the repair of collapsed replication forks
in STN1 -OE cells whilst simultaneously suppressing the cell cycle checkpoint that would
be activated by said collapsed forks. This would result in cells entering mitosis with sister
chromatids connected by DNA replication intermediates, which in turn become chromatin
bridges and micronuclei as sister chromatids attempt to segregate into separate daughter
cells [303].
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7.8.2 STN1 Supports The Non-Homologous End Joining-Dependant DNA
Damage Response Following Etoposide Treatment
HCT116 cells with raised STN1 levels are more viable following etoposide exposure than
cells with endogenous levels of STN1 (Fig. 42). The STN1 -OE cells also present fewer
γH2AX foci and markers of genomic instability such as chromatin bridges and micronuclei
(Fig. 37) following etoposide exposure. As etoposide-induced DSBs are repaired by the
NHEJ pathway (after an initial processing by MRN-CtIP) [304], this implies that high
levels of STN1 are capable of not only inhibiting HDR, but also actively promoting or
supporting NHEJ.
Published evidence indicates that the CST complex is capable of promoting fill-in by Pol-α
at resected DSBs. This DSB fill-in was hypothesised to be inhibiting HDR in BRCA1-
deficient cancers, and that the purpose of CST-mediated Pol-α recruitment at DSBs in
wild type cells was to inhibit hyper-resection and the mutagenic SSA pathway [175][189]
(Fig. 14). It was hypothesised that the fill-in of the DSB could make it a substrate for
Ku70/Ku80 binding and the initiation of NHEJ. Data presented here indicate that high
STN1 levels in otherwise HDR-proficient cells can inhibit HDR, resulting in a switch to
the less accurate NHEJ pathway (Fig. 49).
The promotion of the NHEJ DNA repair pathway by high levels of STN1 presents a pos-
sible reason for degradation of STN1 mRNA by NMD. Data in this chapter demonstrate
a negative impact on overall genomic stability by high levels of STN1, but for most genes
low protein expression does not require NMD [305]. Many proteins exist in the cell at
low levels due to transcriptional regulation, translational regulation, or by fast protein
turnover. STN1 is one of a small fraction of proteins that is maintained at a low level
by NMD. This could be because whilst it is important to maintain low levels of STN1
under most conditions, higher levels of STN1 are beneficial in the situations that NMD is
downregulated. For example, NMD is downregulated when G0 cells experience persistent
DNA damage [237], and it is demonstrated in chapter 5 that this correlates with STN1
mRNA stabilisation. Because HDR is dependant on readily available template DNA,
cells in G0 may have to rely on NHEJ to repair DNA damage. As STN1 overexpression
appears to promote or support the repair of DNA damage by NHEJ, NMD may be used
as the pathway of STN1 regulation so that last ditch efforts by non-cycling cells to repair
persistent DNA damage get a supportive boost from higher STN1 levels.
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Figure 49. Proposed model of HDR inhibition and NHEJ promotion by high levels of STN1. HDR is dependent on resection of DSBs to
produce ssDNA overhangs. The CST complex promotes the fill-in of these resected breaks. In cells with wild-type levels of STN1 this fill-in
may be limited to hyper-resected DSBs as proposed by Barazas et al. (2018) [175]. However, high levels of STN1 appear capable of
significantly inhibiting HDR in otherwise HDR-competent cells. As NHEJ appears to be supported by high STN1, it is proposed here that
highly abundant STN1 inhibits the accurate HDR pathway and promotes the use of the inaccurate NHEJ pathway. It is also possible that
some breaks are not repaired at all as a result of HDR inhibition.
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7.8.3 High STN1 Levels Affect Telomere Length Regulation
Telomeres protect the integrity of the genome by providing a buffer of non-coding DNA
at the end of chromosome. This DNA can be gradually eroded as cells progress through
multiple replication cycles. If telomeres become critically short, cells risk losing genetic
information so induce cell cycle-arrest. However, if the ssDNA overhang is overextended
this can erroneously attract the DDR, inappropriate activity of nucleases and other DDR
factors can result in chromosomal fusions and fragmentation. Maintaining the balance
between under and over-extension of the telomeric G and C-rich strands is therefore
important for the integrity of the chromosome. HCT116 cells that have overexpressed
STN1 for approximately 90 cell divisions have shorter telomeres than HCT116 cells of
equivalent age and endogenous levels of STN1. This mirrors the short telomere phenotype
of STN1 -OE budding yeast [298]. The CST complex is a telomerase inhibitor, it is
possible that high levels of STN1 alters the stoichiometry of the CST complex binding to
the telomere, enhancing the inhibition of telomerase.
The majority of human cells do not have active telomerase, their telomeres gradually
shorten until the cells become senescent, contributing to ageing and age-related diseases
[306]. The long-term health impacts from higher than normal expression of STN1 have
not been investigated. Individuals with high levels of STN1 expression may have earlier
onset of cellular senescence and ageing-related diseases. Conversely, high STN1 levels
(either naturally or artificially induced) may impact the ability of cancers to develop
and proliferate indefinitely, as their ability to regenerate and maintain telomeric DNA is
hindered.
7.8.4 The Partial Suppression of CTC1∆ by Overexpression of STN1
Knockout of CTC1 , like STN1 overexpression, induces telomere C-strand shortening. In
CTC1∆ cells the G-rich overhang is also extended as telomerase inhibition is lost [171].
The CTC1∆ induced shortening of the C-strand is likely related to the role of the CST
complex in recruiting Pol-α and promoting the fill-in of the C-strand [182]. Interestingly,
when CTC1 is knocked-out in STN1 -OE HCT116 cells, the short telomere phenotype seen
in both genotypes individually is suppressed. One model to explain this phenomenon is
outlined in figure 45, when CTC1 is lost in STN1 -OE HCT116 the inhibition of telom-
erase is limited (returning it to near-normal levels), whilst the fill in of the C-strand (or
the inhibition of its degradation by nucleases) is still possible due to the high STN1 levels
compensating for CTC1 loss (and the ability of STN1-TEN1 to weakly bind DNA still
[300]). In support of this model, loss of CTC1 also induces less telomeric γH2AX accumu-
lation at the telomere of STN1 -OE cells than it does in wild-type STN1 cells (Fig. 46b).
This is consistent with less ssDNA accumulation (which would attract RPA and trigger
a DDR), due to either telomerase inhibition or recovery of C-Strand fill-in by Pol-α.
As CTC1 knockout was induced in HCT116 cells that already overexpress STN1 (and
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therefore already have short telomeres), the near-normal telomere lengths after 10 days
without CTC1 suggests that telomere length has not merely stabilised, but rather the
C-rich strand of telomeres has been actively re-extended. It is not known if the telomeres
had returned to a relatively static state of length homeostasis, or if they would have
continued to extend were it not for the growth arrest and cell death of these CTC1∆
STN1 -OE cells. Although the difference between the telomere C-strand lengths of wild-
type HCT116 cells and CTC1∆ STN1 -OE HCT116 cells was not significant, the mean
length of the CTC1∆ STN1 -OE telomere C-strands were slightly greater than in the WT.
Furthermore, the standard deviation of the CTC1∆ STN1 -OE telomere C-strand lengths
was much greater than in the wild type. This variation in telomere length suggests the
telomere length regulation is still far from perfect. Data in this chapter are consistent with
the ability of Stn1 to partially compensate for telomere uncapping in cdc13-1 budding
yeast [299].
Whilst high levels of STN1 appear to make telomeres of HCT116 cells more tolerant of
CTC1 loss, non-telomeric DNA damage is exacerbated, manifested in increased γH2AX
foci. Unlike in wild-type STN1 cells, loss of CTC1 in STN1 -OE HCT116 cells induces
a strong cell-death response, likely related to the significant increase in non-telomeric
DNA damage. A possible explanation of this increase in DNA damage is high levels of
STN1 permitting entry of CTC1∆ cells from S-phase into G2 despite the presence of
stalled replication forks (which has been reported in S. cerevisiae [292]). The result of
which would be cells entering mitosis with double-strand breaks or unresolved replication
intermediates, and the generation of ultra-fine bridge (UFB)s and DNA damage. However,
in this model the increase in DNA damage would be expected to mostly occur at the
telomere, as telomeric DNA is the most dependent on CTC1 and the CST complex for
replication [185]. Alternatively, it may be that the collapsed replication forks induced
by loss of CTC1 cannot be repaired in the context of high STN1 (HDR plays a key role
in the repair of collapsed replication forks [307], but high STN1 levels appear to inhibit
HDR). Again however, if this is the case it is strange that the increase in γH2AX does not
colocalise with the telomeres of these cells, as telomeric replication forks are particularly
dependant on CTC1. Perhaps the explanation is simply that telomeric DNA is estimated
to make up only 0.02% of the genome of HCT116 cells (based on an average telomere
length of 7 kb [174] and a total genome size of 3235 mb), and as such non-telomeric
damage has an overwhelming statistical likelihood over telomeric damage. Additionally
the CST complex does support replication fork restart in non-telomeric regions of DNA
as long as the region is GC-rich [185].
In summary, high levels of STN1 appear to inhibit HDR in human cells, compromising
genomic stability. However, high levels of STN1 may be beneficial to the cell under certain
conditions, such as when telomere homeostasis is compromised by loss of CTC1 function,
or when NHEJ is the necessary repair pathway for DNA damage.
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8 The role of dna-2 in Caenorhabditis elegans
The nuclease/helicase Dna2 in S. cerevisiae has been demonstrated to resect elongated
5′ flaps of Okazaki fragments produced during lagging strand DNA synthesis [308]; DNA
double strand breaks [309]; and telomeres uncapped by the loss of functional Cdc13 [310].
Recently reported data suggested an essential telomeric role for budding yeast Dna2 [311]:
dna2∆ cells have telomere defects; Dna2 colocalises with RPA and Cdc13; and the tem-
perature sensitive dna2∆ lethality can be suppressed by DNA damage checkpoint and
telomeric helicase mutations (such as the 9-1-1 complex and Mph1 respectively). Suppres-
sion by knockout of DNA damage checkpoint genes implies an essential telomeric function
of Dna2. When the telomere is somehow uncapped or accumulates ssDNA the DDR can
identify the chromosome ends as deleterious breaks in DNA. Consequently the cell cycle
is arrested by the DNA damage checkpoint. Therefore a key indicator of Dna2 having an
essential telomeric function is that its mutation lethality can be bypassed by deactivating
the DNA damage checkpoint. Furthermore, suppression of this growth defect by knockout
of the helicase MPH1 supports the hypothesis of a telomeric role for Dna2 as Mph1 has
been shown to unwind telomeric DNA [312]. Markiewicz-Potoczny et al. [311] proposed a
function of Dna2 in cleaving the C-rich 5′ strand of partially unwound telomeres, limiting
the activation of the DDR by exposed ssDNA (Fig. 50 I).
The goal of this chapter is to determine if this telomeric role of Dna2 could be conserved
in higher eukaryotes. Like the budding yeast homologue, C. elegans dna-2∆ mutations
are temperature sensitive, conveying embryonic lethality at 25oC. dna-2∆ also delays
C. elegans embryo hatching at lower temperatures (observable at 20oC but strongest at
16oC). This presents a good opportunity for determining if DNA-2 has a telomeric role in
a multicellular model organism, as knockout strains of both the telomeric helicase fncm-1
(homologue of budding yeast MPH1 and human FANCM ) and the DNA damage check-
point 9-1-1 complex component mrt-2 (homologue of human RAD1 ) are available. Null
mutations of both MPH1 and 9-1-1 complex components in yeast are dna2∆ suppressors,
supporting the hypothesis that Dna2 resects the 5′ strand of unwound telomeres (Fig. 50
I). If fncm-1∆ and mrt-2∆ are also able to suppress the C. elegans dna-2∆ embryonic
lethality, that would suggest a telomeric role for Dna2 is conserved in higher eukaryotes.
The delayed hatching of dna-2∆ worms at lower temperatures has be been hypothesised
to be due to the role of dna-2 in DNA synthesis which occurs less efficiently without
DNA2 [313]. As such knockout of mrt-2 or fncm-1 might be expected to improve the vi-
ability of dna-2∆ embryos at 25oC without suppressing the slow development of embryos
at 16 or 20oC. To address this, double-mutant worm strains were generated by crossing
the dna-2 (jh115) mutant strain with fncm-1 (tm3148) or mrt-2 (e2663) strains.
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Figure 50. A proposed model of the telomeric role of S. cerevisiae Dna2.
Markiewicz-Potoczny et al. proposed 3 potential functions of Dna2 at the telomere in
budding yeast. (I) The primary proposed role of Dna2 at the telomere.
Helicases/polymerases unwind 5′ telomeric DNA. RPA binds the ssDNA which is then
cleaved by Dna2. (II) Long flaps of Okazaki fragments near the telomere are bound by
RPA and cleaved by Dna2. (III) G-quadruplex structures that form on unwound
telomeric DNA are unwound by Dna2. Figure from Markiewicz-Potoczny et al., 2018
[311].
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8.1 fncm-1∆ and mrt-2∆ are Partial Suppressors of dna-2∆
Embryo Lethality
The budding yeast helicase Mph1 appears to be capable of remodelling telomeres, making
them more accessible to nucleases [312]. The suppression of dna2∆ lethality by deletion
of Mph1 [311] is therefore consistent with a telomeric role of Dna2. An explanation
being that the need for Dna2 to resect telomeric ssDNA is reduced if Mph1 is no-longer
unwinding telomeres and producing excessive ssDNA (Fig. 50 I).
dna-2∆ C. elegans embryos are >90% viable when grown at 20oC or lower (Fig. 51).
However, when grown at 25oC less than 20% of embryos will hatch. The remaining
embryos will die before hatching. At 25oC typically 100% of wild-type worm embryos will
hatch, as will approximately 90% of fncm-1∆ (deletion of the S. cerevisiae homologue
of MPH1 ) embryos. A dna-2∆ fncm-1∆ double-mutant worm was produced through
crosses, and embryo hatching assessed. Consistent with the data from budding yeast
[311], loss of fncm-1 is capable of partially suppressing the embryo viability defect of
dna-2∆ C. elegans embryos. At 25oC approximately 50% of eggs from dna-2∆ fncm-1∆
worms hatched, compared to less than 20% of dna-2∆ single-mutant worms (Fig. 51).
Deletion of the budding yeast 9-1-1 complex component MEC3 was also capable of par-
tially suppressing dna2∆ lethality [311]. The 9-1-1 complex is a key part of the DNA
damage checkpoint. As suppression of mutation growth defects by inactivation of the
DDR is a hallmark of telomere dysfunction, these data supported a telomeric role for
Dna2.
A C. elegans strain with hus-1 (homologue of MEC3 ) deleted was not readily available,
however a strain with mrt-2 (a different C. elegans 9-1-1 complex component) deleted was
available and consequently used. As with fncm-1, the mrt-2∆ strain was crossed with the
dna-2∆ mutant, and embryo hatching of the double-mutant was assessed. The absence of
mrt-2 results in a significant compromise to genomic stability due to the importance of the
9-1-1 complex in detecting and repairing real DNA damage. As such it is not surprising
that after 36 hours less than 70% of mrt-2∆ embryos were viable (Fig. 51). Despite
this significant viability defect, deletion of mrt-2 in C. elegans appears to be capable of
Figure 51 . The dna-2 (-/-) embryo hatching defect is partially suppressed by
fncm-1 (-/-) or mrt-2 (-/-). Homozygous worms were grown from the L1 stage at 16oC,
20oC, or 25oC for 3-5 days (for strains carrying a dna-2 mutation, these L1 worms were
the dna-2 -/- homozygous progeny of a dna-2 (+/-) heterozygous parent). Adults were
picked onto a fresh plate and allowed to lay eggs for 3 hours before being removed. The
eggs were returned to 16/20/25oC and the percentage of hatched eggs was scored every
6 hours for 36 hours. Bars represent standard deviation between three separate
experimental repeats.
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partially suppressing the embryonic viability defect of dna-2∆ worms (Fig. 51). After
36 hours more than 40% of dna-2∆ mrt-2∆ embryos at 25oC had hatched (compared to
less than 20% of dna-2∆ single-mutant embryos).
8.2 fncm-1∆ and mrt-2∆ Do Not Suppress dna-2∆ Embryo
Hatching Delay
Whilst dna-2∆ embryos are 80-90% viable at 20oC and 16oC, they exhibit a delayed
development rate. Wild-type embryos typically complete hatching after 18 hours at 20oC
and 16oC, but it takes dna-2∆ eggs 30-36 hours to reach 100% hatching of viable eggs.
The cells of C. elegans embryos are dividing very rapidly, and as such any delay in DNA
replication is likely to have a significant impact of development rate. The delay seen in
dna-2∆ embryos was proposed to be due to its role in Okazaki fragment processing during
DNA synthesis [313]. Unlike the embryonic viability defect at 25oC, neither deletion of
fncm-1 or mrt-2 was able to suppress the slow development of dna-2∆ embryos at 20oC
or 16oC (Fig. 51). This supports the hypothesis that the interaction of FNCM-1 and
MRT-2 with DNA-2 is due to a role of DNA-2 that is separate to the known role of
DNA-2 in DNA synthesis.
8.3 Discussion
The C. elegans data presented in this chapter are consistent with the proposed essential
telomeric role of Dna2 in S. cerevisiae. The embryonic lethality at 25oC of the dna-2∆
worm can be significantly suppressed by inhibiting the DNA damage checkpoint or by
knockout of a telomeric helicase. Whilst the CST complex binds G-rich ssDNA highly
efficiently, it binds to C-rich ssDNA with less efficiency. This potentially leaves the C-rich
strand exposed to the DDR. As Dna2 is capable of degrading RPA-bound ssDNA [35],
the proposed role of Dna2 is the degradation of the 5′ C-rich strand should the dsDNA
of the telomere become unwound. This degradation of the C-rich ssDNA would inhibit
RPA-binding triggering the DDR (Fig. 50 I) [311].
In contrast to the embryo inviability, the slow rate of dna-2∆ embryo development at
lower temperatures was unaffected by mrt-2∆ or fncm-1∆. This suggests the slow em-
bryo development is due to a different pathway than the low embryo viability of dna-2
worms. A possible model is that the slow embryonic development is due to a role of DNA-2
in Okazaki fragment long flap cleavage during DNA synthesis (which has been demon-
strated in budding yeast [308]). Cleavage is necessary but performed redundantly by other
nucleases, which means that in the absence of Dna2 DNA synthesis still occurs, but less
efficiently. Less efficient DNA synthesis could translate into slower embryo development
as it is the stage in the life cycle of the worm in which cell division is happening rapidly
[313]. MRT-2 and FNCM-1 are not necessarily involved in the processing of Okazaki
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fragment flaps which may be why their knockout would not suppress this developmental
phenotype of dna-2∆ embryos.
An interesting consistency between dna2∆ S. cerevisiae and dna-2∆ C. elegans is the
temperature sensitivity of the lethality, which is exacerbated at higher temperatures. This
could be explained by temperature dependent telomere unwinding creating the 5′ ssDNA
substrate for RPA binding and DNA-2 cleavage.
The data in this chapter are congruent with an essential role of DNA-2 in C. elegans
in suppressing the activation of the DNA damage response to ssDNA at the telomere.
This role is likely separate from a role in Okazaki fragment flap processing (Fig. 50
I). Nematodes and humans both belong to the kingdom animalia whilst budding yeast
belongs to the fungi kingdom. Fungi and animalia diverged approximately 1.1 billion
years ago, therefore if functions of Dna2 are conserved between S. cerevisiae and C.
elegans then there is a good chance this essential telomeric function of Dna2 is preserved
in other metazoans such as humans.
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9 Discussion
Following its discovery in 2009, the list of known roles the human CST complex plays in
maintaining genomic integrity has continued to grow. In S. cerevisiae the CST complex
is the main telomere capping complex, it is responsible for regulating and promoting the
replication of the telomere. When the human homologues of CDC13, STN1 and TEN1
were discovered, evidence suggested they played a similar role in maintaining the integrity
of the human telomere. CST does this by inhibiting the overextension of the G-rich 3′
overhang by telomerase [171], promoting the fill-in of the C-rich strand [182], and by
supporting the replication of the telomere [184]. The ability of the human CST complex to
aid replication fork restart during replication stress extends beyond the telomere however,
this was the first piece of evidence pointing towards a role for the human CST complex
outside of the telomere [173]. It is now known that the CST complex promotes the restart
of stalled replication forks by recruiting RAD51 [185]. An additional non-telomeric role for
the CST complex was recently discovered, the complex is capable of binding to resected
DSBs and promoting the fill-in of duplex DNA [189][175]. Investigating how these newly
discovered non-telomeric roles of the CST complex are regulated and how they impact
genomic stability on a cellular level is important for understanding CST related disease
pathogenesis.
9.1 Genomic Instability and Cell Cycle Arrest after Loss of
CTC1
Here we confirm the role of CTC1 in maintaining the C-rich strand of the human telomere.
C-strand erosion coincides with activation of the DNA damage response at the telomere,
supporting the proposed role of CTC1 in promoting the fill-in of the C-rich strand by Pol-
α and minimising the accumulation of ssDNA. The loss of telomere homeostasis observed
correlates with a gradual growth arrest. Whilst these data closely mirror what is seen
in cdc13-1 S. cerevisiae cells, the arrest of CTC1∆ human cells appears to be mediated
by a separate pathway to that seen in budding yeast. Instead of being mediated by
CHK1 (a DDR kinase that targets CDC25, inhibiting the formation of cyclin-dependant
kinase complexes) the arrest of CTC1∆ cells is mediated by the p53/p21 pathway. The
lack of CHK1 activation is surprising, as loss of CTC1 does result in γH2AX and RPA
accumulation at the telomere, which is an upstream activator of CHK1. The apparent
disconnect between telomeric RPA accumulation and the CHK1-independent cell cycle
arrest might reflect the more complex role that the CST complex plays in human cells
compared to budding yeast, and the importance of the complex’s additional non-telomeric
functions.
136



















Wild-Type CTC1 CTC1 Deficient
Cell cycle arrest / cell death
Figure 52. Proposed model of CTC1 influence on hyper-resected DSBs. In cells with functional CTC1 hyper-resection of DSBs is counteracted
by Pol-α. If this fill-in is incomplete and a template strand is available the cell is capable of performing HDR. If a template strand is not
available and fill-in has either completed or left only a short overhang then NHEJ could be used to repair the break. In CTC1∆ cells
hyper-resected breaks can still be repaired by HDR if the template DNA is available. If no template DNA is available it is possible that the
break may be repaired by SSA, but it may not be repaired at all, resulting in cell cycle arrest or death.
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Perhaps related to the different (CHK1 independent) cell-cycle arrest pathway seen in
CTC1∆ human cells, we report here a rapid onset of genomic instability after CTC1
knockout that appears unrelated to telomere misregulation and is instead due to defective
DNA repair. It was recently discovered that the CST complex can localise to resected
DSBs and promote the fill-in of duplex DNA. When the CST complex is depleted, HDR
(which is dependent on a long ssDNA overhang) is recovered in BRCA1-deficient cancers
as the overhang is no-longer eliminated by Pol-α (which was recruited by CST). Whilst
this loss of CST complex components was beneficial to BRCA1 deficient cells exposed
to PARP inhibitors because it restored HDR functionality, it may be the cause of the
genomic instability see in CTC1∆ HCT116 cells (Fig. 53b). HDR is dependant on the
availability of template DNA in order to repair breaks. If a DSB is hyper-resected during
the stages of the cell cycle when template DNA is not readily available, and the CST
complex is not available to counteract the resection, then the repair process may stall,
unable to use either HDR or NHEJ (Fig. 52). It is also possible that the persistence of
hyper-resected DSBs as a result of CTC1 loss results in an increase in SSA which can
result in the loss of long tracts of DNA and as such is highly mutagenic [175].
9.2 The Impact of High STN1 Levels on Genomic Stability
The negative impact of high STN1 levels on genomic stability and HDR reported here
further underscores the importance of the CST complex in DDR regulation beyond the
telomere. As previously discussed, the CST complex has been shown to promote the
fill-in of hyper-resected DSBs [189]. Here we expand upon this discovery, demonstrating
the ability of high levels of STN1 to inhibit HDR in cells that would otherwise be HDR
competent. HDR inhibition is a possible explanation for the high levels of DNA damage
in STN1 -OE HCT116 cells (manifested in an increase in γH2AX foci and micronuclei).
HDR is the more accurate pathway of DNA repair due to its use of a template sequence
[314]. HDR is also crucial for the repair of stalled replication forks [315]. It is therefore
important that the CST complex is not just expressed to any degree above a minimal level,
but tightly regulated so as to not interfere with DNA repair pathways. Furthermore, high
STN1 levels appear to convey resistance to the chemotherapeutic etoposide, which induces
DSBs that rely on NHEJ for repair (after an initial processing by MRN-CtIP). A cancer
tissue’s STN1 level may therefore affect the efficacy of etoposide as a treatment option
(Fig. 53c).
Additionally, high levels of STN1 resulted in shorter telomeres in HCT116 cells, likely due
to the ability of the CST complex to inhibit telomerase [171]. This is consistent with what
is seen in S. cerevisiae [298]. Stn1 was initially identified as a gene that suppressed the
effects of the cdc13-1 mutation in budding yeast. Whilst raising STN1 levels did appear
to compensate for the loss of CTC1 at the telomere in human cells, the affect on genome-



























Figure 53. The regulation of CST complex components and their influence on DNA
repair. (A) In a normal cell NMD suppresses STN1 levels, allowing the cell to use HDR
and NHEJ as appropriate. (B) Loss of a CST complex component conveys PARP
inhibitor resistance in BRCA1-deficient cancers by restoring HDR. Additionally loss of a
CST component could inhibit any repair if a template strand for HDR is not available
but the break has already been resected. (C) High STN1 levels convey resistance to
etoposide, possibly by promoting NHEJ. Loss of NMD function may therefore correlate
with cancer etoposide resistance. The promotion of NHEJ can however result in repair
errors such as chromosome fusions. (D) NMD is inhibited as part of the stress response
to prolonged DNA damage in G0. This increases STN1 levels, which might act to
support repair of the damage by NHEJ.
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overexpression on CTC1∆ human cells highlights the importance of the extra-telomeric
roles of the human CST complex, and further illustrates the importance of limiting STN1
levels.
9.3 Regulation of STN1 by Nonsense Mediated Decay
As tightly controlling STN1 levels appears necessary for maintaining genomic stability, it
is important to understand the pathways that regulate STN1 abundance. Here we report
evidence that like STN1 in budding yeast [231], human STN1 mRNA is degraded by
NMD. When NMD was chemically inhibited the abundance of STN1 mRNA and protein
increased, and when NMD was down-regulated in RPE-1 cells the degradation rate of
STN1 mRNA was reduced. The question remains however, why is STN1 regulated by
NMD and not simply regulated at the transcriptional level? The answer may simply be
that degradation of STN1 by NMD enables a higher transcription rate, and the kinetics of
STN1 levels are therefore shifted to benefit the cell. The high transcription rate of STN1
might be beneficial immediately after mitosis when transcription has been inhibited by the
condensation of DNA. Having a high production and turnover rate could mean that newly
divided daughter cells are more rapidly able to return STN1 mRNA abundance to the
desired level having been unable to transcribe it during mitosis. There are however other
explanations for regulating STN1 by NMD. High STN1 levels have been demonstrated
here to be beneficial to the cell under specific circumstances, such as when challenged with
DNA damage that needs to be repaired by NHEJ. Interestingly, it has been reported [237]
(and replicated here) that NMD is down-regulated when non-cycling cells are challenged
with persistent DNA damage (Fig. 53d). As these cells in G0 will not have easy access
to the template DNA necessary for HDR, NHEJ is particularly important. It may be
that one reason STN1 is regulated by NMD is so that high STN1 levels can promote and
support NHEJ in a final effort to repair such damage.
9.4 CTC1 and Chromosome Segregation
An interesting impact loss of CTC1 has that is unaddressed in the literature is the failure
of the cell to ensure correct segregation of chromosomes during mitosis. Feng et al. [182]
noted that knockout of CTC1 resulted in an increase in ≥4N cells but did not speculate
as to the cause or investigate the phenotype further. An increase in ≥4N cells indicates
mitotic slippage could be occurring, this is when the SAC is activated for too long and
consequently is deactivated despite failure to achieve appropriate binding and alignment
of chromosomes at the spindle equator. As a result the spindle collapses, and (if the
cell avoids an apoptotic response) the result is a single cell in G1 with four copies of
the genome (4N), instead of two daughter cells each with two copies [316]. Should the
process of attempting replication but failing to segregate chromosomes happen again the
genomic content is increased further, producing a >4N cell. Alternatively, these ≥4N
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CTC1 -/- cells may be bi/multi-nucleated cells produced as a result of chromatin bridges
obstructing cytokinesis. Here we do observe an increase in chromatin bridges in CTC1-/-
cells, suggesting the chromatin bridge-induced 4N cell model is very possible. Further
investigation is necessary to determine the mechanism conclusively. Investigating whether
the CTC1 -/--induced ≥4N cells are mono or multi-nucleated may aid that determination.
In contrast, data presented here indicate that in some CTC1∆ cells anaphase, telophase
and cytokinesis are performed unimpeded, but mis-segregation of chromosomes still occurs
and daughter cells are left with whole chromosomes isolated in micronuclei. A potential
novel role of CTC1 is hypothesised here to explain the combination of ≥4N cells and the
presence of mis-segregated chromosomes in CTC1∆ HCT116 cells. It is possible that
CTC1 allows kinetochores that are inappropriately bound to the mitotic spindle to re-
lease, and therefore have the opportunity to rebind correctly. If both kinetochores of
a chromosome attach to the same spindle pole (syntelic binding) or if one kinetochore
attached to both spindle poles (merotelic binding), and the kinetochores are unable to
detach and correct due to a lack of CTC1, the observed occurrence of both ≥4N cells
and whole-chromosome micronuclei would result (Fig. 33). Whilst this model fits the ob-
served CTC1∆ phenotypes with a single mechanism, the evidence of a role for CTC1 at
the kinetochore is indirect. Furthermore the ≥4N CTC1 -/- cells may be due to chromatin
bridge-induced cytokinesis abortion, and not lagging merotelic chromosomes. Whilst some
of the chromosome segregation errors here could be explained by a role for the CST com-
plex in mitosis, as of yet no members of the CST complex have been reported to localise to,
or interact with, the kinetochore. However, the CST complex does interact and co-purify
with Shelterin complex members [276], and depletion of TRF1 (a component of Shel-
terin) abolishes centromeric recruitment of Aurora-B [273]. As a result sister centromere
cohesion is loosened, resulting in more merotelic kinetochores, lagging chromosomes, and
micronuclei. It is possible that CTC1 is involved in this process, maintaining the integrity
of mitosis, but further investigation is necessary to confirm it.
9.5 The Conservation of an Essential Role for Dna2 at The
Telomere in Metazoans
Dna2 is a protein originally identified as having a role in DNA replication and the DDR
that has only recently been proposed to have an essential function at the telomere [311].
An essential telomeric role of Dna2 was proposed in budding yeast based in part on its
colocalisation with Cdc13 and the bypass of dna2 mutation lethality by knocking out
DNA damage checkpoint genes or helicases. As a nuclease/helicase Dna2 is hypothesised
to resect unwound 5′ ssDNA at the telomere that the CST complex is unable to bind to.
By resecting the 5′ DNA the strand no longer attracts RPA and subsequently does not
activate the DDR (Fig. 50). Here we demonstrate the temperature sensitive embryonic
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lethality of dna-2∆ C. elegans can be partially suppressed by knockout of either the 9-1-1
complex component (and DNA damage checkpoint gene) mrt-2 or the telomeric helicase
fncm-1. The fact that neither fncm-1 or mrt-2 knockout affected the reduced embryonic
development rate of the dna-2 mutants supports the notion that this essential role of
dna-2 is functionally separate from its role in Okazaki fragment processing during DNA
synthesis. This is the first indication that the essential telomeric function of Dna2 is
conserved in metazoans.
9.6 In Summary
In summary, the list of proteins with perhaps counter-intuitive roles in both supporting
the DDR throughout the genome whilst simultaneously suppressing DDR activation at the
telomere continues to grow. Data presented here underscore how important the regulation
of these genes is in maintaining genomic stability. The data suggest a novel role for CTC1
in chromosome separation during mitosis, and demonstrates the crucial role of CTC1 and
STN1 in DNA damage repair. The telomeric role of Dna2 appears conserved between
S. cerevisiae and C. elegans, and is therefore likely to also be conserved in humans.
CTC1 and STN1 mutations have been linked to Coats Plus syndrome [176][177] and
antineoplastic resistance [175], whilst DNA2 mutations are associated with microcephalic
primordial dwarfism [317]. By understanding the full range of roles these proteins play
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